

# Appendix A. Exact Search Strings

## PubMed® search strategy (November 17, 2015)

### Key Question 1

Set #	Terms
#1	"Attention Deficit Disorder with Hyperactivity"[Mesh] OR "attention deficit hyperactivity disorder"[tiab] OR "ADHD"[tiab] OR "attention deficit disorder"[tiab]
#2	"Pediatrics"[Mesh] OR "Adolescent"[Mesh] OR "Infant"[Mesh] OR "Child"[Mesh] OR child[tiab] OR children[tiab] OR infant[tiab] OR infants[tiab] OR preschool[tiab] OR preschooler[tiab] OR pediatric[tiab] OR teenager[tiab] OR teenagers[tiab] OR teenaged[tiab] OR teen[tiab] OR teens[tiab] OR adolescent[tiab] OR adolescents[tiab] OR adolescence[tiab] OR youth[tiab]
#3	"Attention Deficit and Disruptive Behavior Disorders/diagnosis"[Majr] OR mass screening[mesh] OR questionnaires[mesh] OR Interviews as Topic[Mesh] OR Psychometrics[Mesh] OR Psychiatric Status Rating Scales[Mesh] OR diagnosis[mesh:noexp] OR "Diagnostic Techniques and Procedures"[Mesh] OR "Diagnostic and Statistical Manual of Mental Disorders"[Mesh] OR "Referral and Consultation"[Mesh] OR questionnaire[tiab] OR questionnaires[tiab] OR screening[tiab] OR screen[tiab] OR scale[tiab] OR instrument[tiab] OR instruments[tiab] OR interview[tiab] OR interviews[tiab] OR DSM*[tiab] OR diagnosis[tiab] OR diagnostic[tiab] OR diagnosed[tiab] OR (Vanderbilt[tiab] AND scale[tiab]) OR conners[tiab] OR cprs[tiab] OR ctrs[tiab] OR cprs[tiab] OR crs[tiab] OR "snap-IV"[tiab] OR "snap-4"[tiab] OR "basc-2"[tiab] OR "behavioral assessment system for children"[tiab] OR dbdrs[tiab] OR "disruptive behavior disorder rating scale"[tiab] OR adhd-rs[tiab] OR "adhd rating scale"[tiab] OR ksads[tiab] OR k-sads[tiab] OR kiddie-sads[tiab] OR DISC[tiab] OR "dominance inducement submission and compliance"[tiab] OR "diagnostic interview schedule for children"[tiab] OR "diagnostic inventory for screening children"[tiab] OR "mini-kid"[tiab] OR "Mini Interational Neuropsychiatric interview"[tiab] OR "iva-2"[tiab] OR "iva-qs"[tiab] OR "iva-ae2"[tiab] OR tova[tiab] OR "test of variables of attention"[tiab] OR "neuropsychiatric eeg-based assessment aid"[tiab] OR neba[tiab]
#4	"Sensitivity and Specificity"[Mesh] OR "Diagnostic Errors"[Mesh] OR sensitivity[tiab] OR specificity[tiab] OR accuracy[tiab] OR accurate[tiab] OR accurately[tiab] OR misdiagnos*[tiab] OR (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomisation[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR Clinical trial[pt] OR "clinical trial"[tiab] OR "clinical trials"[tiab] OR "evaluation studies"[pt] OR "evaluation studies as topic"[MeSH] OR "evaluation study"[tiab] OR evaluation studies[tiab] OR "intervention studies"[MeSH] OR "intervention study"[tiab] OR "intervention studies"[tiab] OR "case-control studies"[MeSH] OR "case-control"[tiab] OR "cohort studies"[MeSH] OR cohort[tiab] OR "longitudinal studies"[MeSH] OR "longitudinal"[tiab] OR longitudinally[tiab] OR "prospective"[tiab] OR prospectively[tiab] OR "retrospective studies"[MeSH] OR "retrospective"[tiab] OR "Cross-Sectional Studies"[Mesh] OR cross-sectional[tiab] OR "comparative study"[pt] OR "comparative study"[tiab] OR systematic[sb] OR "meta-analysis"[pt] OR "meta-analysis as topic"[MeSH] OR "meta-analysis"[tiab] OR "meta-analyses"[tiab]) NOT (Editorial[ptyp] OR Letter[pt] OR Case Reports[pt] OR Comment[pt]) NOT (animals[mh] NOT humans[mh]) AND English[la]
#5	#1 AND #2 AND #3 AND #4
	Publication date from 2009/01/01

### Key Question 2

Set #	Terms
#1	"Attention Deficit Disorder with Hyperactivity"[Mesh] OR "attention deficit hyperactivity disorder"[tiab] OR "ADHD"[tiab] OR "attention deficit disorder"[tiab]
#2	"Pediatrics"[Mesh] OR "Adolescent"[Mesh] OR "Infant"[Mesh] OR "Child"[Mesh] OR child[tiab] OR children[tiab] OR infant[tiab] OR infants[tiab] OR preschool[tiab] OR preschooler[tiab] OR pediatric[tiab] OR teenager[tiab] OR teenagers[tiab] OR teenaged[tiab] OR teen[tiab] OR teens[tiab] OR adolescent[tiab] OR adolescents[tiab] OR adolescence[tiab] OR youth[tiab]
#3	#1 AND #2
#4	"Attention Deficit Disorder with Hyperactivity/drug therapy"[Majr] OR "Central Nervous System Stimulants"[MeSH] OR "Methylphenidate"[MeSH] OR "Dexmethylphenidate"[MeSH] OR "Dextroamphetamine"[MeSH] OR "Adderall"[Supplementary Concept] OR "lisdexamfetamine

Set #	Terms
	<p>dimesylate"[Supplementary Concept] OR "Amphetamine"[MeSH] OR "Guanfacine"[MeSH] OR "Sympatholytics"[MeSH] OR "Clonidine"[MeSH] OR "Adrenergic Uptake Inhibitors"[MeSH] OR "Adrenergic Uptake Inhibitors"[Pharmacological Action] OR "Receptors, Adrenergic, alpha-2"[MeSH] OR "Adrenergic alpha-Agonists"[Mesh] OR "Adrenergic alpha-2 Receptor Agonists"[Mesh] OR "atomoxetine"[Supplementary Concept] OR "Antidepressive Agents, Tricyclic"[MeSH] OR "Desipramine"[MeSH] OR "Dopamine Uptake Inhibitors"[MeSH] OR "Sympathomimetics"[MeSH] OR "modafinil"[Supplementary Concept] OR "Serotonin Uptake Inhibitors"[MeSH] OR "Serotonin Uptake Inhibitors"[Pharmacological Action] OR "duloxetine" [Supplementary Concept] OR "Monoamine Oxidase Inhibitors"[MeSH] OR "Monoamine Oxidase"[MeSH] OR "Selegiline"[MeSH] OR "Bupropion"[MeSH] OR "armodafinil" [Supplementary Concept] OR "venlafaxine"[Supplementary Concept] OR "Receptors, N-Methyl-D-Aspartate"[MeSH] OR "Memantine"[MeSH] OR "Amantadine"[MeSH] OR "duloxetine"[Supplementary Concept] OR "Central Nervous System Stimulants" [Pharmacological Action] OR "Adrenergic alpha-2 Receptor Agonists" [Pharmacological Action] OR "Antidepressive Agents, Tricyclic" [Pharmacological Action] OR "Dopamine Uptake Inhibitors" [Pharmacological Action] OR "Monoamine Oxidase Inhibitors" [Pharmacological Action] OR "Central Nervous System Stimulants"[tiab] OR "psychostimulant"[tiab] OR "Methylphenidate"[tiab] OR "Methylphenidate Hydrochloride"[tiab] OR "Aptensio"[tiab] OR "Concerta"[tiab] OR "Ritalin"[tiab] OR "Ritalin LA"[tiab] OR "Medikinet"[tiab] OR "Equasym"[tiab] OR "Quillivant"[tiab] OR "Metadate"[tiab] OR "Daytrana"[tiab] OR "Dexamethylphenidate"[tiab] OR "Dexamethylphenidate Hydrochloride"[tiab] OR "Focalin"[tiab] OR "Dextroamphetamine"[tiab] OR "Dexedrine"[tiab] OR "Dextrostat"[tiab] OR "ProCoral"[tiab] OR "Zenzedi"[tiab] OR "mixed amphetamine salts"[tiab] OR "Adderall" [tiab] OR "lisdexamfetamine"[tiab] OR "lisdexamfetamine dimesylate"[tiab] OR "Vyvanse"[tiab] OR "Venvanse"[tiab] OR "Elvanse"[tiab] OR "Tyvance"[tiab] OR "Dyanavel"[tiab] OR "Evekeo"[tiab] OR "Guanfacine"[tiab] OR "Sympatholytics"[tiab] OR "Central alpha-2 Adrenergic Agonist"[tiab] OR "Clonidine"[tiab] OR "Intuniv"[tiab] OR "Estulic"[tiab] OR "Tenex"[tiab] OR "Catapres"[tiab] OR "Clophelin"[tiab] OR "Kapvay"[tiab] OR "Nexiclon"[tiab] OR "Duraclon"[tiab] OR "Norepinephrine Reuptake Inhibitors"[tiab] OR "Selective Norepinephrine Reuptake Inhibitors"[tiab] OR "Adrenergic Uptake Inhibitors"[tiab] OR "atomoxetine"[tiab] OR "Strattera"[tiab] OR "Tricyclic antidepressants"[tiab] OR "Desipramine"[tiab] OR "Norpramin"[tiab] OR "Nortriptyline"[tiab] OR "Pamelor"[tiab] OR "Dopamine Reuptake Inhibitors"[tiab] OR "modafinil"[tiab] OR "Provigil"[tiab] OR "Armodafinil"[tiab] OR "Norepinephrine-dopamine Reuptake Inhibitors"[tiab] OR "Bupropion"[tiab] OR "Wellbutrin"[tiab] OR "Forfivo"[tiab] OR "Cymbalta"[tiab] OR "venlafaxine"[tiab] OR "reboxetine"[tiab] OR "Monoamine Oxidase Type B inhibitors"[tiab] OR "Selegiline"[tiab] OR "Eldepryl"[tiab] OR "Zelapar"[tiab] OR "NMDA receptors"[tiab] OR "N-Methyl-D-aspartate receptor Antagonists"[tiab] OR "Amantadine"[tiab] OR "Memantine"[tiab] OR "Pertofrane"[tiab] OR "Nuvigil"[tiab] OR "Cymbalta"[tiab] OR "duloxetine"[tiab] OR "Effexor"[tiab] OR "Eldepryl"[tiab] OR "Emsam"[tiab] OR "Trevilor"[tiab] OR "Symmetrel"[tiab] OR "Namenda"[tiab] OR "Zelapar"[tiab]</p>
#5	<p>"Attention Deficit Disorder with Hyperactivity/diet therapy"[Majr] OR "Attention Deficit Disorder with Hyperactivity/rehabilitation"[Majr] OR "Psychotherapy"[MeSH] OR "Behavior Therapy"[MeSH] OR "Parent-Child Relations"[MeSH] OR "Play Therapy"[MeSH] OR "Cognitive Therapy"[MeSH] OR "Time Management"[MeSH] OR "Computer-Assisted Instruction"[MeSH] OR "Diet Therapy"[MeSH] OR "Fatty Acids, Omega-3/therapeutic use"[MeSH] OR "Vitamins/administration and dosage"[Mesh] OR "Vitamins/therapeutic use"[MeSH] OR "Food Additives/adverse effects"[MeSH] OR "Probiotics/therapeutic use"[MeSH] OR "Acupuncture Therapy"[MeSH] OR "Remedial Teaching"[MeSH] OR "Early Intervention (Education)"[MeSH] OR "Complementary Therapies"[MeSH] OR "Combined Modality Therapy"[MeSH] OR "psychosocial therapy"[tiab] OR "psychosocial intervention"[tiab] OR "psychosocial interventions"[tiab] OR "psychosocial approach"[tiab] OR "psychosocial approaches"[tiab] OR "psychosocial treatment"[tiab] OR "psychosocial support"[tiab] OR "psychoeducation"[tiab] OR "nonpharmacologic therapy"[tiab] OR "nondrug therapy"[tiab] OR "non-drug therapy"[tiab] OR "Play Therapy"[tiab] OR "cognitive behavioral therapy"[tiab] OR "cognitive behavior therapy"[tiab] OR "cognitive behavioural therapy"[tiab] OR "cognitive behavioural therapy"[tiab] OR "Mindfulness"[tiab] OR "complementary"[tiab] OR "alternative medicine"[tiab] OR "alternative therapy"[tiab] OR "alternative therapies"[tiab] OR "Interpersonal skills training"[tiab] OR "Parent-Child Interaction Therapy"[tiab] OR "parent training"[tiab] OR "parent engagement"[tiab] OR "parent management"[tiab] OR "parenting skills"[tiab] OR "parenting intervention"[tiab] OR "parenting interventions"[tiab] OR "Barkley's defiant child"[tiab] OR "Teacher-Child Interaction Training"[tiab] OR "Incredible Years"[tiab] OR "New Forest Parenting"[tiab] OR "Triple P"[tiab] OR "Helping the Noncompliant Child"[tiab] OR "child life and attention skills"[tiab] OR "clas"[tiab] OR PCIT[tiab] OR "parent child interaction therapy"[tiab] OR "Summer Treatment Program"[tiab] OR "Daily Report Card"[tiab] OR "organization skills"[tiab] OR "organizational skills"[tiab] OR "time management"[tiab] OR "homework intervention"[tiab] OR braintrain[tiab] OR "memory training"[tiab] OR "Captain's log mindpower builder"[tiab] OR "memory gyms"[tiab] OR "attention gym"[tiab] OR "smartdriver plus"[tiab] OR "smartmind pro"[tiab] OR "RoboMemo"[tiab] OR "play attention"[tiab] OR metronome[tiab] OR brainmaster[tiab] OR</p>

Set #	Terms
	mindmed[tiab] OR "attention lab"[tiab] OR (activate[tiab] AND c8[tiab]) OR "attention training"[tiab] OR "CogniPlus"[tiab] OR cogmed[tiab] OR "working memory training"[tiab] OR biofeedback[tiab] OR neurofeedback[tiab] OR neuroagility[tiab] OR neuroptimal[tiab] OR acupuncture[tiab] OR "vision training"[tiab] OR "visual training"[tiab] OR "vision therapy"[tiab] OR "education intervention"[tiab] OR "cognitive remediation"[tiab] OR neurotherapy[tiab] OR "elimination diet"[tiab] OR "diet therapy"[tiab] OR ("low carb" OR "low carbohydrate" OR "low carbohydrates"[tiab] OR "gluten free") AND diet[tiab] OR "feingold diet"[tiab] OR "red dye"[tiab] OR ((vitamin[tiab] OR vitamins[tiab]) AND (supplement[tiab] OR supplements[tiab])) OR "herbal supplement"[tiab] OR "herbal supplements"[tiab] OR probiotics[tiab] OR "omega 3"[tiab] OR "slow cortical potentials"[tiab] OR "few foods diet"[tiab] OR "oligoantigenic diet"[tiab] OR "restriction diet"[tiab] OR "food intolerance"[tiab] OR "food allergy"[tiab] OR "food allergies"[tiab] OR "food sensitivity"[tiab] OR "food sensitivities"[tiab] OR "multimodal treatment"[tiab] OR homeopathy[tiab] OR homeopathic[tiab] OR chiropractic[tiab] OR chiropractor[tiab]
#6	#4 OR #5
#7	#3 AND #6
#8	(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomisation[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR Clinical trial[pt] OR "clinical trial"[tiab] OR "clinical trials"[tiab] OR "evaluation studies"[pt] OR "evaluation studies as topic"[MeSH] OR "evaluation study"[tiab] OR "evaluation studies"[tiab] OR "intervention studies"[MeSH] OR "intervention study"[tiab] OR "intervention studies"[tiab] OR "case-control studies"[MeSH] OR "case-control"[tiab] OR "cohort studies"[MeSH] OR cohort[tiab] OR "longitudinal"[tiab] OR longitudinally[tiab] OR "prospective"[tiab] OR prospectively[tiab] OR "retrospective"[tiab] OR "comparative study"[pt] OR "comparative study"[tiab] OR systematic[sb] OR "meta-analysis"[pt] OR "meta-analysis as topic"[MeSH] OR "meta-analysis"[tiab] OR "meta-analyses"[tiab]) NOT (Editorial[ptyp] OR Letter[pt] OR Case Reports[pt] OR Comment[pt]) NOT (animals[mh] NOT humans[mh]) AND English[la]
#9	#7 AND #8
	Publication date from 2009/01/01

### Key Question 3

Set #	Terms
#1	"Attention Deficit Disorder with Hyperactivity"[Mesh] OR "attention deficit hyperactivity disorder"[tiab] OR "ADHD"[tiab] OR "attention deficit disorder"[tiab]
#2	"Pediatrics"[Mesh] OR "Adolescent"[Mesh] OR "Infant"[Mesh] OR "Child"[Mesh] OR child[tiab] OR children[tiab] OR infant[tiab] OR infants[tiab] OR preschool[tiab] OR preschooler[tiab] OR pediatric[tiab] OR teenager[tiab] OR teenagers[tiab] OR teenaged[tiab] OR teen[tiab] OR teens[tiab] OR adolescent[tiab] OR adolescents[tiab] OR adolescence[tiab] OR youth[tiab]
#3	"Secondary Care"[Mesh] OR "Comprehensive Health Care"[Mesh] OR "primary care"[tiab] OR monitor[tiab] OR monitored[tiab] OR monitoring[tiab] OR "follow up"[tiab] OR "followed up"[tiab] OR visit[tiab] OR visits[tiab] OR session[tiab] OR sessions[tiab] OR appointment[tiab] OR appointments[tiab]
#4	(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR randomization[tiab] OR randomisation[tiab] OR placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab] OR Clinical trial[pt] OR "clinical trial"[tiab] OR "clinical trials"[tiab] OR "evaluation studies"[pt] OR "evaluation studies as topic"[MeSH] OR "evaluation study"[tiab] OR "evaluation studies"[tiab] OR "intervention studies"[MeSH] OR "intervention study"[tiab] OR "intervention studies"[tiab] OR "case-control studies"[MeSH] OR "case-control"[tiab] OR "cohort studies"[MeSH] OR cohort[tiab] OR "longitudinal"[tiab] OR longitudinally[tiab] OR "prospective"[tiab] OR prospectively[tiab] OR "retrospective"[tiab] OR "comparative study"[pt] OR "comparative study"[tiab] OR systematic[sb] OR "meta-analysis"[pt] OR "meta-analysis as topic"[MeSH] OR "meta-analysis"[tiab] OR "meta-analyses"[tiab]) NOT (Editorial[ptyp] OR Letter[pt] OR Case Reports[pt] OR Comment[pt]) NOT (animals[mh] NOT humans[mh]) AND English[la]
#5	#1 AND #2 AND #3 AND #4
	Publication date from 2009/01/01

# Embase® search strategy (November 18, 2015)

Platform: Embase.com

## Key Question 1

Set #	Terms
#1	'attention deficit disorder'/exp OR "attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#2	'pediatrics'/exp OR 'adolescent'/exp OR 'infant'/exp OR 'child'/exp OR child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#3	'attention deficit disorder'/exp/mj/dm_di OR 'screening'/exp OR 'questionnaire'/exp OR 'interview'/exp OR 'psychometry'/exp OR 'psychological rating scale'/exp OR 'diagnosis'/exp OR 'assessment of humans'/exp OR 'checklist'/exp OR 'clinical assessment tool'/exp OR 'clinical observation'/exp OR 'Diagnostic and Statistical Manual of Mental Disorders'/exp OR 'patient referral'/exp OR questionnaire:ab,ti OR questionnaires:ab,ti OR screening:ab,ti OR screen:ab,ti OR scale:ab,ti OR instrument:ab,ti OR instruments:ab,ti OR interview:ab,ti OR interviews:ab,ti OR DSM*:ab,ti OR diagnosis:ab,ti OR diagnostic:ab,ti OR diagnosed:ab,ti OR (Vanderbilt:ab,ti AND scale:ab,ti) OR conners:ab,ti OR cprs:ab,ti OR ctrs:ab,ti OR cprs:ab,ti OR crs:ab,ti OR "snap-IV":ab,ti OR "snap-4":ab,ti OR "basc-2":ab,ti OR "behavioral assessment system for children":ab,ti OR dbdrs:ab,ti OR "disruptive behavior disorder rating scale":ab,ti OR adhd-rs:ab,ti OR "adhd rating scale":ab,ti OR ksads:ab,ti OR k-sads:ab,ti OR kiddie-sads:ab,ti OR DISC:ab,ti OR "dominance inducement submission and compliance":ab,ti OR "diagnostic interview schedule for children":ab,ti OR "diagnostic inventory for screening children":ab,ti OR "mini-kid":ab,ti OR "Mini Interational Neuropsychiatric interview":ab,ti OR "iva-2":ab,ti OR "iva-qs":ab,ti OR "iva-ae2":ab,ti OR tova:ab,ti OR "test of variables of attention":ab,ti OR "neuropsychiatric eeg-based assessment aid":ab,ti OR neba:ab,ti
#4	('sensitivity and specificity'/exp OR 'predictive value'/exp OR 'diagnostic error'/exp OR sensitivity:ab,ti OR specificity:ab,ti OR accuracy:ab,ti OR accurate:ab,ti OR accurately:ab,ti OR misdiagnos*:ab,ti OR 'randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR (cross NEAR/1 over*):ab,ti OR placebo*:ab,ti OR (doubl* NEAR/1 blind*):ab,ti OR (singl* NEAR/1 blind*):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR 'clinical study'/exp OR 'clinical trial':ti,ab OR 'clinical trials':ti,ab OR 'controlled study'/exp OR 'evaluation'/exp OR 'evaluation study':ab,ti OR 'evaluation studies':ab,ti OR 'intervention study':ab,ti OR 'intervention studies':ab,ti OR 'case control':ab,ti OR 'cohort analysis'/exp OR cohort:ab,ti OR longitudinal*:ab,ti OR prospective:ab,ti OR prospectively:ab,ti OR retrospective:ab,ti OR 'follow up'/exp OR 'follow up':ab,ti OR 'comparative effectiveness'/exp OR 'comparative study'/exp OR 'comparative study':ab,ti OR 'comparative studies':ab,ti OR 'evidence based medicine'/exp OR 'systematic review':ab,ti OR 'meta-analysis':ab,ti OR 'meta-analyses':ab,ti) NOT ('case report'/exp OR 'case study'/exp OR 'editorial'/exp OR 'letter'/exp OR 'note'/exp)
#5	#1 AND #2 AND #3 AND #4
#6	#5 AND [embase]/lim NOT [medline]/lim
#7	#6 AND [humans]/lim AND [2009-2015]/py

## Key Question 2

Set #	Terms
#1	'attention deficit disorder'/exp OR "attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#2	'pediatrics'/exp OR 'adolescent'/exp OR 'infant'/exp OR 'child'/exp OR child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#3	#1 AND #2

Set #	Terms
#4	'attention deficit disorder'/exp/mj/dm_dt OR 'central stimulant agent'/exp OR 'psychostimulant agent'/exp OR 'guanfacine'/exp OR 'adrenergic receptor affecting agent'/exp OR 'atomoxetine'/exp OR 'antidepressant agent'/exp OR 'dopamine uptake inhibitor'/exp OR 'n methyl dextro aspartic acid receptor'/exp OR 'memantine'/exp OR 'amantadine'/exp OR 'dopamine uptake inhibitor'/exp OR 'Central Nervous System Stimulants':ab,ti OR 'psychostimulant':ab,ti OR 'Methylphenidate':ab,ti OR 'Methylphenidate Hydrochloride':ab,ti OR 'Aptensio':ab,ti OR 'Concerta':ab,ti OR 'Ritalin':ab,ti OR 'Ritalin LA':ab,ti OR 'Medikinet':ab,ti OR 'Equasym':ab,ti OR 'Quillivant':ab,ti OR 'Metadate':ab,ti OR 'Daytrana':ab,ti OR 'Dexmethylphenidate':ab,ti OR 'Dexmethylphenidate Hydrochloride':ab,ti OR 'Focalin':ab,ti OR 'Dextroamphetamine':ab,ti OR 'Dexedrine':ab,ti OR 'Dextrostat':ab,ti OR 'ProCentra':ab,ti OR 'Zenedi':ab,ti OR 'mixed amphetamine salts':ab,ti OR 'Adderall':ab,ti OR 'lisdexamfetamine':ab,ti OR 'lisdexamfetamine dimesylate':ab,ti OR 'Vyvanse':ab,ti OR 'Venvanse':ab,ti OR 'Elvanse':ab,ti OR 'Tyvense':ab,ti OR 'Dyanavel':ab,ti OR 'Evekeo':ab,ti OR 'Guanfacine':ab,ti OR 'Sympatholytics':ab,ti OR 'Central alpha-2 Adrenergic Agonist':ab,ti OR 'Clonidine':ab,ti OR 'Intuniv':ab,ti OR 'Estulic':ab,ti OR 'Tenex':ab,ti OR 'Catapres':ab,ti OR 'Clophelin':ab,ti OR 'Kapvay':ab,ti OR 'Nexiclon':ab,ti OR 'Duraclon':ab,ti OR 'Norepinephrine Reuptake Inhibitors':ab,ti OR 'Selective Norepinephrine Reuptake Inhibitors':ab,ti OR 'Adrenergic Uptake Inhibitors':ab,ti OR 'atomoxetine':ab,ti OR 'Strattera':ab,ti OR 'Tricyclic antidepressants':ab,ti OR 'Desipramine':ab,ti OR 'Norpramin':ab,ti OR 'Nortriptyline':ab,ti OR 'Pamelor':ab,ti OR 'Dopamine Reuptake Inhibitors':ab,ti OR 'modafinil':ab,ti OR 'Provigil':ab,ti OR 'Armodafinil':ab,ti OR 'Norepinephrine-dopamine Reuptake Inhibitors':ab,ti OR 'Bupropion':ab,ti OR 'Wellbutrin':ab,ti OR 'Forfivo':ab,ti OR 'Cymbalta':ab,ti OR 'venlafaxine':ab,ti OR 'reboxetine':ab,ti OR 'Monoamine Oxidase Type B inhibitors':ab,ti OR 'Selegiline':ab,ti OR 'Eldepryl':ab,ti OR 'Zelapar':ab,ti OR 'NMDA receptors':ab,ti OR 'N-Methyl-D-aspartate receptor Antagonists':ab,ti OR 'Amantadine':ab,ti OR 'Memantine':ab,ti OR 'Pertofrane':ab,ti OR 'Nuvigil':ab,ti OR 'Cymbalta':ab,ti OR 'duloxetine':ab,ti OR 'Effexor':ab,ti OR 'Eldepryl':ab,ti OR 'Emsam':ab,ti OR 'Trevilor':ab,ti OR 'Symmetrel':ab,ti OR 'Namenda':ab,ti OR 'Zelapar':ab,ti
#5	'attention deficit disorder'/exp/mj/dm_rh,dm_dm OR 'psychotherapy'/exp OR 'child psychiatry'/exp OR 'child parent relation'/exp OR 'time management'/exp OR 'feedback system'/exp OR 'teaching'/exp OR 'adaptive behavior'/exp OR 'diet therapy'/exp OR 'omega 3 fatty acid'/exp OR 'vitamin'/exp/dd_do,dd_dt,dd_ad OR 'food additive'/exp/dd_ae OR 'probiotic agent'/exp OR 'acupuncture'/exp OR 'early childhood intervention'/exp OR 'alternative medicine'/exp OR 'psychosocial therapy':ab,ti OR 'psychosocial intervention':ab,ti OR 'psychosocial interventions':ab,ti OR 'psychosocial approach':ab,ti OR 'psychosocial approaches':ab,ti OR 'psychosocial treatment':ab,ti OR 'psychosocial support':ab,ti OR 'psychoeducation':ab,ti OR 'nonpharmacologic therapy':ab,ti OR 'nondrug therapy':ab,ti OR 'non-drug therapy':ab,ti OR 'Play Therapy':ab,ti OR 'cognitive behavioral therapy':ab,ti OR 'cognitive behavior therapy':ab,ti OR 'cognitive behavioural therapy':ab,ti OR 'cognitive behaviour therapy':ab,ti OR 'Mindfulness':ab,ti OR 'complementary':ab,ti OR 'alternative medicine':ab,ti OR 'alternative therapy':ab,ti OR 'alternative therapies':ab,ti OR 'Interpersonal skills training':ab,ti OR 'Parent-Child Interaction Therapy':ab,ti OR 'parent training':ab,ti OR 'parent engagement':ab,ti OR 'parent management':ab,ti OR 'parenting skills':ab,ti OR 'parenting intervention':ab,ti OR 'parenting interventions':ab,ti OR 'Barkleys defiant child':ab,ti OR 'Teacher-Child Interaction Training':ab,ti OR 'Incredible Years':ab,ti OR 'New Forest Parenting':ab,ti OR 'Triple P':ab,ti OR 'Helping the Noncompliant Child':ab,ti OR 'child life and attention skills':ab,ti OR 'clas':ab,ti OR PCIT:ab,ti OR 'parent child interaction therapy':ab,ti OR 'Summer Treatment Program':ab,ti OR 'Daily Report Card':ab,ti OR 'organization skills':ab,ti OR 'organizational skills':ab,ti OR 'time management':ab,ti OR 'homework intervention':ab,ti OR braintrain:ab,ti OR 'memory training':ab,ti OR 'Captains log mindpower builder':ab,ti OR 'memory gyms':ab,ti OR 'attention gym':ab,ti OR 'smartdriver plus':ab,ti OR 'smartmind pro':ab,ti OR 'RoboMemo':ab,ti OR 'play attention':ab,ti OR metronome:ab,ti OR brainmaster:ab,ti OR mindmed:ab,ti OR 'attention lab':ab,ti OR (activate:ab,ti AND c8:ab,ti) OR 'attention training':ab,ti OR 'CogniPlus':ab,ti OR cogmed:ab,ti OR 'working memory training':ab,ti OR biofeedback:ab,ti OR neurofeedback:ab,ti OR neuroagility:ab,ti OR neurooptimal:ab,ti OR acupuncture:ab,ti OR 'vision training':ab,ti OR 'visual training':ab,ti OR 'vision therapy':ab,ti OR 'education intervention':ab,ti OR 'cognitive remediation':ab,ti OR neurotherapy:ab,ti OR 'elimination diet':ab,ti OR 'diet therapy':ab,ti OR (('low carb' OR 'low carbohydrate' OR 'low carbohydrates':ab,ti OR 'gluten free') AND diet:ab,ti) OR 'feingold diet':ab,ti OR 'red dye':ab,ti OR ((vitamin:ab,ti OR vitamins:ab,ti) AND (supplement:ab,ti OR supplements:ab,ti)) OR 'herbal supplement':ab,ti OR 'herbal supplements':ab,ti OR probiotics:ab,ti OR 'omega 3':ab,ti OR 'slow cortical potentials':ab,ti OR 'few foods diet':ab,ti OR 'oligoantigenic diet':ab,ti OR 'restriction diet':ab,ti OR 'food intolerance':ab,ti OR 'food allergy':ab,ti OR 'food allergies':ab,ti OR 'food sensitivity':ab,ti OR 'food sensitivities':ab,ti OR 'multimodal treatment':ab,ti OR homeopathy:ab,ti OR homeopathic:ab,ti OR chiropractic:ab,ti OR chiropractor:ab,ti
#6	#4 OR #5
#7	#3 AND #6

Set #	Terms
#8	('randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR (cross NEAR/1 over*):ab,ti OR placebo*:ab,ti OR (doubl* NEAR/1 blind*):ab,ti OR (singl* NEAR/1 blind*):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR 'clinical study'/exp OR 'clinical trial':ti,ab OR 'clinical trials':ti,ab OR 'controlled study'/exp OR 'evaluation'/exp OR 'evaluation study':ab,ti OR 'evaluation studies':ab,ti OR 'intervention study':ab,ti OR 'intervention studies':ab,ti OR 'case control':ab,ti OR 'cohort analysis'/exp OR cohort:ab,ti OR longitudinal*:ab,ti OR prospective:ab,ti OR prospectively:ab,ti OR retrospective:ab,ti OR 'follow up'/exp OR 'follow up':ab,ti OR 'comparative effectiveness'/exp OR 'comparative study'/exp OR 'comparative study':ab,ti OR 'comparative studies':ab,ti OR 'evidence based medicine'/exp OR 'systematic review':ab,ti OR 'meta-analysis':ab,ti OR 'meta-analyses':ab,ti) NOT ('case report'/exp OR 'case study'/exp OR 'editorial'/exp OR 'letter'/exp OR 'note'/exp)
#9	#7 AND #8
#10	#9 AND [embase]/lim NOT [medline]/lim
#11	#10 AND [humans]/lim AND [2009-2015]/py

### Key Question 3

Set #	Terms
#1	'attention deficit disorder'/exp OR "attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#2	'pediatrics'/exp OR 'adolescent'/exp OR 'infant'/exp OR 'child'/exp OR child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#3	'evaluation and follow up'/exp OR 'primary health care'/exp OR 'secondary health care'/exp OR 'clinical handover'/exp OR 'patient monitoring'/exp OR monitor:ab,ti OR monitored:ab,ti OR monitoring:ab,ti OR "follow up":ab,ti OR "followed up":ab,ti OR visit:ab,ti OR visits:ab,ti OR session:ab,ti OR sessions:ab,ti OR appointment:ab,ti OR appointments:ab,ti
#4	('randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR random*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR (cross NEAR/1 over*):ab,ti OR placebo*:ab,ti OR (doubl* NEAR/1 blind*):ab,ti OR (singl* NEAR/1 blind*):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR 'clinical study'/exp OR 'clinical trial':ti,ab OR 'clinical trials':ti,ab OR 'controlled study'/exp OR 'evaluation'/exp OR 'evaluation study':ab,ti OR 'evaluation studies':ab,ti OR 'intervention study':ab,ti OR 'intervention studies':ab,ti OR 'case control':ab,ti OR 'cohort analysis'/exp OR cohort:ab,ti OR longitudinal*:ab,ti OR prospective:ab,ti OR prospectively:ab,ti OR retrospective:ab,ti OR 'follow up'/exp OR 'follow up':ab,ti OR 'comparative effectiveness'/exp OR 'comparative study'/exp OR 'comparative study':ab,ti OR 'comparative studies':ab,ti OR 'evidence based medicine'/exp OR 'systematic review':ab,ti OR 'meta-analysis':ab,ti OR 'meta-analyses':ab,ti) NOT ('case report'/exp OR 'case study'/exp OR 'editorial'/exp OR 'letter'/exp OR 'note'/exp)
#5	#1 AND #2 AND #3 AND #4
#6	#5 AND [humans]/lim AND [2009-2015]/py
#7	#6 AND [embase]/lim NOT [medline]/lim

## PsycINFO search strategy (November 17, 2015)

### Key Question 1

Set #	Terms
#1	DE "Attention Deficit Disorder with Hyperactivity" OR TI ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder" ) OR AB ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder"
#2	AG (childhood OR adolescence ) OR DE "Pediatrics" OR TI ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth ) OR AB ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth )
#3	DE "Screening" OR DE "Health Screening" OR DE "Questionnaires" OR DE "Screening Tests" OR DE "Psychological Screening Inventory" OR DE "Psychiatric Evaluation" OR DE "Psychodiagnosis" OR DE

Set #	Terms
	"Psychodiagnostic Interview" OR DE "Psychometrics" OR DE "Rating Scales" OR DE "Diagnosis" OR DE "Diagnostic and Statistical Manual" OR DE "Professional Referral" OR DE "Diagnostic Interview Schedule" OR DE "Behavioral Assessment" OR TI ( questionnaire OR questionnaires OR screening OR screen OR scale OR instrument OR instruments OR interview OR interviews OR DSM* OR diagnosis OR diagnostic OR diagnosed OR (Vanderbilt AND scale) OR conners OR cprs OR ctrs OR cprs OR crs OR "snap-IV" OR "snap-4" OR "basc-2" OR "behavioral assessment system for children" OR dbdrs OR "disruptive behavior disorder rating scale" OR adhd-rs OR "adhd rating scale" OR ksads OR k-sads OR kiddie-sads OR DISC OR "dominance inducement submission and compliance" OR "diagnostic interview schedule for children" OR "diagnostic inventory for screening children" OR "mini-kid" OR "Mini Interational Neuropsychiatric interview" OR "iva-2" OR "iva-qs" OR "iva-ae2" OR tova OR "test of variables of attention" OR "neuropsychiatric eeg-based assessment aid" OR neba ) OR AB ( questionnaire OR questionnaires OR screening OR screen OR scale OR instrument OR instruments OR interview OR interviews OR DSM* OR diagnosis OR diagnostic OR diagnosed OR (Vanderbilt AND scale) OR conners OR cprs OR ctrs OR cprs OR crs OR "snap-IV" OR "snap-4" OR "basc-2" OR "behavioral assessment system for children" OR dbdrs OR "disruptive behavior disorder rating scale" OR adhd-rs OR "adhd rating scale" OR ksads OR k-sads OR kiddie-sads OR DISC OR "dominance inducement submission and compliance" OR "diagnostic interview schedule for children" OR "diagnostic inventory for screening children" OR "mini-kid" OR "Mini Interational Neuropsychiatric interview" OR "iva-2" OR "iva-qs" OR "iva-ae2" OR tova OR "test of variables of attention" OR "neuropsychiatric eeg-based assessment aid" OR neba )
#4	(DE "Misdiagnosis" OR ZC "longitudinal study" OR ZC "empirical study" OR ZC "followup study" OR ZC "longitudinal study" OR ZC "meta analysis" OR ZC "prospective study" OR ZC "retrospective study" OR ZC "systematic review" OR ZC "treatment outcome/clinical trial" OR DE "Clinical Trials" OR DE "Cohort Analysis" OR DE "Followup Studies" OR DE "Longitudinal Studies" OR DE "Prospective Studies" OR DE "Meta Analysis" OR TI ( sensitivity OR specificity OR accuracy OR accurate OR accurately OR misdiagnos* OR randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR "cross-sectional" OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" ) OR AB ( sensitivity OR specificity OR accuracy OR accurate OR accurately OR misdiagnos* OR randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR "cross-sectional" OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" )) AND (ZZ "journal article")
#5	#1 AND #2 AND #3 AND #4
#6	#5, since 2009, English

### Key Question 2

Set #	Terms
#1	DE "Attention Deficit Disorder with Hyperactivity" OR TI ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder" ) OR AB ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder"
#2	AG (childhood OR adolescence ) OR DE "Pediatrics" OR TI ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth ) OR AB ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth )
#3	#1 AND #2
#4	DE "CNS Stimulating Drugs" OR DE "Methylphenidate" OR DE "Dextroamphetamine" OR DE "Amphetamine" OR DE "Clonidine" OR DE "Serotonin Norepinephrine Reuptake Inhibitors" OR DE "Atomoxetine" OR DE "Tricyclic Antidepressant Drugs" OR DE "Desipramine" OR DE "Nortriptyline" OR DE "Bupropion" OR DE "Serotonin Norepinephrine Reuptake Inhibitors" OR DE "Venlafaxine" OR DE "Monoamine Oxidase Inhibitors" OR DE "Amantadine" OR TI ( psychostimulants OR "CNS stimulating" OR "Central Nervous System stimulants" OR methylphenidate OR Dexmethylphenidate OR Dextroamphetamine OR lisdexamfetamine OR Amphetamine OR aptensio OR concerta OR Ritalin OR methylin OR medikinet OR equasym OR quillivant OR metadate OR daytrana OR focalin OR Dexedrine OR dextrostat OR procentra OR zenzedi OR Adderall OR vyvanse OR elvanse OR tyvanse OR dyanavel

Set #	Terms
	<p>OR evekeo OR "alpha-2 agonists" OR guanfacine OR intuniv OR tenex OR estulic OR afken OR clonidine OR catapres OR clophelin OR kapvay OR nexiclon OR duraclon OR "Serotonin Norepinephrine Reuptake Inhibitors" OR Strattera OR atomoxetine OR "Tricyclic Antidepressants" OR "Desipramine" OR "Nortriptyline" OR norpramin OR pertofrane OR pamelor OR "dopamine reuptake inhibitors" OR modanifil OR Provigil OR alerotec OR modavigil OR modiodal OR modalert OR armodafinil OR nuvigil OR "norepinephrine-dopamine reuptake inhibitors" OR bupropion OR Wellbutrin OR zyban OR forfivo OR "Serotonin Norepinephrine Reuptake Inhibitors" OR duloxetine OR Cymbalta OR "serotonin norepinephrine dopamine reuptake inhibitors" OR "Venlafaxine" OR Effexor OR trevilor OR (Monoamine Oxidase AND Inhibitors) OR selegiline OR eldepryl OR emsam OR selgene OR zelapar OR "n methyl d aspartate receptor agonists" OR "Amantadine" OR symmetrel OR memantine OR Namenda ) OR AB ( psychostimulants OR "CNS stimulating" OR "Central Nervous System stimulants" OR methylphenidate OR Dexmethylphenidate OR Dextroamphetamine OR lisdexamfetamine OR Amphetamine OR aptensio OR concerta OR Ritalin OR methylin OR medikinet OR equasym OR quillivant OR metadate OR daytrana OR focalin OR Dexedrine OR dextrostat OR procentra OR zenzedi OR Adderall OR vyvanse OR elvanse OR tyvense OR dyanavel OR evekeo OR "alpha-2 agonists" OR guanfacine OR intuniv OR tenex OR estulic OR afken OR clonidine OR catapres OR clophelin OR kapvay OR nexiclon OR duraclon OR "Serotonin Norepinephrine Reuptake Inhibitors" OR Strattera OR atomoxetine OR "Tricyclic Antidepressants" OR "Desipramine" OR "Nortriptyline" OR norpramin OR pertofrane OR pamelor OR "dopamine reuptake inhibitors" OR modanifil OR Provigil OR alerotec OR modavigil OR modiodal OR modalert OR armodafinil OR nuvigil OR "norepinephrine-dopamine reuptake inhibitors" OR bupropion OR Wellbutrin OR zyban OR forfivo OR "Serotonin Norepinephrine Reuptake Inhibitors" OR duloxetine OR Cymbalta OR "serotonin norepinephrine dopamine reuptake inhibitors" OR "Venlafaxine" OR Effexor OR trevilor OR (Monoamine Oxidase AND Inhibitors) OR selegiline OR eldepryl OR emsam OR selgene OR zelapar OR "n methyl d aspartate receptor agonists" OR "Amantadine" OR symmetrel OR memantine OR Namenda )</p>
#5	<p>DE "Psychotherapy" OR DE "Adolescent Psychotherapy" OR DE "Multisystemic Therapy" OR DE "Behavior Therapy" OR DE "Dialectical Behavior Therapy" OR DE "Brief Psychotherapy" OR DE "Child Psychotherapy" OR DE "Play Therapy" OR DE "Client Centered Therapy" OR DE "Cognitive Behavior Therapy" OR DE "Group Psychotherapy" OR DE "Therapeutic Community" OR DE "Integrative Psychotherapy" OR DE "Psychotherapeutic Counseling" OR DE "Family Therapy" OR DE "Supportive Psychotherapy" OR DE "Cognitive Therapy" OR DE "Parent Training" OR DE "Parent Child Relations" OR DE "Time Management" OR DE "Mindfulness" OR DE "School Based Intervention" OR DE "Memory Training" OR DE "Biofeedback Training" OR DE "Biofeedback" OR DE "Computer Assisted Instruction" OR DE "Intelligent Tutoring Systems" OR DE "Diets" OR DE "Dietary Supplements" OR DE "Food Additives" OR DE "Fatty Acids" OR DE "Acupuncture" OR DE "Remedial Education" OR DE "Early Intervention" OR DE "Alternative Medicine" OR TI ( "psychosocial therapy" OR "psychosocial intervention" OR "psychosocial interventions" OR "psychosocial approach" OR "psychosocial approaches" OR "psychosocial treatment" OR "psychosocial support" OR "psychoeducation" OR "nonpharmacologic therapy" OR "nondrug therapy" OR "non-drug therapy" OR "Play Therapy" OR "cognitive behavioral therapy" OR "cognitive behavior therapy" OR "cognitive behavioural therapy" OR "cognitive behaviour therapy" OR Mindfulness OR complementary OR "alternative medicine" OR "alternative therapy" OR "alternative therapies" OR "Interpersonal skills training" OR "Parent-Child Interaction Therapy" OR "parent training" OR "parent engagement" OR "parent management" OR "parenting skills" OR "parenting intervention" OR "parenting interventions" OR "Barkley's defiant child" OR "Teacher-Child Interaction Training" OR "Incredible Years" OR "New Forest Parenting" OR "Triple P" OR "Helping the Noncompliant Child" OR "child life and attention skills" OR "clas" OR PCIT OR "parent child interaction therapy" OR "Summer Treatment Program" OR "Daily Report Card" OR "organization skills" OR "organizational skills" OR "time management" OR "homework intervention" OR braintrain OR "memory training" OR "Captain's log mindpower builder" OR "memory gyms" OR "attention gym" OR "smartdriver plus" OR "smartmind pro" OR "RoboMemo" OR "play attention" OR metronome OR brainmaster OR mindmed OR "attention lab" OR (activate AND c8) OR "attention training" OR "CogniPlus" OR cogmed OR "working memory training" OR biofeedback OR neurofeedback OR neuroagility OR neurooptimal OR acupuncture OR "vision training" OR "visual training" OR "vision therapy" OR "education intervention" OR "cognitive remediation" OR neurotherapy OR "elimination diet" OR "diet therapy" OR ("low carb" OR "low carbohydrate" OR "low carbohydrates" OR "gluten free") AND diet OR "feingold diet" OR "red dye" OR ((vitamin OR vitamins) AND (supplement OR supplements)) OR "herbal supplement" OR "herbal supplements" OR probiotics OR "omega 3" OR "slow cortical potentials" OR "few foods diet" OR "oligoantigenic diet" OR "restriction diet" OR "food intolerance" OR "food allergy" OR "food allergies" OR "food sensitivity" OR "food sensitivities" OR "multimodal treatment" OR homeopathy OR homeopathic OR chiropractic OR chiropractor ) OR AB ( "psychosocial therapy" OR "psychosocial intervention" OR "psychosocial interventions" OR "psychosocial approach" OR "psychosocial approaches" OR "psychosocial treatment" OR "psychosocial support" OR</p>

Set #	Terms
	"psychoeducation" OR "nonpharmacologic therapy" OR "nondrug therapy" OR "non-drug therapy" OR "Play Therapy" OR "cognitive behavioral therapy" OR "cognitive behavior therapy" OR "cognitive behavioural therapy" OR "cognitive behaviour therapy" OR Mindfulness OR complementary OR "alternative medicine" OR "alternative therapy" OR "alternative therapies" OR "Interpersonal skills training" OR "Parent-Child Interaction Therapy" OR "parent training" OR "parent engagement" OR "parent management" OR "parenting skills" OR "parenting intervention" OR "parenting interventions" OR "Barkley's defiant child" OR "Teacher-Child Interaction Training" OR "Incredible Years" OR "New Forest Parenting" OR "Triple P" OR "Helping the Noncompliant Child" OR "child life and attention skills" OR "clas" OR PCIT OR "parent child interaction therapy" OR "Summer Treatment Program" OR "Daily Report Card" OR "organization skills" OR "organizational skills" OR "time management" OR "homework intervention" OR braintrain OR "memory training" OR "Captain's log mindpower builder" OR "memory gyms" OR "attention gym" OR "smartdriver plus" OR "smartmind pro" OR "RoboMemo" OR "play attention" OR metronome OR brainmaster OR mindmed OR "attention lab" OR (activate AND c8) OR "attention training" OR "CogniPlus" OR cogmed OR "working memory training" OR biofeedback OR neurofeedback OR neuroagility OR neuroptimal OR acupuncture OR "vision training" OR "visual training" OR "vision therapy" OR "education intervention" OR "cognitive remediation" OR neurotherapy OR "elimination diet" OR "diet therapy" OR ("low carb" OR "low carbohydrate" OR "low carbohydrates" OR "gluten free") AND diet) OR "feingold diet" OR "red dye" OR ((vitamin OR vitamins) AND (supplement OR supplements)) OR "herbal supplement" OR "herbal supplements" OR probiotics OR "omega 3" OR "slow cortical potentials" OR "few foods diet" OR "oligoantigenic diet" OR "restriction diet" OR "food intolerance" OR "food allergy" OR "food allergies" OR "food sensitivity" OR "food sensitivities" OR "multimodal treatment" OR homeopathy OR homeopathic OR chiropractic OR chiropractor )
6	#4 OR #5
7	#3 AND #6
8	ZC "longitudinal study" OR ZC "empirical study" OR ZC "followup study" OR ZC "longitudinal study" OR ZC "meta analysis" OR ZC "prospective study" OR ZC "retrospective study" OR ZC "systematic review" OR ZC "treatment outcome/clinical trial" OR DE "Clinical Trials" OR DE "Cohort Analysis" OR DE "Followup Studies" OR DE "Longitudinal Studies" OR DE "Prospective Studies" OR DE "Meta Analysis" OR TI (randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" ) OR AB (randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" ) AND (ZZ "journal article")
9	#7 AND #8
10	#9, since 2009

### Key Question 3

Set #	Terms
#1	DE "Attention Deficit Disorder with Hyperactivity" OR TI ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder" ) OR AB ( "attention deficit hyperactivity disorder" OR ADHD OR "attention deficit disorder"
#2	AG (childhood OR adolescence ) OR DE "Pediatrics" OR TI ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth ) OR AB ( child OR children OR infant OR infants OR preschool OR preschooler OR pediatric OR teenager OR teenagers OR teenaged OR teen OR teens OR adolescent OR adolescents OR adolescence OR youth )
#3	(((((DE "Continuum of Care") OR (DE "Outpatient Treatment"))) OR (DE "Primary Health Care"))) OR (DE "Monitoring")) OR (DE "Community Psychiatry")) OR TI ( "primary care" OR monitor OR monitored OR monitoring OR "follow up" OR "followed up" OR visit OR visits OR session OR sessions OR appointment OR appointments ) OR AB ( "primary care" OR monitor OR monitored OR monitoring OR "follow up" OR "followed up" OR visit OR visits OR session OR sessions OR appointment OR appointments )
#4	ZC "longitudinal study" OR ZC "empirical study" OR ZC "followup study" OR ZC "longitudinal study" OR ZC "meta analysis" OR ZC "prospective study" OR ZC "retrospective study" OR ZC "systematic review" OR ZC "treatment outcome/clinical trial" OR DE "Clinical Trials" OR DE "Cohort Analysis" OR DE "Followup Studies" OR DE "Longitudinal Studies" OR DE "Prospective Studies" OR DE "Meta Analysis"

Set #	Terms
	OR TI (randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" ) OR AB (randomized OR randomised OR randomization OR randomisation OR randomly OR trial OR groups OR trials OR "evaluation study" OR evaluation studies OR "intervention study" OR "intervention studies" OR "case-control" OR cohort OR longitudinal OR longitudinally OR prospective OR prospectively OR retrospective OR "comparative study" OR "meta-analysis" OR "meta-analyses" ) AND (ZZ "journal article")
#5	#1 AND #2 AND #3 AND #4
#6	#5, since 2009 and English

## Cochrane search strategy (November 18, 2015)

Platform: Wiley

Database searched: Cochrane Database of Systematic Reviews

### Key Question 1

Set #	Terms
#1	[mh "Attention Deficit Disorder with Hyperactivity"]
#2	"attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#3	#1 OR #2
#4	[mh Pediatrics] OR [mh Adolescent] OR [mh Infant] OR [mh Child]
#5	child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#6	#4 OR #5
#7	[mh "Attention Deficit Disorder with Hyperactivity"/DI] OR [mh "mass screening"] OR [mh questionnaires] OR [mh "Interviews as Topic"] OR [mh Psychometrics] OR [mh "Psychiatric Status Rating Scales"] OR [mh ^diagnosis] OR [mh "Diagnostic Techniques and Procedures"] OR [mh "Diagnostic and Statistical Manual of Mental Disorders"] OR [mh "Referral and Consultation"]
#8	questionnaire:ab,ti OR questionnaires:ab,ti OR screening:ab,ti OR screen:ab,ti OR scale:ab,ti OR instrument:ab,ti OR instruments:ab,ti OR interview:ab,ti OR interviews:ab,ti OR DSM*:ab,ti OR diagnosis:ab,ti OR diagnostic:ab,ti OR diagnosed:ab,ti OR (Vanderbilt:ab,ti AND scale:ab,ti) OR conners:ab,ti OR cprs:ab,ti OR ctrs:ab,ti OR cprs:ab,ti OR crs:ab,ti OR "snap-IV":ab,ti OR "snap-4":ab,ti OR "basc-2":ab,ti OR "behavioral assessment system for children":ab,ti OR dbdrs:ab,ti OR "disruptive behavior disorder rating scale":ab,ti OR adhd-rs:ab,ti OR "adhd rating scale":ab,ti OR ksads:ab,ti OR k-sads:ab,ti OR kiddie-sads:ab,ti OR DISC:ab,ti OR "dominance inducement submission and compliance":ab,ti OR "diagnostic interview schedule for children":ab,ti OR "diagnostic inventory for screening children":ab,ti OR "mini-kid":ab,ti OR "Mini Interational Neuropsychiatric interview":ab,ti OR "iva-2":ab,ti OR "iva-qs":ab,ti OR "iva-ae2":ab,ti OR tova:ab,ti OR "test of variables of attention":ab,ti OR "neuropsychiatric eeg-based assessment aid":ab,ti OR neba:ab,ti
#9	#7 OR #8
#10	#3 AND #6 AND #9
#11	#10, since 2009, in CDSR only

### Key Question 2

Set #	Terms
#1	[mh "Attention Deficit Disorder with Hyperactivity"]
#2	"attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#3	#1 OR #2
#4	[mh Pediatrics] OR [mh Adolescent] OR [mh Infant] OR [mh Child]
#5	child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#6	#4 OR #5

Set #	Terms
#7	[mh "Attention Deficit Disorder with Hyperactivity"/DT] OR [mh "Central Nervous System Stimulants"] OR [mh Methylphenidate] OR [mh Dexmethylphenidate] OR [mh Dextroamphetamine] OR [mh Amphetamine] OR [mh Guanfacine] OR [mh Sympatholytics] OR [mh Clonidine] OR [mh "Adrenergic Uptake Inhibitors"] OR [mh "alpha-2 Adrenergic Receptors"] OR [mh "Adrenergic alpha-Agonists"] OR [mh "Adrenergic alpha-2 Receptor Agonists"] OR [mh "Tricyclic Antidepressive Agents"] OR [mh Desipramine] OR [mh "Dopamine Uptake Inhibitors"] OR [mh Sympathomimetics] OR [mh "Serotonin Uptake Inhibitors"] OR [mh "Monoamine Oxidase Inhibitors"] OR [mh "Monoamine Oxidase"] OR [mh Selegiline] OR [mh Bupropion] OR [mh "N-Methyl-D-Aspartate Receptors"] OR [mh Memantine] OR [mh Amantadine]
#8	"Central Nervous System Stimulants":ab,ti OR "psychostimulant":ab,ti OR "Methylphenidate":ab,ti OR "Methylphenidate Hydrochloride":ab,ti OR "Aptensio":ab,ti OR "Concerta":ab,ti OR "Ritalin":ab,ti OR "Ritalin LA":ab,ti OR "Medikinet":ab,ti OR "Equasym":ab,ti OR "Quillivant":ab,ti OR "Metadate":ab,ti OR "Daytrana":ab,ti OR "Dexmethylphenidate":ab,ti OR "Dexmethylphenidate Hydrochloride":ab,ti OR "Focalin":ab,ti OR "Dextroamphetamine":ab,ti OR "Dexedrine":ab,ti OR "Dextrostat":ab,ti OR "ProCentra":ab,ti OR "Zenedi":ab,ti OR "mixed amphetamine salts":ab,ti OR "Adderall":ab,ti OR "lisdexamfetamine":ab,ti OR "lisdexamfetamine dimesylate":ab,ti OR "Vyvanse":ab,ti OR "Venvanse":ab,ti OR "Elvanse":ab,ti OR "Tyvanse":ab,ti OR "Dyanavel":ab,ti OR "Evekeo":ab,ti OR "Guanfacine":ab,ti OR "Sympatholytics":ab,ti OR "Central alpha-2 Adrenergic Agonist":ab,ti OR "Clonidine":ab,ti OR "Intuniv":ab,ti OR "Estulic":ab,ti OR "Tenex":ab,ti OR "Catapres":ab,ti OR "Clophelin":ab,ti OR "Kapvay":ab,ti OR "Nexiclon":ab,ti OR "Duraclon":ab,ti OR "Norepinephrine Reuptake Inhibitors":ab,ti OR "Selective Norepinephrine Reuptake Inhibitors":ab,ti OR "Adrenergic Uptake Inhibitors":ab,ti OR "atomoxetine":ab,ti OR "Strattera":ab,ti OR "Tricyclic antidepressants":ab,ti OR "Desipramine":ab,ti OR "Norpramin":ab,ti OR "Nortriptyline":ab,ti OR "Pamelor":ab,ti OR "Dopamine Reuptake Inhibitors":ab,ti OR "modafinil":ab,ti OR "Provigil":ab,ti OR "Armodafinil":ab,ti OR "Norepinephrine-dopamine Reuptake Inhibitors":ab,ti OR "Bupropion":ab,ti OR "Wellbutrin":ab,ti OR "Forfivo":ab,ti OR "Cymbalta":ab,ti OR "venlafaxine":ab,ti OR "reboxetine":ab,ti OR "Monoamine Oxidase Type B inhibitors":ab,ti OR "Selegiline":ab,ti OR "Eldepryl":ab,ti OR "Zelapar":ab,ti OR "NMDA receptors":ab,ti OR "N-Methyl-D-aspartate receptor Antagonists":ab,ti OR "Amantadine":ab,ti OR "Memantine":ab,ti OR "Pertofrane":ab,ti OR "Nuvigil":ab,ti OR "Cymbalta":ab,ti OR "duloxetine":ab,ti OR "Effexor":ab,ti OR "Eldepryl":ab,ti OR "Emsam":ab,ti OR "Trevilor":ab,ti OR "Symmetrel":ab,ti OR "Namenda":ab,ti OR "Zelapar":ab,ti
#9	#7 OR #8
#10	[mh "Attention Deficit Disorder with Hyperactivity"/DH] OR [mh "Attention Deficit Disorder with Hyperactivity"/RH] OR [mh Psychotherapy] OR [mh "Behavior Therapy"] OR [mh "Parent-Child Relations"] OR [mh "Play Therapy"] OR [mh "Cognitive Therapy"] OR [mh "Time Management"] OR [mh "Computer-Assisted Instruction"] OR [mh "Diet Therapy"] OR [mh "Omega-3 Fatty Acids"/TU] OR [mh Vitamins/AD] OR [mh Vitamins/TU] OR [mh "Food Additives"/AE] OR [mh Probiotics/TU] OR [mh "Acupuncture Therapy"] OR [mh "Remedial Teaching"] OR [mh "Early Intervention (Education)"] OR [mh "Complementary Therapies"] OR [mh "Combined Modality Therapy"]
#11	"psychosocial therapy":ab,ti OR "psychosocial intervention":ab,ti OR "psychosocial interventions":ab,ti OR "psychosocial approach":ab,ti OR "psychosocial approaches":ab,ti OR "psychosocial treatment":ab,ti OR "psychosocial support":ab,ti OR "psychoeducation":ab,ti OR "nonpharmacologic therapy":ab,ti OR "nondrug therapy":ab,ti OR "non-drug therapy":ab,ti OR "Play Therapy":ab,ti OR "cognitive behavioral therapy":ab,ti OR "cognitive behavior therapy":ab,ti OR "cognitive behavioural therapy":ab,ti OR "cognitive behaviour therapy":ab,ti OR Mindfulness:ab,ti OR complementary:ab,ti OR "alternative medicine":ab,ti OR "alternative therapy":ab,ti OR "alternative therapies":ab,ti OR "Interpersonal skills training":ab,ti OR "Parent-Child Interaction Therapy":ab,ti OR "parent training":ab,ti OR "parent engagement":ab,ti OR "parent management":ab,ti OR "parenting skills":ab,ti OR "parenting intervention":ab,ti OR "parenting interventions":ab,ti OR "Barkley's defiant child":ab,ti OR "Teacher-Child Interaction Training":ab,ti OR "Incredible Years":ab,ti OR "New Forest Parenting":ab,ti OR "Triple P":ab,ti OR "Helping the Noncompliant Child":ab,ti OR "child life and attention skills":ab,ti OR "clas":ab,ti OR PCIT:ab,ti OR "parent child interaction therapy":ab,ti OR "Summer Treatment Program":ab,ti OR "Daily Report Card":ab,ti OR "organization skills":ab,ti OR "organizational skills":ab,ti OR "time management":ab,ti OR "homework intervention":ab,ti OR braintrain:ab,ti OR "memory training":ab,ti OR "Captain's log mindpower builder":ab,ti OR "memory gyms":ab,ti OR "attention gym":ab,ti OR "smartdriver plus":ab,ti OR "smartmind pro":ab,ti OR "RoboMemo":ab,ti OR "play attention":ab,ti OR metronome:ab,ti OR brainmaster:ab,ti OR mindmed:ab,ti OR "attention lab":ab,ti OR (activate:ab,ti AND c8:ab,ti) OR "attention training":ab,ti OR "CogniPlus":ab,ti OR cogmed:ab,ti OR "working memory training":ab,ti OR biofeedback:ab,ti OR neurofeedback:ab,ti OR neuroagility:ab,ti OR neuroptimal:ab,ti OR acupuncture:ab,ti OR "vision training":ab,ti OR "visual training":ab,ti OR "vision therapy":ab,ti OR "education intervention":ab,ti OR "cognitive remediation":ab,ti OR neurotherapy:ab,ti OR "elimination diet":ab,ti OR "diet therapy":ab,ti OR ("low carb" OR "low carbohydrate" OR "low carbohydrates":ab,ti OR "gluten free") AND diet:ab,ti OR "feingold diet":ab,ti OR "red dye":ab,ti OR ((vitamin:ab,ti OR vitamins:ab,ti) AND (supplement:ab,ti OR

Set #	Terms
	supplements:ab,ti) OR "herbal supplement":ab,ti OR "herbal supplements":ab,ti OR probiotics:ab,ti OR "omega 3":ab,ti OR "slow cortical potentials":ab,ti OR "few foods diet":ab,ti OR "oligoantigenic diet":ab,ti OR "restriction diet":ab,ti OR "food intolerance":ab,ti OR "food allergy":ab,ti OR "food allergies":ab,ti OR "food sensitivity":ab,ti OR "food sensitivities":ab,ti OR "multimodal treatment":ab,ti OR homeopathy:ab,ti OR homeopathic:ab,ti OR chiropractic:ab,ti OR chiropractor:ab,ti
#12	#10 OR #11
#13	#12 OR #9
#14	#3 AND #6 AND #13
#15	#14, since 2009, limited to CDSR

### Key Question 3

Set #	Terms
#1	[mh "Attention Deficit Disorder with Hyperactivity"]
#2	"attention deficit hyperactivity disorder":ab,ti OR "ADHD":ab,ti OR "attention deficit disorder":ab,ti
#3	#1 OR #2
#4	[mh Pediatrics] OR [mh Adolescent] OR [mh Infant] OR [mh Child]
#5	child:ab,ti OR children:ab,ti OR infant:ab,ti OR infants:ab,ti OR preschool:ab,ti OR preschooler:ab,ti OR pediatric:ab,ti OR teenager:ab,ti OR teenagers:ab,ti OR teenaged:ab,ti OR teen:ab,ti OR teens:ab,ti OR adolescent:ab,ti OR adolescents:ab,ti OR adolescence:ab,ti OR youth:ab,ti
#6	#4 OR #5
#7	[mh "Secondary Care"] OR [mh "Comprehensive Health Care"]
#8	"primary care":ab,ti OR monitor:ab,ti OR monitored:ab,ti OR monitoring:ab,ti OR "follow up":ab,ti OR "followed up":ab,ti OR visit:ab,ti OR visits:ab,ti OR session:ab,ti OR sessions:ab,ti OR appointment:ab,ti OR appointments:ab,ti
#9	#7 OR #8
#10	#3 AND #6 AND #9
#11	#10, since 2009, limit to CDSR

## Gray Literature Searches

### ClinicalTrials.gov (May 4, 2016)

Conditions	ADHD OR attention deficit
Recruitment	Completed studies
Study Results	All studies
Study type	Interventional studies
Age group	Child
Phase	Phase 2, Phase 3, Phase 4

Total number of results for screening: 377

### WHO: International Clinical Trials Registry Platform Search Portal (May 12, 2016)

Conditions	ADHD OR attention deficit
Recruiting status	All

Total number of results exported: 945 records/828 trials

Results were imported into an Excel file and refined as follows:

- 1) Removed records with a registration date of December 31, 2004 or earlier; records with an enrollment start date of December 31, 2004 or earlier; records of recruiting studies; records with a population age above 17 years; studies that were explicitly designated as Phase 0 or 1 — 497 records.
- 2) Removal of records originating from ClinicalTrials.gov (the ClinicalTrials.gov database was searched separately) — 302 records removed, 195 remaining.

Total number of results for screening: 195

**National Guidelines Clearinghouse (March 31, 2016)**

Platform: [www.guideline.gov](http://www.guideline.gov)

Keywords	ADHD OR "attention deficit disorder" OR "attention deficit hyperactivity disorder"
Age of Target Population	Adolescent (13 to 18 years), Child (2 to 12 years), Infant (1 to 23 months), Infant, Newborn (to 1 month)
Publication Year	2009, 2010, 2011, 2012, 2013, 2014, 2015

Total number of results: 37

# Appendix B. Data Abstraction Elements

## Study Characteristics

- Study Identifiers
  - Study Name or Acronym
  - NCT number or other trial registry identifier
  - Last name of first author
- Additional Articles Used in This Abstraction
- Study Sites
  - Single center, Multicenter, Unclear/Not reported
  - Number of sites
- Geographic Location (Select all that apply)
  - US, Canada, UK/Europe, Latin America, Middle East (including Israel), Asia, Africa, Australia/NZ, Unclear/Not reported
- Study Design
  - RCT
  - Observational
- Funding Source (Select all that apply)
  - Government, Industry, Non-government/non-industry, Unclear/Not reported
- Setting (Select all that apply)
  - Primary Care; Specialty Care; Community Resource; School; Other; Unclear/Not reported
- Study Enrollment/Study Completion
  - N enrolled/included
  - N completed
- Key Question Applicability (Select all that apply)
  - KQ 1, KQ 2, KQ 3
- Comments

**Baseline Characteristics** – Record the following elements for Total Population, Total ADHD Population, Arm 1, Arm 2, Arm 3, and Arm 4 (as applicable)

- Number of Patients (N and %)
- Gender (N and %)
  - Male
  - Female
- Age in years
  - Mean
  - Median
  - Standard Deviation
  - Min. age
  - Max. age
  - 25% IQR
  - 75% IQR
  - Categorical
  - Other, specify

- Race/Ethnicity (N and %)
  - Hispanic or Latino
  - Black/African American
  - American Indian or Alaska Native
  - Asian
  - Native Hawaiian or Pacific Islander
  - White
  - Multiracial
  - Other (specify)
- ADHD Subtype (N and %)
  - Inattentive
  - Hyperactive
  - Combined
- Were there significant differences noted between groups in any baseline characteristic? (Yes/No)
  - If yes, please explain the differences
- Comments

### **Intervention Characteristics**

- What intervention comparison is being tested in this study? Mark all that apply.
  - Pharmacological vs. pharmacological,
  - Pharmacological vs. non-pharmacological
  - Pharmacological vs. placebo/usual care
    - Placebo, Pharmacological Usual Care, Non-pharmacological Usual Care
  - Non-pharmacological vs. non-pharmacological
  - Non-pharmacological vs. placebo/usual care
    - Placebo, Pharmacological Usual Care, Non-pharmacological Usual Care
- Intervention Descriptors
  - Describe the intervention received by each patient group (For each Arm).
- Indicate components of the intervention (For each Arm)
  - Pharmacological
  - Nonpharmacological
  - Placebo or usual/standard care
- Indicate all intervention characteristics that are varied in this study
  - Pharmacological Details
    - Psychostimulants
      - Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Lisdexamphetamine, Mixed amphetamine salts, Amphetamine
    - Tricyclic antidepressants
      - Desipramine, Nortriptyline
    - Selective norepinephrine reuptake inhibitors
      - Atomoxetine
    - Alpha-2 agonists
      - Clonidine, Guanfacine extended release
    - Dopamine reuptake inhibitors
      - Modafinil

- Armodafinil
  - Norepinephrine-dopamine reuptake inhibitors
    - Bupropion
  - Serotonin-norepinephrine reuptake inhibitors
    - Duloxetine
  - Serotonin-norepinephrine-dopamine reuptake inhibitors
    - Venlafaxine
  - Monoamine oxidase type B inhibitors
    - Selegiline
  - N-methyl-D-aspartate receptor antagonists
    - Amantadine, Memantine
- Nonpharmacological Details
  - Psychosocial interventions
  - Behavioral interventions
  - Cognitive behavioral therapy
  - Play therapy
  - Mindfulness-based therapies
  - School interventions
  - Cognitive training therapies
  - Biofeedback or neurofeedback
  - Parent behavior training
  - Dietary supplements
  - Homeopathy
  - Acupuncture
  - Elimination diets
  - Vision training
  - Exercise
  - Chiropractic treatment
- Placebo/Control details
  - Placebo
  - Usual care control/optimal medical therapy
  - Other (specify)
- Indicate the intervention target
  - ADHD patients
  - Parents
  - Teachers
  - Other (Specify)
- Indicate the Intervention Setting
  - Primary Care
  - Specialty Care
  - Home
  - School
  - Other (specify)
- Duration of Follow-up reported for Total overall study f/u, Arm 1 f/u, Arm 2 f/u, Arm 3 f/u, Arm 4 f/u (Reported or Not reported)
  - Mean follow-up in months or years (include units)

- Mean Variability
    - SD, SE, IQR, NR
  - Median Follow-up in months or years (include units)
  - Median variability
    - SD, SE, IQR, NR
- Comments

### **KQ 1 Diagnostic Tools**

- Gold Standard
  - Is confirmation of diagnosis by a specialist including psychologist or psychiatrist or other care provider using a well-validated and reliable process of confirming the diagnosis of ADHD according to the DSM-IV or DSM-V the gold standard?
    - Yes (Describe the gold standard)
    - No (Article may be eligible for exclusion. Please check with the team)
  - Who performed the diagnosis?
    - Specialist, other care, provider, researcher, unclear/NR, other (specify)
- Select the outcome(s) reported on this form:
  - Diagnostic Accuracy, Misdiagnosis/risk of missed condition, labeling/stigma
- Select the Age Group
  - Under 7 with any diagnostic tool, 7-17 with a novel diagnostic tool, labeling/stigma
- Subgroup Analyses
  - Is this outcome form for a subgroup of interest? (Y or N)
    - If Y, indicate the factor being considered
      - Age
      - Sex
      - ADHD presentation
      - Comorbidity (e.g. anxiety, depression)
      - Risk factors
      - Race/ethnicity
      - Socioeconomic status
      - Insurance status
      - Geographic location
      - Clinical setting
      - Any additional description/clarification of subgroup reported on this form
- Diagnostic Accuracy
  - Timing of the outcome data
  - Test results reported for each instrument (Select instrument used)
    - True positive (# patients)
    - True negative (# patients)
    - False positive (# patients)
    - False negative (# patients)
    - Sensitivity

- %, Std dev, Upper confidence interval bound, lower confidence interval bound
  - Specificity
    - %, Std dev, Upper confidence interval bound, lower confidence interval bound
  - Positive predictive value
    - %, Std dev, Upper confidence interval bound, lower confidence interval bound
  - Negative predictive value
    - %, Std dev, Upper confidence interval bound, lower confidence interval bound
  - Positive likelihood ratio
  - Negative likelihood ratio
- Reliability
  - Test-retest
  - Kappa statistics
  - Inter-rater
  - Intra-rater
  - Intraclass correlation
  - Diagnostic concordance of primary care provider with specialist
  - Internal consistency
- Misdiagnosis/Risk of Missed Condition Measure
  - Timing of the outcome reported
  - Describe outcome
- Labeling/Stigma
  - Timing of the outcome data reported
  - Describe outcome
- Comments

## **KQ 2 Outcomes**

- Select the outcome reported on this form:
  - Academic performance
  - Acceptability of treatment
  - Aggression
  - Behavior changes
  - Cardiac arrhythmias
  - Changes in appetite
  - Changes in standardized symptom scores or progress toward patient-identified goals
  - Chemical leukoderma
  - Conduction abnormalities
  - Depression or anxiety
  - Diversion of pharmacotherapy
  - Divorce/relationship status
  - Elevated blood pressure
  - Functional impairment

- Gastrointestinal symptoms
- Growth suppression
- Hallucination
- Incarceration or other interactions with the legal system
- Increased heart rate
- Loss of spontaneity
- Mood disorders
- Mortality
- Motor vehicle collisions or other accidents
- Motor vehicle violations
- Obesity
- Overtreatment
- Parental stress
- Personality change
- Priapism
- Quality of peer relationships
- Risk of sudden cardiac death
- Risk-taking behaviors
- Self-injurious non-suicidal behavior
- Sleep disturbance
- Substance abuse
- Suicide (attempted or completed)
- Suicide ideation
- Tics or other movement disorders
- Time demands/opportunity cost
- Tobacco use
- Weight decrease
- Workforce participation
- Any additional description / clarification of the outcome reported on this form
- Is this outcome form for a subgroup of interest? (Yes/No)
  - What subpopulation is this outcome reported for on this form?
    - Age
    - Sex
    - ADHD presentation
    - Comorbidity
    - Risk factors
    - Race/ethnicity
    - Socioeconomic status
    - Insurance status
    - Geographic location
    - Clinical setting
  - Any additional description / clarification of subgroup reported on this form
- Total N Analyzed for this outcome
- Timepoint reported on this form
  - Short-term
  - Long-term

- Specify actual timing of the outcome (in months)
- For each arm:
  - N Analyzed (enter UNK if unknown)
  - Unadjusted Result
    - Number of patients with outcome
    - % of patients with outcome
    - Events/denominator
    - Odds ratio
    - Hazard ratio
    - Relative risk
    - Mean
    - Median
    - Mean within group change
    - Mean between group change
    - Other (specify)
  - Unadjusted Result Variability
    - 95% CI
    - IQR
    - Standard Error (SE)
    - Standard Deviation (SD)
    - Other % CI (specify)
    - Other (specify)
  - Unadjusted Result, p-value between groups
  - Unadjusted Result, indicate reference group (for comparison between groups)
  - Adjusted Result
    - Number of patients with outcome
    - % of patients with outcome
    - Events/denominator
    - Odds ratio
    - Hazard ratio
    - Relative risk
    - Mean
    - Median
    - Mean within group change
    - Mean between group change
    - Other (specify)
  - Adjusted Result Variability
    - 95% CI
    - IQR
    - Standard Error (SE)
    - Standard Deviation (SD)
    - Other % CI (specify)
    - Other (specify)
  - Adjusted Result, p-value between groups
  - Adjusted Result, indicate reference group (for comparison between groups)
  - If adjusted data is recorded, indicate the adjustments applied

- Comments

### Quality

- Study Type (select one): RCT, Observational
- If RCT, select Yes/No/Unclear for each of the following questions:
  - Sequence Generation
    - Was the allocation sequence generated adequately (e.g., random number table, computer-generated randomization)?
  - Allocation concealment
    - Was the allocation of treatment adequately concealed (e.g., pharmacy-controlled randomization or use of sequentially numbered sealed envelopes)?
  - Blinding of participants, personnel and outcome assessors
    - Was knowledge of the allocated intervention adequately prevented during the study?
  - Incomplete outcome data
    - Were incomplete outcome data adequately addressed?
  - Selective outcome reporting
    - Are reports of the study free of suggestion of selective outcome reporting?
  - Other sources of bias
    - Was the study apparently free of other problems that could put it at a high risk of bias?
  - Comments
- If Observational, Study design (select one)
  - Case-control, Cohort
- If Case-Control:
  - Selection
    - Is the case definition adequate?
      - Yes, with independent validation
      - Yes, eg record linkage or based on self reports?
      - No description
      - comments
    - Representativeness of the cases
      - Consecutive or obviously representative series of cases
      - Potential for selection biases or not stated
      - comments
    - Selection of controls
      - Community controls
      - Hospital controls
      - No description
      - Comments
    - Definition of controls
      - No history of disease (endpoint)
      - No description of source
      - comments

- Comparability
  - Comparability of cases and controls on the basis of the design or analysis
    - Study controls for severity of ADHD
    - Study controls for any additional factor
    - Comments
- Exposure
  - Ascertainment of exposure
    - Secure record
    - Structured interview where blind to case/control status
    - Interview not blinded to case/control status
    - Written self report or medical record only
    - No description
    - comments
  - same method of ascertainment for cases and controls (Y, N, comments)
  - Non-response rate
    - Same rate for both groups
    - Non respondent described
    - Rate different and no designation
    - Comments
- If Cohort:
  - Selection
    - Representativeness of the exposed cohort Yes, with independent validation
      - truly representative of the average ADHD patient in the community
      - somewhat representative of the average ADHD patient in the community
      - selected group of users (eg nurses, volunteers)
      - no description of the derivation of the cohort
      - comments
    - Selection of the non exposed cohort
      - drawn from the same community as the exposed cohort
      - drawn from a different source
      - no description of the derivation of the non exposed cohort
      - comments
    - Ascertainment of exposure
      - secure record (eg surgical records)
      - structured interview
      - written self report
      - no description
      - Comments
    - Demonstration that outcome of interest was not present at start of study (Y, N, Comments)
  - Comparability
    - Comparability of cohorts on the basis of the design or analysis
      - Study controls for severity of ADHD

- Study controls for any additional factor
    - Comments
  - Outcome
    - Assessment of Outcome
      - Independent blind assortment
      - Record linkage
      - Self report
      - No description
      - comments
    - Was follow-up long enough for outcome to occur (Y, N, comments)
    - Adequacy of follow up of cohorts
      - complete follow up - all subjects accounted for
      - subjects lost to follow up unlikely to introduce bias - small number lost - >80% follow up, or description provided of those lost
      - follow up rate
      - no statement
      - Comments
- Overall Study Rating (Good/Fair/Poor)
  - **Good** (low risk of bias). These studies have the least bias, and the results are considered valid. These studies adhere to the commonly held concepts of high quality, including the following: a clear description of the population, setting, approaches, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytical methods and reporting; no reporting errors; a low dropout rate; and clear reporting of dropouts.
  - **Fair**. These studies are susceptible to some bias, but not enough to invalidate the results. They do not meet all the criteria required for a rating of good quality because they have some deficiencies, but no flaw is likely to cause major bias. The study may be missing information, making it difficult to assess limitations and potential problems.
  - **Poor** (high risk of bias). These studies have significant flaws that may have invalidated the results. They have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.
  - If the study is rated as “Fair” or “Poor,” provide rationale.
- Outcome-specific quality rating
  - Do you think that any of the outcomes abstracted for this study should be assigned a quality rating DIFFERENT from the overall study rating? (No/Yes)
    - If you think any of the abstracted outcomes should have a quality rating different from the overall study, please provide the outcome(s), rating(s) and rationale(s).

**Applicability** – Use the PICOS format to identify specific issues, if any, that may limit the applicability of the study.

- Population (P)
  - Narrow eligibility criteria and exclusion of those with comorbidities
  - More complex patients than typical of the community
  - Run-in period with high exclusion rate for non adherence or side effects

- DSM-4/5 diagnosis unclear
- Intervention (I)
  - as recommended or commonly used in practice
  - Dosing not reflective of current practice
  - Co-intervention that are likely to modify the effectiveness of therapy
  - Highly selected intervention team or level of training/proficiency not widely available
  - Follow-up not reflective of current practice
  - Co-intervention that are likely to modify monitoring strategies
- Comparator (C)
  - Diagnostic tools used differently than as recommended or commonly used in practice
  - Comparator unclear
  - Inadequate comparison therapy or use of a substandard alternative therapy
- Outcomes (O)
  - Composite outcomes that mix outcomes of different significance
  - Short-term follow-up
  - Surrogate outcomes
- Setting (S)
  - Level of care different from that in the community
- Do you have other concerns regarding applicability of this study? (Y, N, describe concerns)
- Comment

## Appendix C. List of Included Studies

Abikoff H, Gallagher R, Wells KC, et al. Remediating organizational functioning in children with ADHD: immediate and long-term effects from a randomized controlled trial. *J Consult Clin Psychol* 2013;81(1):113-28. PMID: 22889336.

Abikoff HB, Thompson M, Laver-Bradbury C, et al. Parent training for preschool ADHD: a randomized controlled trial of specialized and generic programs. *J Child Psychol Psychiatry* 2015;56(6):618-31. PMID: 25318650.

Arcieri R, Germinario EA, Bonati M, et al. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. *J Child Adolesc Psychopharmacol* 2012;22(6):423-431. PMID: 23362511.

Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. *J Child Adolesc Psychopharmacol* 2011;21(1):1-19. PMID: 21309695.

Bai GN, Wang YF, Yang L, et al. Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: Improvement of medication adherence and symptoms. *Neuropsychiatric Disease and Treatment* 2015;11:2721-2735.

Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. *CNS Drugs* 2014;28(12):1191-203. PMID: 25139785.

Barragan E, Breuer D and Dopfner M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. *J Atten Disord* 2014. PMID: 24464327.

Beck SJ, Hanson CA, Puffenberger SS, et al. A controlled trial of working memory training for children and adolescents with ADHD. *J Clin Child Adolesc Psychol* 2010;39(6):825-36. PMID: 21058129.

Berger I and Goldzweig G. Objective measures of attention-deficit/hyperactivity disorder: a pilot study. *Isr Med Assoc J* 2010;12(9):531-5. PMID: 21287795.

Bink M, van Nieuwenhuizen C, Popma A, et al. Behavioral effects of neurofeedback in adolescents with ADHD: a randomized controlled trial. *Eur Child Adolesc Psychiatry* 2015;24(9):1035-48. PMID: 25477074.

Bloch Y, Fixman M, Maoz H, et al. Can computerized cognitive tests assist in the clinical diagnosis of attention-deficit hyperactivity disorder?. *J Neuropsychiatry Clin Neurosci* 2012;24(1):111-4. PMID: 22450621.

Boyer BE, Geurts HM, Prins PJ, et al. Two novel CBTs for adolescents with ADHD: the value of planning skills. *Eur Child Adolesc Psychiatry* 2015;24(9):1075-90. PMID: 25549767.

Bunte TL, Schoemaker K, Hessen DJ, et al. Clinical usefulness of the Kiddie-Disruptive Behavior Disorder Schedule in the diagnosis of DBD and ADHD in preschool children. *J Abnorm Child Psychol* 2013;41(5):681-90. PMID: 23474833.

Carballo JJ, Rodriguez-Blanco L, Garcia-Nieto R, et al. Screening for the ADHD Phenotype Using the Strengths and Difficulties Questionnaire in a Clinical Sample of Newly Referred Children and Adolescents. *J Atten Disord* 2014. PMID: 25515677.

Castro-Cabrera P, Gomez-Garcia J, Restrepo F, et al. Evaluation of feature extraction techniques on event-related potentials for detection of attention-deficit/hyperactivity disorder. *Conf Proc IEEE Eng Med Biol Soc* 2010;2010:851-4. PMID: 21096317.

Caudal F. New marker using bioimpedance technology in screening for attention deficit/hyperactivity disorder (ADHD) in children as an adjunct to conventional diagnostic methods. *Psychol Res Behav Manag* 2011;4:113-7. PMID: 22114541.

Çetin FH, Taş Torun Y and Işık Taner Y. Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: A six-month follow up study for efficacy and adverse effects. *Türkiye Klinikleri Journal of Medical Sciences* 2015;35(2):88-96.

Chacko A, Bedard AC, Marks DJ, et al. A randomized clinical trial of Cogmed Working Memory Training in school-age children with ADHD: a replication in a diverse sample using a control condition. *J Child Psychol Psychiatry* 2014;55(3):247-55. PMID: 24117656.

Chacko A, Wymbs BT, Wymbs FA, et al. Enhancing traditional behavioral parent training for single mothers of children with ADHD. *J Clin Child Adolesc Psychol* 2009;38(2):206-18. PMID: 19283599.

Clemow DB, Mason OW, Sarkis EH, et al. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. *Expert Rev Neurother* 2015;:1-14. PMID: 26488905.

- Cortese S, Panei P, Arcieri R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. *CNS Drugs* 2015;29(10):865-77. PMID: 26293742.
- Didoni A, Sequi M, Panei P, et al. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. *Eur J Clin Pharmacol* 2011;67(10):1061-7. PMID: 21538145.
- dosReis S, Barksdale CL, Sherman A, et al. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. *Psychiatric Services* 2010;61(8):811-816. PMID: 2010-16657-009.
- Dovis S, Van der Oord S, Wiers RW, et al. Improving executive functioning in children with ADHD: training multiple executive functions within the context of a computer game. a randomized double-blind placebo controlled trial. *PLoS One* 2015;10(4):e0121651. PMID: 25844638.
- Duric NS, Assmus J, Gundersen D, et al. Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports. *BMC Psychiatry* 2012;12:107. PMID: 22877086.
- Dutta B, Barua TK, Ray J, et al. A study of evaluation of safety and efficacy of memomet, a multi herbal formulation (memomet) in the treatment of behavioural disorder in children. *International Journal of Research in Pharmaceutical Sciences* 2012;3(2):282-286.
- Egeland J, Aarli AK and Saunes BK. Few effects of far transfer of working memory training in ADHD: a randomized controlled trial. *PLoS One* 2013;8(10):e75660. PMID: 24124503.
- Ercan ES, Ardic UA, Kutlu A, et al. No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. *J Atten Disord* 2014;18(2):145-57. PMID: 22522574.
- Evans SW, Langberg JM, Schultz BK, et al. Evaluation of a School-Based Treatment Program for Young Adolescents With ADHD. *Journal of Consulting and Clinical Psychology* 2015.
- Ferrin M and Vance A. Examination of neurological subtle signs in ADHD as a clinical tool for the diagnosis and their relationship to spatial working memory. *J Child Psychol Psychiatry* 2012;53(4):390-400. PMID: 22141455.
- Ferrin M, Moreno-Granados JM, Salcedo-Marin MD, et al. Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: immediate and long-term effects using a blind randomized controlled trial. *Eur Child Adolesc Psychiatry* 2014;23(8):637-47. PMID: 24292412.
- Findling RL, Adeyi B, Chen G, et al. Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit/hyperactivity disorder. *CNS Spectrums* 2010;15(9):559-568.
- Gevensleben H, Holl B, Albrecht B, et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. *J Child Psychol Psychiatry* 2009;50(7):780-9. PMID: 19207632.
- Gonzalez JJ, Mendez LD, Manas S, et al. Performance analysis of univariate and multivariate EEG measurements in the diagnosis of ADHD. *Clin Neurophysiol* 2013;124(6):1139-50. PMID: 23332776.
- Gustafsson PA, Birberg-Thornberg U, Duchon K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr* 2010;99(10):1540-9. PMID: 20491709.
- Hammerness P, Petty C, Faraone SV, et al. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. *J Atten Disord* 2012. PMID: 23264367.
- Hariri M, Djazayeri A, Djalali M, et al. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. *Malays J Nutr* 2012;18(3):329-35. PMID: 24568073.
- Hiscock H, Sciberras E, Mensah F, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. *Bmj* 2015;350:h68. PMID: 25646809.
- Huang YH, Chung CY, Ou HY, et al. Treatment effects of combining social skill training and parent training in Taiwanese children with attention deficit hyperactivity disorder. *Journal of the Formosan Medical Association* 2015;114(3):260-267.
- Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. *J Atten Disord* 2009;12(5):394-401. PMID: 18448859.
- Katz M, Levine AA, Kol-Degani H, et al. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. *J Atten Disord* 2010;14(3):281-91. PMID: 20228219.
- Kim J, Lee Y, Han D, et al. The utility of quantitative electroencephalography and Integrated Visual and Auditory Continuous Performance Test as auxiliary tools for the Attention Deficit Hyperactivity Disorder diagnosis. *Clin Neurophysiol* 2015;126(3):532-40. PMID: 25088931.

- Kim JW, Lee J, Kim BN, et al. Theta-phase gamma-amplitude coupling as a neurophysiological marker of attention deficit/hyperactivity disorder in children. *Neurosci Lett* 2015;603:25-30. PMID: 26170246.
- Klenberg L, Jamsa S, Hayrinen T, et al. The Attention and Executive Function Rating Inventory (ATTEX): Psychometric properties and clinical utility in diagnosing ADHD subtypes. *Scand J Psychol* 2010;51(5):439-448. PMID: 20338019.
- Li JJ, Li ZW, Wang SZ, et al. Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder. *Psychopharmacology (Berl)* 2011;216(4):501-9. PMID: 21416235.
- Liechti MD, Valko L, Muller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. *Brain Topogr* 2013;26(1):135-51. PMID: 23053601.
- Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. *Eur Psychiatry* 2012;27(5):335-42. PMID: 21807480.
- Martin-Martinez D, Casaseca-de-la-Higuera P, Alberola-Lopez S, et al. Nonlinear analysis of actigraphic signals for the assessment of the attention-deficit/hyperactivity disorder (ADHD). *Med Eng Phys* 2012;34(9):1317-29. PMID: 22297088.
- Mautone JA, Marshall SA, Sharman J, et al. Development of a Family-School Intervention for Young Children With Attention Deficit Hyperactivity Disorder. *School Psych Rev* 2012;41(4):447-466. PMID: 24353368.
- Milte CM, Parletta N, Buckley JD, et al. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. *Nutrition* 2012;28(6):670-7. PMID: 22541055.
- Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. *Iran J Psychiatry* 2012;7(2):87-92. PMID: 22952551.
- Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. *J Am Acad Child Adolesc Psychiatry* 2009;48(5):484-500. PMID: 19318991.
- Moreno-García I, Delgado-Pardo G, de Reya CC-V, et al. Neurofeedback, pharmacological treatment and behavioral therapy in hyperactivity: Multilevel analysis of treatment effects on electroencephalography. *International Journal of Clinical and Health Psychology* 2015;15(3):217-225. PMID: 2015-48012-005.
- Myers K, Vander Stoep A, Zhou C, et al. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2015;54(4):263-74. PMID: 25791143.
- Oberai P, Gopinadhan S, Varanasi R, et al. Homoeopathic management of attention deficit hyperactivity disorder: A randomised placebo-controlled pilot trial. *Indian Journal of Research in Homeopathy* 2013;7(4):158-67.
- Ogrim G, Kropotov J and Hestad K. The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: sensitivity, specificity, and behavioral correlates. *Psychiatry Res* 2012;198(3):482-8. PMID: 22425468.
- Ohan JL, Visser TAW, Strain MC, et al. Teachers' and education students' perceptions of and reactions to children with and without the diagnostic label 'ADHD'. *Journal of School Psychology* 2011;49(1):81-105. PMID: 2011-00464-004.
- Ostberg M and Rydell AM. An efficacy study of a combined parent and teacher management training programme for children with ADHD. *Nord J Psychiatry* 2012;66(2):123-30. PMID: 22150634.
- Pane P, Arcieri R, Bonati M, et al. Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. *Adverse Drug Reaction Bulletin* 2010;(260):999-1002.
- Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. *Lancet* 2011;377(9764):494-503. PMID: 21296237.
- Perera H, Jeewandara KC, Seneviratne S, et al. Combined omega3 and omega6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. *J Child Neurol* 2012;27(6):747-53. PMID: 22596014.
- Pfiffner LJ, Hinshaw SP, Owens E, et al. A two-site randomized clinical trial of integrated psychosocial treatment for ADHD-inattentive type. *J Consult Clin Psychol* 2014;82(6):1115-27. PMID: 24865871.
- Power TJ, Mautone JA, Soffer SL, et al. A family-school intervention for children with ADHD: results of a randomized clinical trial. *J Consult Clin Psychol* 2012;80(4):611-23. PMID: 22506793.
- Raz R, Carasso RL and Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. *J Child Adolesc Psychopharmacol* 2009;19(2):167-77. PMID: 19364294.

- Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2010;34(1):76-80. PMID: 19815048.
- Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(3):215-26. PMID: 19519256.
- Shakibaei F, Radmanesh M, Salari E, et al. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. *Complement Ther Clin Pract* 2015;21(2):61-7. PMID: 25925875.
- Soliva JC, Fauquet J, Bielsa A, et al. Quantitative MR analysis of caudate abnormalities in pediatric ADHD: proposal for a diagnostic test. *Psychiatry Res* 2010;182(3):238-43. PMID: 20488672.
- Steiner NJ, Frenette EC, Rene KM, et al. Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. *J Dev Behav Pediatr* 2014;35(1):18-27. PMID: 24399101.
- Storebo OJ, Gluud C, Winkel P, et al. Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial. *PLoS One* 2012;7(6):e37280. PMID: 22745657.
- Tamm L, Epstein JN, Peugh JL, et al. Preliminary data suggesting the efficacy of attention training for school-aged children with ADHD. *Dev Cogn Neurosci* 2013;4:16-28. PMID: 23219490.
- Thorell LB, Eninger L, Brocki KC, et al. Childhood executive function inventory (CHEXI): a promising measure for identifying young children with ADHD?. *J Clin Exp Neuropsychol* 2010;32(1):38-43. PMID: 19381995.
- Tobaiqy M, Stewart D, Helms PJ, et al. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK. *Drug Saf* 2011;34(3):211-9. PMID: 21332245.
- Trzepacz PT, Spencer TJ, Zhang S, et al. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011;27 Suppl 2:45-52. PMID: 21973230.
- van der Donk M, Hiemstra-Beernink AC, Tjeenk-Kalff A, et al. Cognitive training for children with ADHD: a randomized controlled trial of cogmed working memory training and 'paying attention in class'. *Front Psychol* 2015;6:1081. PMID: 26284005.
- van Dongen-Boomsma M, Vollebregt MA, Buitelaar JK, et al. Working memory training in young children with ADHD: a randomized placebo-controlled trial. *J Child Psychol Psychiatry* 2014;55(8):886-96. PMID: 24628438.
- Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2015;54(4):275-82. PMID: 25791144.
- Webster-Stratton CH, Reid MJ and Beauchaine T. Combining parent and child training for young children with ADHD. *J Clin Child Adolesc Psychol* 2011;40(2):191-203. PMID: 21391017.
- Widenhorn-Muller K, Schwanda S, Scholz E, et al. Effect of supplementation with long-chain omega-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. *Prostaglandins Leukot Essent Fatty Acids* 2014;91(1-2):49-60. PMID: 24958525.
- Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. *Pediatrics* 2009;124(1):e75-80. PMID: 19564272.
- Zelnik N, Bennett-Back O, Miari W, et al. Is the test of variables of attention reliable for the diagnosis of attention-deficit hyperactivity disorder (ADHD)?. *J Child Neurol* 2012;27(6):703-7. PMID: 22378668.
- Zhang H, Du M and Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. *Neuropediatrics* 2010;41(2):55-9. PMID: 20799150.

## Appendix D. List of Excluded Studies

All studies listed below were reviewed in their full-text version and excluded for the reasons cited. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

### Not a full publication or full text not available

Bakhshayesh AR, Esser G and Wyschkon A. Effectiveness of EEG-biofeedback in the treatment of attention deficit/hyperactivity disorder. *Psychological Research* 2010;13(1):7-29. PMID: 2010-23964-001.

Emmerson NA. Monitoring patterns of physical activity, problematic behaviors, and moods in children with and without ADHD using electronic diaries. US: ProQuest Information & Learning; 2011.

FDA-approved drugs to treat ADHD. *J Psychosoc Nurs Ment Health Serv* 2012;50(3):11-2. PMID: 22390784.

Hall CL, Walker GM and Valentine AZ. Correction. Protocol investigating the clinical utility of an objective measure of activity and attention (QbTest) on diagnostic and treatment decision-making in children and young people with ADHD - 'Assessing QbTest Utility in ADHD' (AQUA): a randomised controlled trial. *BMJ Open* 2015;5(5):e006838corr1. PMID: 25948406.

Hauser ME. Prediction of stimulant response in patients with adhd utilizing acute medication challenge studies. US: ProQuest Information & Learning; 2014.

Helwig JR. Sleep disturbance in children and adolescents with adhd: Unique effects of medication, adhd subtype, and comorbid status. US: ProQuest Information & Learning; 2012.

Henriksen N. Impulsive choice in unmedicated and medicated children diagnosed with adhd: Examining the variables of reward type and adhd subtype. US: ProQuest Information & Learning; 2015.

Herbert SD. Parent training for families of hyperactive preschool-aged children. US: ProQuest Information & Learning; 2014.

Ishii-Takahashi A, Takizawa R, Nishimura Y, et al. Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial. *Neuropsychopharmacology* 2015;40(12):2852. PMID: 26152808.

La Marca JP. Neurofeedback as an intervention to improve reading achievement in students with attention deficit hyperactivity disorder, inattentive subtype. US: ProQuest Information & Learning; 2015.

Moodi M, Alizadeh H, Bonab BG, et al. Effectiveness of cognitive behavior therapy on anger management in children with attention deficit/hyperactivity disorder. *Psychological Research* 2015;17(2):112-127.

Music A. *Direct Behavior Ratings (DBR): A possible tool for monitoring the behavior and interventions of students with symptoms of Attention Deficit Hyperactivity Disorder (ADHD)*. US: ProQuest Information & Learning; 2012.

Nupdal JB. *Implementing clinical practice guidelines in family practice: Caring for children with ADHD*. US: ProQuest Information & Learning; 2015.

Reading R. ADHD drugs and serious cardiovascular events in children and young adults. *Child: Care, Health and Development* 2012;38(1):149-151.

Rostain AL. Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder. *Curr Psychiatry Rep* 2009;11(5):339-40. PMID: 19785972.

Rutledge KJ. *Review and comparative effectiveness of parent training and cognitive training for treating attention-deficit / hyperactivity disorder*. US: ProQuest Information & Learning; 2014.

Rynczak D. *Effectiveness of mindfulness in reducing impulsivity in youth with attention-deficit/hyperactivity disorder*. US: ProQuest Information & Learning; 2013.

Saheban F, Amiri S, Kajbaf MB, et al. The efficacy of short-term executive functions training on the reduction of symptoms of attention deficit and hyperactivity of elementary boy students in Esfahan metropolitan area. *Advances in Cognitive Science* 2010;12(1):52-58.

Shecter C. *Mindfulness training for adolescents with ADHD and their families: A time-series evaluation*. US: ProQuest Information & Learning; 2015.

Shemmassian SK. *Optimizing assessment procedures for attention-deficit/hyperactivity disorder (adhd)*. US: ProQuest Information & Learning; 2015.

Sibley MH. *Supporting Teens' Academic Needs Daily (STAND): A parent-adolescent collaborative intervention for ADHD*. US: ProQuest Information & Learning; 2013.

Sidhu P. *The efficacy of mindfulness meditation in increasing the attention span in children with ADHD*. US: ProQuest Information & Learning; 2015.

Sobanski E, Dopfner M, Ose C, et al. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: effectiveness, safety and adherence to treatment. *Atten Defic Hyperact Disord* 2013;5(4):387-95. PMID: 23794192.

Sohn M. *The off-label use of atypical antipsychotics and its impact on Attention Deficit/Hyperactivity Disorder (ADHD)*. US: ProQuest Information & Learning; 2015.

Steger CM. *Combined cognitive and parent training interventions for adolescents with adhd and their mothers: A randomized, controlled trial*. US: ProQuest Information & Learning; 2014.

van Dongen-Boomsma M, Vollebregt MA, Slaats-Willemse D, et al. 'A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder': Reply. *Journal of Clinical Psychiatry* 2014;75(3):290-290.

Wagner SM. The effects of parent-child interaction therapy on symptoms and impairment in young children with attention-deficit/hyperactivity disorder. US: ProQuest Information & Learning; 2012.

Walker P, Jr.. The effects of Ritalin and cognitive behavioral therapy on the academic functioning of African American children diagnosed with attention deficit hyperactivity disorder: A longitudinal study. US: ProQuest Information & Learning; 2011.

Worth DE. Mindfulness meditation and attention-deficit/hyperactivity disorder symptom reduction in middle school students. US: ProQuest Information & Learning; 2014.

## **Not available in English**

Babaki ME, Ashtiani RD, Razjooyan K, et al. Comparing the effects of buspirone and methylphenidate in children with attention deficit hyperactivity disorder. *Iranian Journal of Psychiatry and Clinical Psychology* 2009;15(3):223-230.

Blasco-Fontecilla H, Gonzalez-Perez M, Garcia-Lopez R, et al. Efficacy of chess training for the treatment of ADHD: A prospective, open label study. *Rev Psiquiatr Salud Ment* 2015. PMID: 25911280.

Davari-Ashtiani R, Jazayeri F, Arabgol F, et al. Psychometric properties of Persian version of Conners' Adult Attention Deficit/Hyperactivity Disorder Rating Scale (screening form-self reporting). *Iranian Journal of Psychiatry and Clinical Psychology* 2014;20(3):243-251.

Delgado-Mejía ID, Palencia-Avenidaño ML, Mogollón-Rincón C, et al. Theta/beta ratio (NEBA) in the diagnosis of attention deficit hyperactivity disorder. *Revista de Neurologia* 2014;58(SUPPL. 1):S57-S63.

Fazeli Z, Shirazi E, Farid AA, et al. Effectiveness of medication and combined medication and parent management training on visuo-constructive, attentional, behavioral and emotional indicators of children with attention deficit/hyperactivity disorder. *Iranian Journal of Psychiatry and Clinical Psychology* 2014;19(4):264-274.

Garcia Ron A, Serrano Grasa R, Blanco Lago R, et al. Pilot study of the efficacy of empowering patients through coaching as a complementary therapy in attention deficit hyperactivity disorder. *Neurologia* 2015. PMID: 26383058.

Ghasabi S, Tajrishi MPMR and Zamani SMM. The effect of verbal self-instruction training on decreasing impulsivity symptoms in ADHD children. *Journal of Iranian Psychologists* 2009;5(19):209-220.

Karakurt MN, Karabekiroğlu MK, Akbaş S, et al. Association between symptom profiles and iron and ferritine serum levels in children with attention deficit hyperactivity disorder. *Noropsikiyatri Arsivi* 2011;48(2):125-128.

Khanjani Z, Amini S, Malek A, et al. The effectiveness of parents management training on improvement of attention deficit hyperactivity disorder syndrome in children. *Journal of Iranian Psychologists* 2014;10(39):311-320.

Lazaratou H. Attention-deficit hyperactivity disorder or bipolar disorder in childhood?. *Psychiatriki* 2012;23(4):304-313.

Maleki ZH, Mashhadi A, Soltanifar A, et al. Effectiveness of working memory training, Barkley's parent training program, and combination of these two interventions on improvement of working memory in children with ADHD. *Advances in Cognitive Science* 2014;15(4[60]):53-63.

Meftagh SD, Mohammadi N, Ghanizadeh A, et al. Comparison of the effectiveness of different treatment methods in children's attention deficit-hyperactivity disorders. *Journal of Isfahan Medical School* 2011;29(148):965-976.

Mulas F, Roca P, Ros-Cervera G, et al. Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy. *Revista de Neurologia* 2014;58(SUPPL. 1):S43-S49.

Shahrbabaki ME, Sabzevari L, Haghdoost A, et al. A randomized double blind crossover study on the effectiveness of buspirone and methylphenidate in treatment of attention deficit/hyperactivity disorder in children and adolescents. *Iranian Journal of Psychiatry and Clinical Psychology* 2013;18(4):292-297.

Zamora J, Velasquez A, Troncoso L, et al. [Zinc in the therapy of the attention-deficit/hyperactivity disorder in children. A preliminar randomized controlled trial]. *Arch Latinoam Nutr* 2011;61(3):242-6. PMID: 22696891.

## **Does not include original data**

Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. *J Dev Behav Pediatr* 2014;35(7):448-57. PMID: 25180895.

Bikic A, Leckman JF, Lindschou J, et al. Cognitive computer training in children with attention deficit hyperactivity disorder (ADHD) versus no intervention: study protocol for a randomized controlled trial. *Trials* 2015;16(1):480. PMID: 26499057.

Boyes C. Question 2 Should a child with ADHD and epilepsy be given ritalin?. *Arch Dis Child* 2010;95(9):759-61. PMID: 20716679.

Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. *Adv Ther* 2012;29(5):385-400. PMID: 22610723.

Cole E. Qb test improves diagnosis of attention deficit disorder. *Nurs Child Young People* 2015;27(2):10-1. PMID: 25759995.

Cowles BJ. Update on the management of attention-deficit/hyperactivity disorder in children and adults: Patient considerations and the role of lisdexamfetamine. *Therapeutics and Clinical Risk Management* 2009;5(1):943-948.

Croxtall JD. Clonidine extended-release: in attention-deficit hyperactivity disorder. *Paediatr Drugs* 2011;13(5):329-36. PMID: 21888447.

Frances A. Better safe than sorry. *Australian and New Zealand Journal of Psychiatry* 2012;46(8):695-696.

Hansen S. Kids Together: A group therapy program for children using cognitive-behavioral play therapy interventions. In: Drewes AA, Schaefer CE, Drewes AA, Schaefer CE, eds. *Play therapy in middle childhood*. Washington, DC, US: American Psychological Association; 2016:153-69.

Hechtman L. Effects of treatment on the overall functioning of children with ADHD. *Journal of the Canadian Academy of Child and Adolescent Psychiatry / Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent* 2009;18(2,Suppl):11-16.

Hennessy S, Schelleman H, Daniel GW, et al. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study. *Pharmacoepidemiol Drug Saf* 2010;19(9):934-41. PMID: 20623519.

Hinshaw SP and Arnold LE. ADHD, Multimodal Treatment, and Longitudinal Outcome: Evidence, Paradox, and Challenge. *Wiley Interdiscip Rev Cogn Sci* 2015;6(1):39-52. PMID: 25558298.

Huang YS, Tsai MH and Guilleminault C. Pharmacological treatment of ADHD and the short and long term effects on sleep. *Curr Pharm Des* 2011;17(15):1450-8. PMID: 21476954.

Hvolby A and Bilenberg N. Use of Ball Blanket in attention-deficit/hyperactivity disorder sleeping problems. *Nord J Psychiatry* 2011;65(2):89-94. PMID: 20662681.

Johnson M. The lure of an ADHD treatment minus the meds. *US News World Rep* 2009;146(11):80-1. PMID: 20027829.

Kean JD, Camfield D, Sarris J, et al. A randomized controlled trial investigating the effects of PCSO-524, a patented oil extract of the New Zealand green lipped mussel (*Perna canaliculus*), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066. *Nutr J* 2013;12:100. PMID: 23866813.

Keating GM. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report. *Drugs R D* 2012;12(3):171-3. PMID: 22934753.

Keating GM. Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents. *CNS Drugs* 2011;25(4):333-42. PMID: 21425884.

Kerson C. A proposed multisite double-blind randomized clinical trial of neurofeedback for ADHD: need, rationale, and strategy. *J Atten Disord* 2013;17(5):420-36. PMID: 23590978.

Kieling R and Rohde LA. ADHD in children and adults: diagnosis and prognosis. *Curr Top Behav Neurosci* 2012;9:1-16. PMID: 21499858.

Kohn MR, Tsang TW and Clarke SD. Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder. *Clin Med Insights Pediatr* 2012;6:95-162. PMID: 23641171.

Leben N. Directive group play therapy for children with attention-deficit/hyperactivity disorder. In: Kaduson HG, Schaefer CE, Kaduson HG, Schaefer CE, eds. *Short-term play therapy for children* (3rd ed.). New York, NY, US: Guilford Press; 2015:325-52.

McCann DC, Thompson M, Daley D, et al. Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD. *Trials* 2014;15:142. PMID: 24767423.

Methylphenidate: growth retardation. *Prescrire Int* 2011;20(120):238-9. PMID: 21970086.

Muir VJ and Perry CM. Guanfacine extended-release: in attention deficit hyperactivity disorder. *Drugs* 2010;70(13):1693-702. PMID: 20731476.

Ondrejka I, Abali O, Paclt I, et al. A prospective observational study of attention-deficit/hyperactivity disorder in Central and Eastern Europe and Turkey: Symptom severity and treatment options in a paediatric population. *Int J Psychiatry Clin Pract* 2010;14(2):116-26. PMID: 24922471.

Parens E and Johnston J. Troubled children: diagnosing, treating, and attending to context. A Hastings Center special report. *Hastings Cent Rep* 2011;41(2):S1-32. PMID: 21495513.

Pataki C and Carlson GA. The comorbidity of ADHD and bipolar disorder: any less confusion?. *Curr Psychiatry Rep* 2013;15(7):372. PMID: 23712723.

Pelsser LM, Steijn DJ and Frankena K. 'A randomized controlled pilot study into the effects of a restricted elimination diet on family structure in families with ADHD and ODD': Comment. *Journal of Developmental and Behavioral Pediatrics* 2013;34(9):734-734.

Peyre H, Hoertel N, Cortese S, et al. Long-term effects of ADHD medication on adult height: Results from the NESARC. *Journal of Clinical Psychiatry* 2013;74(11):1123-1125.

Pulgaron ER. Childhood obesity: a review of increased risk for physical and psychological comorbidities. *Clin Ther* 2013;35(1):A18-32. PMID: 23328273.

Reddy LA. Child ADHD multimodal program: Use of cognitive-behavioral group play interventions. In: Reddy LA, Files-Hall TM, Schaefer CE, Reddy LA, Files-Hall TM, Schaefer CE, eds. *Empirically based play interventions for children* (2nd ed.). Washington, DC, US: American Psychological Association; 2016:181-201.

Ross SM. Omega-3 fatty acids, part I: the effects of n-3 polyunsaturated fatty acid in the treatment of attention-deficit hyperactivity disorder in children. *Holist Nurs Pract* 2012;26(6):356-9. PMID: 23075752.

Sciberras E, Efron D, Gerner B, et al. Study protocol: the sleeping sound with attention-deficit/hyperactivity disorder project. *BMC Pediatr* 2010;10:101. PMID: 21192797.

Srinivasaraghavan R, Kattimani S and Mahadevan S. Duration of untreated illness and early treatment response in children with attention deficit/hyperactivity disorder—A preliminary study. *Asian Journal of Psychiatry* 2014;9:87-88.

Storebo OJ, Pedersen J, Skoog M, et al. Randomised social-skills training and parental training plus standard treatment versus standard treatment of children with attention deficit hyperactivity disorder - the SOSTRA trial protocol. *Trials* 2011;12:18. PMID: 21255399.

Study shows no link between stimulant use in ADHD treatment and cardiovascular events. *Expert Review of Neurotherapeutics* 2012;12(4):369-369.

Swanson JM, Schuck S, Porter MM, et al. Categorical and dimensional definitions and evaluations of symptoms of ADHD: History of the SNAP and the SWAN rating scales. *The International Journal of Educational and Psychological Assessment* 2012;10(1):51-70.

Vaughan BS, March JS and Kratochvil CJ. The evidence-based pharmacological treatment of paediatric ADHD. *Int J Neuropsychopharmacol* 2012;15(1):27-39. PMID: 21329553.

Waxmonsky JG, Waschbusch DA, Glatt SJ, et al. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. *J Clin Psychiatry* 2011;72(10):1366-75. PMID: 21367347.

Weder N. Here/in this issue and there/abstract thinking: Are we there yet? Electroencephalography as a diagnostic tool for attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry* 2013;52(11):1119-1120.

Zwi M, Jones H, Thorgaard C, et al. Parent training interventions for attention deficit hyperactivity disorder. *Cochrane Database Syst Rev* 2009;(3). PMID: 25419178.

**Does not meet study design or sample size requirements**

Aagaard L, Thstrup S and Hansen EH. Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. *Pharmacoepidemiol Drug Saf* 2009;18(5):401-11. PMID: 19326364.

Abbasi SH, Heidari S, Mohammadi MR, et al. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. *Child Psychiatry Hum Dev* 2011;42(3):367-75. PMID: 21336630.

Abdollahian E, Mokhber N, Balaghi A, et al. The effectiveness of cognitive-behavioural play therapy on the symptoms of attention-deficit/hyperactivity disorder in children aged 7-9 years. *Atten Defic Hyperact Disord* 2013;5(1):41-6. PMID: 23179507.

Abibullaev B and An J. Decision support algorithm for diagnosis of ADHD using electroencephalograms. *J Med Syst* 2012;36(4):2675-88. PMID: 21671069.

Accorsi A, Lucci C, Di Mattia L, et al. Effect of osteopathic manipulative therapy in the attentive performance of children with attention-deficit/hyperactivity disorder. *J Am Osteopath Assoc* 2014;114(5):374-81. PMID: 24778002.

Adler LA, Wilens T, Zhang S, et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. *Clin Ther* 2012;34(2):363-73. PMID: 22285724.

Aebi M, Winkler Metzke C and Steinhausen HC. Accuracy of the DSM-oriented attention problem scale of the child behavior checklist in diagnosing attention-deficit hyperactivity disorder. *J Atten Disord* 2010;13(5):454-63. PMID: 19372495.

Ahmed R, Raynor DK, McCaffery KJ, et al. The design and user-testing of a question prompt list for attention-deficit/hyperactivity disorder. *BMJ Open* 2014;4(12):e006585. PMID: 25515843.

Albertin SV. Diagnosis of attention deficit hyperactivity disorder using a conditioned reflex approach. *Neuroscience and Behavioral Physiology* 2011;41(9):906-910.

Albrecht B, Brandeis D, Uebel H, et al. Action monitoring in children with or without a family history of ADHD--effects of gender on an endophenotype parameter. *Neuropsychologia* 2010;48(4):1171-7. PMID: 20026087.

Alda JA and Serrano-Troncoso E. Attention-deficit hyperactivity disorder: agreement between clinical impression and the SNAP-IV screening tool. *Actas Esp Psiquiatr* 2013;41(2):76-83. PMID: 23592067.

Allen R and Pammer K. The Impact of Concurrent Noise on Visual Search in Children With ADHD. *J Atten Disord* 2015. PMID: 26396146.

Altin M, El-Shafei AA, Yu M, et al. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries. *Drugs Context* 2013;2013:212260. PMID: 24432046.

- Arabgol F, Panaghi L and Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2009;18(1):53-9. PMID: 18563471.
- Arabgol F, Panaghi L and Nikzad V. Risperidone Versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder. *Iran J Pediatr* 2015;25(1):e265. PMID: 26199694.
- Ardic UA, Ercan ES, Ercan E, et al. Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: A retrospective chart review in turkish children with attention deficit hyperactivity disorder. *Klinik Psikofarmakoloji Bulteni* 2014;24(4):342-349.
- Ari ME, Cetin II, Ekici F, et al. Assessment of cardiovascular risks due to methylphenidate in six months of treatment in children with attention deficit and hyperactivity disorder. *Klinik Psikofarmakoloji Bulteni* 2014;24(3):248-252.
- Armstrong RB, Damaraju CV, Ascher S, et al. Time course of treatment effect of OROS(R) methylphenidate in children with ADHD. *J Atten Disord* 2012;16(8):697-705. PMID: 22084448.
- Arnold LE, Hurt E and Lofthouse N. Attention-deficit/hyperactivity disorder: dietary and nutritional treatments. *Child Adolesc Psychiatr Clin N Am* 2013;22(3):381-402, v. PMID: 23806311.
- Arnold LE, Ganocy SJ, Mount K, et al. Three-year latent class trajectories of attention-deficit/hyperactivity disorder (ADHD) symptoms in a clinical sample not selected for ADHD. *J Am Acad Child Adolesc Psychiatry* 2014;53(7):745-60. PMID: 24954824.
- Arnold LE, Lofthouse N, Hersch S, et al. EEG neurofeedback for ADHD: double-blind sham-controlled randomized pilot feasibility trial. *J Atten Disord* 2013;17(5):410-9. PMID: 22617866.
- Ashare RL, Hawk LW, Jr., Shiels K, et al. Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder. *Psychophysiology* 2010;47(5):838-45. PMID: 20233343.
- Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. *Pediatr Neurol* 2011;45(6):381-6. PMID: 22115000.
- Au A, Lau KM, Wong AHC, et al. The efficacy of a group Triple P (positive parenting program) for Chinese parents with a child diagnosed with ADHD in Hong Kong: A pilot randomised controlled study. *Australian Psychologist* 2014;49(3):151-162.
- Babinski DE, Waxmonsky JG and Pelham WE, Jr.. Treating parents with attention-deficit/hyperactivity disorder: the effects of behavioral parent training and acute stimulant medication treatment on parent-child interactions. *J Abnorm Child Psychol* 2014;42(7):1129-40. PMID: 24687848.

Babinski DE. Treating parents with attention-deficit/hyperactivity disorder: The effects of behavioral parent training and acute medication treatment on parent-child interactions. US: ProQuest Information & Learning; 2014.

Bakar EE, Taner YI, Soysal AS, et al. Behavioral rating inventory and laboratory tests measure different aspects of executive functioning in boys: A validity study. *Klinik Psikofarmakoloji Bulteni* 2011;21(4):302-316.

Bakhshayesh AR, Hansch S, Wyszkon A, et al. Neurofeedback in ADHD: a single-blind randomized controlled trial. *Eur Child Adolesc Psychiatry* 2011;20(9):481-91. PMID: 21842168.

Ballard W, Hall MN and Kaufmann L. Clinical inquiries. Do dietary interventions improve ADHD symptoms in children?. *J Fam Pract* 2010;59(4):234-5. PMID: 20398584.

Banaschewski T, Soutullo C, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. *CNS Drugs* 2013;27(10):829-40. PMID: 23893527.

Bard DE, Wolraich ML, Neas B, et al. The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic parent rating scale in a community population. *J Dev Behav Pediatr* 2013;34(2):72-82. PMID: 23363972.

Bart O, Raz S and Dan O. Reliability and validity of the Online Continuous Performance Test among children. *Assessment* 2014;21(5):637-43. PMID: 24752387.

Battagliese G, Caccetta M, Luppino OI, et al. Cognitive-behavioral therapy for externalizing disorders: A meta-analysis of treatment effectiveness. *Behaviour Research and Therapy* 2015;75:60-71.

Bayoumy IM, Khaleel SH, Nada M, et al. Efficacy and attributes of repetitive transcranial magnetic stimulation (rTMS) in treatment of a sample of children with attention deficit hyperactivity disorder (ADHD). *Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2014;51(3):361-367.

Beauchaine TP, Neuhaus E, Gatzke-Kopp LM, et al. Electrodermal responding predicts responses to, and may be altered by, preschool intervention for ADHD. *J Consult Clin Psychol* 2015;83(2):293-303. PMID: 25486374.

Bedard AC, Schulz KP, Krone B, et al. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study. *Psychiatry Res* 2015;231(3):353-6. PMID: 25659477.

Bedard AC, Stein MA, Halperin JM, et al. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. *J Child Psychol Psychiatry* 2015;56(1):40-8. PMID: 24942409.

Behdani F, Hebrani P, Naseraee A, et al. Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients?. *J Res Med Sci* 2013;18(8):653-8. PMID: 24379840.

Belanger SA, Vanasse M, Spahis S, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. *Paediatr Child Health* 2009;14(2):89-98. PMID: 19436468.

Berek M, Kordon A, Hargarter L, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS(R) MPH: is treatment response different between children and adolescents?. *Child Adolesc Psychiatry Ment Health* 2011;5:26. PMID: 21791096.

Beriault M, Turgeon L, Labrosse M, et al. Comorbidity of ADHD and Anxiety Disorders in School-Age Children: Impact on Sleep and Response to a Cognitive-Behavioral Treatment. *J Atten Disord* 2015. PMID: 26396144.

Beyer von Morgenstern S, Becker I and Sinzig J. Improvement of facial affect recognition in children and adolescents with attention-deficit/hyperactivity disorder under methylphenidate. *Acta Neuropsychiatr* 2014;26(4):202-8. PMID: 25142287.

Bishry Z, Ramy HA, El-Shahawi HH, et al. Screening for ADHD in a Sample of Egyptian Adolescent School Students. *J Atten Disord* 2014. PMID: 24891559.

Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. *Am J Psychiatry* 2009;166(12):1392-401. PMID: 19884222.

Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. *J Am Acad Child Adolesc Psychiatry* 2009;48(9):884-93. PMID: 19625978.

Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. *Clin Pediatr (Phila)* 2009;48(7):723-33. PMID: 19420182.

Blum NJ, Jawad AF, Clarke AT, et al. Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder. *Dev Med Child Neurol* 2011;53(9):843-9. PMID: 21585365.

Boellner SW, Stark JG, Krishnan S, et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. *Clin Ther* 2010;32(2):252-64. PMID: 20206783.

Bor W, Heath F, Heussler H, et al. Can a multi-disciplinary assessment approach improve outcomes for children with attention deficit hyperactivity disorder?. *Australasian Psychiatry* 2013;21(5):499-503.

Bouwman C, van der Kolk A, Oppe M, et al. Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD. *Eur J Health Econ* 2014;15(9):967-77. PMID: 24233919.

Brams M, Turnbow J, Pestreich L, et al. A randomized, double-blind study of 30 versus 20 mg dexamethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control. *J Clin Psychopharmacol* 2012;32(5):637-44. PMID: 22926597.

Bruchmuller K, Margraf J and Schneider S. Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. *J Consult Clin Psychol* 2012;80(1):128-38. PMID: 22201328.

Bruxel EM, Salatino-Oliveira A, Akutagava-Martins GC, et al. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. *Genes Brain Behav* 2015;14(5):419-27. PMID: 25989180.

Bubnik MG, Hawk LW, Jr., Pelham WE, Jr., et al. Reinforcement enhances vigilance among children with ADHD: comparisons to typically developing children and to the effects of methylphenidate. *J Abnorm Child Psychol* 2015;43(1):149-61. PMID: 24931776.

Buchhorn R, Conzelmann A, Willaschek C, et al. Heart rate variability and methylphenidate in children with ADHD. *Atten Defic Hyperact Disord* 2012;4(2):85-91. PMID: 22328340.

Buitelaar J, Asherson P, Soutullo C, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. *Eur Neuropsychopharmacol* 2015;25(10):1611-21. PMID: 26169574.

Bukstein OG and Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. *Expert Opin Pharmacother* 2012;13(15):2207-13. PMID: 22957772.

Burns GL, Servera M, Bernad Mdel M, et al. Ratings of ADHD symptoms and academic impairment by mothers, fathers, teachers, and aides: construct validity within and across settings as well as occasions. *Psychol Assess* 2014;26(4):1247-58. PMID: 24932644.

Bushe CJ and Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. *Child Adolesc Psychiatry Ment Health* 2013;7:19. PMID: 23777626.

Bussing R, Fernandez M, Harwood M, et al. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: Psychometric properties and normative ratings from a school district sample. *Circulation* 2011;124(9):317-328.

Callahan L, Coccozza J, Steadman HJ, et al. A national survey of U.S. juvenile mental health courts. *Psychiatr Serv* 2012;63(2):130-4. PMID: 22302329.

Cannon M, Pelham WH, Sallee FR, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(5):511-7. PMID: 19877975.

Cannon RL. Parietal foci for attention deficit/hyperactivity disorder: Targets for LORETA neurofeedback with outcomes. *Biofeedback* 2014;42(2):47-57.

Cantrill A, Wilkes-Gillan S, Bundy A, et al. An eighteen-month follow-up of a pilot parent-delivered play-based intervention to improve the social play skills of children with attention deficit hyperactivity disorder and their playmates. *Australian Occupational Therapy Journal* 2015;62(3):197-207.

Carboni JA, Roach AT and Fredrick LD. Impact of mindfulness training on the behavior of elementary students with attention-deficit/hyperactive disorder. *Research in Human Development* 2013;10(3):234-251.

Cardo E, Porsdal V, Quail D, et al. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2013;23(4):252-61. PMID: 23683140.

Chan GFC, Lai KYC, Luk ESL, et al. Clinical utility of the Chinese Strengths and Weaknesses of ADHD-Symptoms and Normal-behaviors questionnaire (SWAN) when compared with DISC-IV. *Neuropsychiatric Disease and Treatment* 2014;10:1533-1542.

Chan GF-C, Lai KY-C, Luk ES-L, et al. Clinical utility of the Chinese Version of the Strengths and Weaknesses of ADHD-Symptoms and Normal-Behaviors questionnaire (SWAN) when compared with DISC-IV. *Neuropsychiatric Disease and Treatment* 2014;10.

Chang Y-K, Hung C-L, Huang C-J, et al. Effects of an aquatic exercise program on inhibitory control in children with ADHD: A preliminary study. *Archives of Clinical Neuropsychology* 2014;29(3):217-223.

Chang YK, Liu S, Yu HH, et al. Effect of acute exercise on executive function in children with attention deficit hyperactivity disorder. *Arch Clin Neuropsychol* 2012;27(2):225-37. PMID: 22306962.

Charach A, Chen S, Hogg-Johnson S, et al. Using the Conners' Teacher Rating Scale-Revised in school children referred for assessment. *Can J Psychiatry* 2009;54(4):232-41. PMID: 19321029.

Chen TH, Wu SW, Welge JA, et al. Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD). *J Child Neurol* 2014;29(12):1672-9. PMID: 24413361.

Childress AC, Arnold V, Adeyi B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. *J Atten Disord* 2014;18(2):123-32. PMID: 22740112.

Childress AC, Brams M, Cutler AJ, et al. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. *J Child Adolesc Psychopharmacol* 2015;25(5):402-14. PMID: 25692608.

Childress AC, Spencer T, Lopez F, et al. Efficacy and safety of dexamethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(4):351-61. PMID: 19702487.

Cho S, Lee SI, Yoo H, et al. A randomized, open-label assessment of response to various doses of atomoxetine in korean pediatric outpatients with attention-deficit/hyperactivity disorder. *Psychiatry Investig* 2011;8(2):141-8. PMID: 21852991.

Choi JW, Han DH, Kang KD, et al. Aerobic exercise and attention deficit hyperactivity disorder: brain research. *Med Sci Sports Exerc* 2015;47(1):33-9. PMID: 24824770.

Chou TL, Chia S, Shang CY, et al. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naive children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study. *Eur Neuropsychopharmacol* 2015. PMID: 26409297.

Chou WJ, Chou MC, Tzang RF, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. *Psychiatry Clin Neurosci* 2009;63(2):167-75. PMID: 19335386.

Christiansen H, Reh V, Schmidt MH, et al. Slow cortical potential neurofeedback and self-management training in outpatient care for children with ADHD: study protocol and first preliminary results of a randomized controlled trial. *Front Hum Neurosci* 2014;8:943. PMID: 25505396.

Cockcroft K, Ashwal J and Bentley A. Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD). *Afr J Psychiatry (Johannesbg)* 2009;12(4):275-9. PMID: 20033109.

Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. *Eur Neuropsychopharmacol* 2013;23(10):1208-18. PMID: 23332456.

Coghill DR, Banaschewski T, Lecendreux M, et al. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. *Eur Child Adolesc Psychiatry* 2014;23(2):61-8. PMID: 23708466.

Coghill DR, Banaschewski T, Lecendreux M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. *J Am Acad Child Adolesc Psychiatry* 2014;53(6):647-657.e1. PMID: 24839883.

Coghill DR, Banaschewski T, Lecendreux M, et al. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. *Neuropsychiatr Dis Treat* 2014;10:2039-47. PMID: 25378930.

Cohen-Yavin I, Yoran-Hegesh R, Strous RD, et al. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. *Clin Neuropharmacol* 2009;32(4):179-82. PMID: 19644227.

Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. *J Am Acad Child Adolesc Psychiatry* 2015;54(9):728-36. PMID: 26299294.

Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. *CNS Drugs* 2010;24(9):755-68. PMID: 20806988.

Conzelmann A, Gerdes AB, Mucha RF, et al. Autonomic hypoactivity in boys with attention-deficit/hyperactivity disorder and the influence of methylphenidate. *World J Biol Psychiatry* 2014;15(1):56-65. PMID: 24410179.

Cook A, Johnson C and Bradley-Johnson S. White noise to decrease problem behaviors in the classroom for a child with Attention Deficit Hyperactivity Disorder (ADHD). *Child & Family Behavior Therapy* 2015;37(1):38-50.

Coon ER, Quinonez RA, Moyer VA, et al. Overdiagnosis: how our compulsion for diagnosis may be harming children. *Pediatrics* 2014;134(5):1013-23. PMID: 25287462.

Cordier R, Munro N, Wilkes-Gillan S, et al. The pragmatic language abilities of children with ADHD following a play-based intervention involving peer-to-peer interactions. *Int J Speech Lang Pathol* 2013;15(4):416-28. PMID: 22974071.

Coughlin CG, Cohen SC, Mulqueen JM, et al. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 2015;25(8):611-7. PMID: 26402485.

Cubero-Millan I, Molina-Carballo A, Machado-Casas I, et al. Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. *Int J Mol Sci* 2014;15(9):17115-29. PMID: 25257531.

Curchack-Lichtin JT, Chacko A and Halperin JM. Changes in ADHD symptom endorsement: preschool to school age. *J Abnorm Child Psychol* 2014;42(6):993-1004. PMID: 24343794.

Cutler AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2014;53(10):1092-101. PMID: 25245353.

Cuypers K, De Ridder K and Strandheim A. The effect of therapeutic horseback riding on 5 children with attention deficit hyperactivity disorder: a pilot study. *J Altern Complement Med* 2011;17(10):901-8. PMID: 22010778.

Daley D and O'Brien M. A small-scale randomized controlled trial of the self-help version of the New Forest Parent Training Programme for children with ADHD symptoms. *Eur Child Adolesc Psychiatry* 2013;22(9):543-52. PMID: 23463179.

Dalsgaard S, Kvist AP, Leckman JF, et al. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. *J Child Adolesc Psychopharmacol* 2014;24(6):302-10. PMID: 24956171.

Dalsgaard S, Leckman JF, Nielsen HS, et al. Gender and injuries predict stimulant medication use. *J Child Adolesc Psychopharmacol* 2014;24(5):253-9. PMID: 24813570.

Daniels B, Volpe RJ, Briesch AM, et al. Development of a problem-focused behavioral screener linked to evidence-based intervention. *Sch Psychol Q* 2014;29(4):438-51. PMID: 25485466.

Dashti N, Hekmat H, Soltani HR, et al. Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin((R))) in treating children with attention deficit hyperactivity disorder. *Iran J Psychiatry Behav Sci* 2014;8(4):7-11. PMID: 25798168.

Davari-Ashtiani R, Shahrabaki ME, Razjouyan K, et al. Bupirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. *Child Psychiatry Hum Dev* 2010;41(6):641-8. PMID: 20517641.

Deans P, O'Laughlin L, Brubaker B, et al. Use of eye movement tracking in the differential diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and reading disability. *Psychology* 2010;1(4):238-246.

Dell'Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. *Eur Neuropsychopharmacol* 2009;19(11):822-34. PMID: 19716683.

Devena SE and Watkins MW. Diagnostic utility of WISC-IV general abilities index and cognitive proficiency index difference scores among children with ADHD. *Journal of Applied School Psychology* 2012;28(2):133-154.

Dickson RA, Maki E, Gibbins C, et al. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. *Child Adolesc Psychiatry Ment Health* 2011;5:14. PMID: 21569378.

Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. *CNS Drugs* 2013;27(12):1081-92. PMID: 23959815.

Dittmann RW, Cardo E, Nagy P, et al. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. *CNS Drugs* 2014;28(11):1059-69. PMID: 25038977.

Dittmann RW, Schacht A, Helsing K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. *J Child Adolesc Psychopharmacol* 2011;21(2):97-110. PMID: 21488751.

Docking K, Munro N, Cordier R, et al. Examining the language skills of children with ADHD following a play-based intervention. *Child Language Teaching and Therapy* 2013;29(3):291-304.

Döpfner M, Ise E, Wolff Metternich-Kaizman T, et al. Adaptive multimodal treatment for children with attention-deficit-/hyperactivity disorder: An 18 month follow-up. *Child Psychiatry and Human Development* 2015;46(1):44-56.

Döpfner M, Ose C, Fischer R, et al. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet((R)) retard and Concerta((R))--a randomized, controlled, double-blind multicenter clinical crossover trial. *J Child Adolesc Psychopharmacol* 2011;21(5):445-54. PMID: 21790298.

Dubnov-Raz G, Khoury Z, Wright I, et al. The effect of alpha-linolenic acid supplementation on ADHD symptoms in children: a randomized controlled double-blind study. *Front Hum Neurosci* 2014;8:780. PMID: 25339885.

DuPaul GJ, Kern L, Gormley MJ, et al. Early intervention for young children with ADHD: Academic outcomes for responders to behavioral treatment. *School Mental Health* 2011;3(3):117-126. PMID: 2011-18575-002.

Durand-Rivera A, Alatorre-Miguel E, Zambrano-Sánchez E, et al. Methylphenidate efficacy: Immediate versus extended release at short term in Mexican children with ADHD assessed by Conners scale and EEG. *Neurology Research International* 2015;2015.

Edwards C and Howlett E. Putting knowledge to trial: 'ADHD parents' and the evaluation of alternative therapeutic regimes. *Soc Sci Med* 2013;81:34-41. PMID: 23422058.

Edwards MC and Sigel BA. Estimates of the Utility of Child Behavior Checklist/Teacher Report Form Attention Problems Scale in the Diagnosis of ADHD in Children Referred to a Specialty Clinic. *Journal of Psychopathology and Behavioral Assessment* 2015;37(1):50-59.

Efron D, Sciberras E, Anderson V, et al. Functional status in children with ADHD at age 6-8: a controlled community study. *Pediatrics* 2014;134(4):e992-e1000. PMID: 25266432.

El Baza F, AlShahawi HA, Zahra S, et al. Magnesium supplementation in children with attention deficit hyperactivity disorder. *Egyptian Journal of Medical Human Genetics* 2015.

Elliott GR, Blasey C, Rekshan W, et al. Cognitive Testing to Identify Children With ADHD Who Do and Do Not Respond to Methylphenidate. *J Atten Disord* 2014. PMID: 25122732.

Epstein JN, Brinkman WB, Froehlich T, et al. Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD. *Neuropsychopharmacology* 2011;36(5):1060-72. PMID: 21248722.

Epstein JN, Kelleher KJ, Baum R, et al. Variability in ADHD care in community-based pediatrics. *Pediatrics* 2014;134(6):1136-43. PMID: 25367532.

Erder MH, Xie J, Signorovitch JE, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. *Appl Health Econ Health Policy* 2012;10(6):381-95. PMID: 23113551.

Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(3):253-63. PMID: 19519260.

Evans SW, Schultz BK, Demars CE, et al. Effectiveness of the Challenging Horizons After-School Program for young adolescents with ADHD. *Behav Ther* 2011;42(3):462-74. PMID: 21658528.

Fabiano GA, Vujnovic RK, Pelham WE, et al. Enhancing the effectiveness of special education programming for children with attention deficit hyperactivity disorder using a daily report card. *School Psychology Review* 2010;39(2):219-239.

Faraone SV, Glatt SJ, Bukstein OG, et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. *J Atten Disord* 2009;12(4):308-15. PMID: 18400982.

Farmer CA, Brown NV, Gadow KD, et al. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2015;25(3):213-24. PMID: 25885011.

Fernandes Azevedo A, Seabra-Santos MJ, Gaspar MF, et al. A parent-based intervention programme involving preschoolers with AD/HD behaviours: are children's and mothers' effects sustained over time?. *Eur Child Adolesc Psychiatry* 2014;23(6):437-50. PMID: 23999733.

Findling RL, Adeyi B, Dirks B, et al. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate. *J Child Adolesc Psychopharmacol* 2013;23(1):28-35. PMID: 23410139.

Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2011;50(4):395-405. PMID: 21421179.

Findling RL, McBurnett K, White C, et al. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(5):245-52. PMID: 24945085.

Findling RL, Turnbow J, Burnside J, et al. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. *CNS Spectr* 2010;15(7):419-30. PMID: 20625364.

Fox O, Adi-Japha E and Karni A. The effect of a skipped dose (placebo) of methylphenidate on the learning and retention of a motor skill in adolescents with Attention Deficit Hyperactivity Disorder. *Eur Neuropsychopharmacol* 2014;24(3):391-6. PMID: 24332892.

Funabiki Y, Kawagishi H, Uwatoko T, et al. Development of a multi-dimensional scale for PDD and ADHD. *Res Dev Disabil* 2011;32(3):995-1003. PMID: 21353761.

Gadow KD and Nolan EE. Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD. *J Atten Disord* 2011;15(3):246-56. PMID: 20378921.

Garcia SP, Guimaraes J, Zampieri JF, et al. Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. *J Neural Transm (Vienna)* 2009;116(5):631-6. PMID: 19370390.

Garcia-Barrera MA, Karr JE, Duran V, et al. Cross-Cultural Validation of a Behavioral Screener for Executive Functions: Guidelines for Clinical Use Among Colombian Children With and Without ADHD. *Psychological Assessment* 2015.

Garg J, Arun P and Chavan BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. *Int J Appl Basic Med Res* 2015;5(2):114-8. PMID: 26097819.

Garg J, Arun P and Chavan BS. Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. *Indian Pediatr* 2014;51(7):550-4. PMID: 25031133.

Garnock-Jones KP and Keating GM. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. *CNS Drugs* 2010;24(1):85-8. PMID: 20030421.

Gau SS, Ni HC, Shang CY, et al. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. *Aust N Z J Psychiatry* 2010;44(2):135-43. PMID: 20113302.

Georgiopoulos AM and Hua LL. The diagnosis and treatment of attention deficit-hyperactivity disorder in children and adolescents with cystic fibrosis: a retrospective study. *Psychosomatics* 2011;52(2):160-6. PMID: 21397109.

Gerber WD, Gerber-von Muller G, Andrasik F, et al. The impact of a multimodal Summer Camp Training on neuropsychological functioning in children and adolescents with ADHD: an exploratory study. *Child Neuropsychol* 2012;18(3):242-55. PMID: 21824010.

Gerdes AC, Kapke TL, Lawton KE, et al. Culturally adapting parent training for Latino youth with ADHD: Development and pilot. *Journal of Latina/o Psychology* 2015;3(2):71-87. PMID: 2015-18959-001.

Ghanizadeh A, Sayyari Z and Mohammadi MR. Effect of methylphenidate and folic Acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. *Iran J Psychiatry* 2013;8(3):108-12. PMID: 24454418.

Gharebaghy S, Rassafiani M and Cameron D. Effect of cognitive intervention on children with ADHD. *Phys Occup Ther Pediatr* 2015;35(1):13-23. PMID: 25246134.

Giana G, Romano E, Porfirio MC, et al. Detection of auto-antibodies to DAT in the serum: interactions with DAT genotype and psycho-stimulant therapy for ADHD. *J Neuroimmunol* 2015;278:212-22. PMID: 25468771.

Giblin JM and Strobel AL. Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. *J Atten Disord* 2011;15(6):491-8. PMID: 20574056.

Gibson BS, Gondoli DM, Johnson AC, et al. Component analysis of verbal versus spatial working memory training in adolescents with ADHD: a randomized, controlled trial. *Child Neuropsychol* 2011;17(6):546-63. PMID: 21390920.

Gill KE, Chappell AM, Beveridge TJR, et al. Chronic methylphenidate treatment during early life is associated with greater ethanol intake in socially isolated rats. *Alcoholism: Clinical and Experimental Research* 2014;38(8):2260-2268.

Goez HR, Scott O, Nevo N, et al. Using the test of variables of attention to determine the effectiveness of modafinil in children with attention-deficit hyperactivity disorder (ADHD): a prospective methylphenidate-controlled trial. *J Child Neurol* 2012;27(12):1547-52. PMID: 22447850.

Gonzalez-Heydrich J, Whitney J, Waber D, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. *Epilepsy Behav* 2010;18(3):229-37. PMID: 20493783.

Gray KM, Riggs PD, Min SJ, et al. Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders. *Drug Alcohol Depend* 2011;117(2-3):242-7. PMID: 21411243.

Gray L, Miller BS and Evans SW. Training children with ADHD to minimize impulsivity in auditory contralateral masking. *Int J Pediatr Otorhinolaryngol* 2012;76(4):483-7. PMID: 22297209.

Graziano PA, Geffken GR and Lall AS. Heterogeneity in the pharmacological treatment of children with ADHD: cognitive, behavioral, and social functioning differences. *J Atten Disord* 2011;15(5):382-91. PMID: 20495162.

Green CT, Long DL, Green D, et al. Will working memory training generalize to improve off-task behavior in children with attention-deficit/hyperactivity disorder?. *Neurotherapeutics* 2012;9(3):639-48. PMID: 22752960.

Green JG, Avenevoli S, Finkelman M, et al. Attention deficit hyperactivity disorder: concordance of the adolescent version of the Composite International Diagnostic Interview Version 3.0 (CIDI) with the K-SADS in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement. *Int J Methods Psychiatr Res* 2010;19(1):34-49. PMID: 20191660.

Grizenko N, Cai E, Jolicoeur C, et al. Effects of methylphenidate on acute math performance in children with attention-deficit hyperactivity disorder. *Can J Psychiatry* 2013;58(11):632-9. PMID: 24246434.

Grizenko N, Qi Zhang DD, Polotskaia A, et al. Efficacy of Methylphenidate in ADHD Children across the Normal and the Gifted Intellectual Spectrum. *J Can Acad Child Adolesc Psychiatry* 2012;21(4):282-8. PMID: 23133462.

Grizenko N, Zhang DDQ, Polotskaia A, et al. Efficacy of methylphenidate in ADHD children across the normal and the gifted intellectual spectrum. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2012;21(4):282-288.

Groom MJ, Scerif G, Liddle PF, et al. Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit/hyperactivity disorder. *Biological Psychiatry* 2010;67(7):624-631.

Guertin J, LeLorier J, Durand M, et al. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications. *J Popul Ther Clin Pharmacol* 2014;21(3):e357-69. PMID: 25326915.

Gunther T, Herpertz-Dahlmann B and Konrad K. Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2010;20(3):179-86. PMID: 20578930.

Gunther T, Kahraman-Lanzerath B, Knospe EL, et al. Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day. *J Child Adolesc Psychopharmacol* 2012;22(2):131-8. PMID: 22364402.

Gupta K and Mamidi P. A comparative study on Naladadi Ghrita in attention-deficit/hyperactivity disorder with Kushmanda Ghrita. *International Journal of Green Pharmacy* 2013;7(4):322-327.

Haack LM, Villodas MT, McBurnett K, et al. Parenting Mediates Symptoms and Impairment in Children With ADHD-Inattentive Type. *J Clin Child Adolesc Psychol* 2014;1-12. PMID: 25411896.

Haertling F, Mueller B and Bilke-Hentsch O. Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin (R) LA) in school children under daily practice conditions. *Atten Defic Hyperact Disord* 2015;7(2):157-64. PMID: 25346231.

Haghshenas S, Hosseini MS and Aminjan AS. A possible correlation between vestibular stimulation and auditory comprehension in children with attention-deficit/hyperactivity disorder. *Psychology and Neuroscience* 2014;7(2):159-162.

Hahn-Markowitz J, Manor I and Maeir A. Effectiveness of cognitive-functional (Cog-Fun) intervention with children with attention deficit hyperactivity disorder: a pilot study. *Am J Occup Ther* 2011;65(4):384-92. PMID: 21834453.

Hailpern SM, Egan BM, Lewis KD, et al. Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data. *Front Pediatr* 2014;2:100. PMID: 25285304.

Hale JB, Reddy LA, Semrud-Clikeman M, et al. Executive impairment determines ADHD medication response: implications for academic achievement. *J Learn Disabil* 2011;44(2):196-212. PMID: 21383110.

Hall CL, Walker GM, Valentine AZ, et al. Protocol investigating the clinical utility of an objective measure of activity and attention (QbTest) on diagnostic and treatment decision-making in children and young people with ADHD-'Assessing QbTest Utility in ADHD' (AQUA): a randomised controlled trial. *BMJ Open* 2014;4(12):e006838. PMID: 25448628.

Hamidovic A, Dlugos A, Palmer AA, et al. Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. *Behav Genet* 2010;40(2):255-61. PMID: 20091113.

Hammer R, Cooke GE, Stein MA, et al. Functional neuroimaging of visuospatial working memory tasks enables accurate detection of attention deficit and hyperactivity disorder. *NeuroImage: Clinical* 2015;9:244-252.

Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. *J Child Adolesc Psychopharmacol* 2009;19(5):493-9. PMID: 19877973.

Hannesdottir DK, Ingvarsdottir E and Bjornsson A. The OutSMARTers Program for Children With ADHD: A Pilot Study on the Effects of Social Skills, Self-Regulation, and Executive Function Training. *J Atten Disord* 2014. PMID: 24505061.

Hantson J, Wang PP, Grizenko-Vida M, et al. Effectiveness of a therapeutic summer camp for children with ADHD: Phase I Clinical Intervention Trial. *J Atten Disord* 2012;16(7):610-7. PMID: 21856955.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry* 2012;51(7):733-41. PMID: 22721596.

Hartanto TA, Krafft CE, Iosif AM, et al. A trial-by-trial analysis reveals more intense physical activity is associated with better cognitive control performance in attention-deficit/hyperactivity disorder. *Child Neuropsychol* 2015:1-9. PMID: 26059476.

Hautmann C, Rothenberger A and Dopfner M. An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate. *BMC Psychiatry* 2013;13:219. PMID: 24004962.

Hautmann C, Rothenberger A and Dopfner M. Daily Symptom Profiles of Children With ADHD Treated With Modified-Release Methylphenidate: An Observational Study. *J Atten Disord* 2013. PMID: 24062276.

Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. *J Atten Disord* 2011;15(8):674-83. PMID: 20837981.

Haydicky J, Shecter C, Wiener J, et al. Evaluation of MBCT for adolescents with ADHD and their parents: Impact on individual and family functioning. *Journal of Child and Family Studies* 2015;24(1):76-94.

Haydicky J, Wiener J, Badali P, et al. Evaluation of a mindfulness-based intervention for adolescents with learning disabilities and co-occurring ADHD and anxiety. *Mindfulness* 2012;3(2):151-164.

Heinrich H, Busch K, Studer P, et al. Refining the picture of reduced alerting responses in ADHD - a single-trial analysis of event-related potentials. *Neurosci Lett* 2014;582:49-53. PMID: 25218713.

Helgadottir H, Gudmundsson OO, Baldursson G, et al. Electroencephalography as a clinical tool for diagnosing and monitoring attention deficit hyperactivity disorder: a cross-sectional study. *BMJ Open* 2015;5(1):e005500. PMID: 25596195.

Heller MD, Roots K, Srivastava S, et al. A Machine Learning-Based Analysis of Game Data for Attention Deficit Hyperactivity Disorder Assessment. *Games Health J* 2013;2(5):291-8. PMID: 26196929.

Hellwig-Brida S, Daseking M, Keller F, et al. Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(3):245-53. PMID: 21663427.

Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. *Eur Neuropsychopharmacol* 2014;24(12):1861-72. PMID: 25453486.

Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. *J Hum Nutr Diet* 2014;27(Suppl 2):284-91. PMID: 23495677.

Holzer B, Lopes V and Lehman R. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age. *J Child Adolesc Psychopharmacol* 2013;23(6):415-8. PMID: 23952189.

Hong M, Lee WH, Moon DS, et al. A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(6):341-6. PMID: 24955936.

Hosainzadeh Maleki Z, Mashhadi A, Soltanifar A, et al. Barkley's Parent Training Program, Working Memory Training and their Combination for Children with ADHD: Attention Deficit Hyperactivity Disorder. *Iran J Psychiatry* 2014;9(2):47-54. PMID: 25632280.

Iannaccone R, Hauser TU, Ball J, et al. Classifying adolescent attention-deficit/hyperactivity disorder (ADHD) based on functional and structural imaging. *Eur Child Adolesc Psychiatry* 2015;24(10):1279-89. PMID: 25613588.

Ince Tasdelen B, Karakaya E and Oztop DB. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 2015;25(6):494-500. PMID: 26218871.

Ironside S, Davidson F and Corkum P. Circadian motor activity affected by stimulant medication in children with attention-deficit/hyperactivity disorder. *J Sleep Res* 2010;19(4):546-51. PMID: 20629940.

Isaksson J, Nilsson KW and Lindblad F. The Pressure-Activation-Stress scale in relation to ADHD and cortisol. *Eur Child Adolesc Psychiatry* 2015;24(2):153-61. PMID: 24737123.

Iseman JS and Naglieri JA. A cognitive strategy instruction to improve math calculation for children with ADHD and LD: a randomized controlled study. *J Learn Disabil* 2011;44(2):184-95. PMID: 21383109.

Jafari N, Mohammadi MR, Khanbani M, et al. Effect of play therapy on behavioral problems of maladjusted preschool children. *Iran J Psychiatry* 2011;6(1):37-42. PMID: 22952519.

- Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. *Hum Psychopharmacol* 2012;27(4):411-8. PMID: 22806822.
- Jain R, Babcock T, Burtea T, et al. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. *Child Adolesc Psychiatry Ment Health* 2011;5(1):35. PMID: 22054243.
- Jain R, Babcock T, Burtea T, et al. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use. *Adv Ther* 2013;30(5):472-86. PMID: 23681505.
- Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2011;50(2):171-9. PMID: 21241954.
- Janssen M, Wensing M, van der Gaag RJ, et al. Improving patient care for attention deficit hyperactivity disorder in children by organizational redesign (Tornado program) and enhanced collaboration between psychiatry and general practice: a controlled before and after study. *Implement Sci* 2014;9:155. PMID: 25359002.
- Jensen LS, Pagsberg AK and Dalhoff KP. Differences in abuse potential of ADHD drugs measured by contrasting poison centre and therapeutic use data. *Clin Toxicol (Phila)* 2015;53(4):210-4. PMID: 25738696.
- Johnson KA, Barry E, Lambert D, et al. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. *J Child Adolesc Psychopharmacol* 2013;23(10):655-64. PMID: 24350812.
- Johnston C, Weiss MD, Murray C, et al. The effects of instructions on mothers' ratings of attention-deficit/hyperactivity disorder symptoms in referred children. *J Abnorm Child Psychol* 2014;42(3):479-88. PMID: 23963544.
- Johnstone SJ, Roodenrys S, Phillips E, et al. A pilot study of combined working memory and inhibition training for children with AD/HD. *Atten Defic Hyperact Disord* 2010;2(1):31-42. PMID: 21432588.
- Jonkman LM, Hurks PP and Schleepen TM. Effects of memory strategy training on performance and event-related brain potentials of children with ADHD in an episodic memory task. *Neuropsychol Rehabil* 2015:1-32. PMID: 26251965.
- Kahbazi M, Ghoreishi A, Rahiminejad F, et al. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. *Psychiatry Res* 2009;168(3):234-7. PMID: 19439364.
- Kaiser ML, Schoemaker MM, Albaret JM, et al. What is the evidence of impaired motor skills and motor control among children with attention deficit hyperactivity disorder (ADHD)? Systematic review of the literature. *Res Dev Disabil* 2014;36c:338-357. PMID: 25462494.

Katic A, Dirks B, Babcock T, et al. Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments. *J Child Adolesc Psychopharmacol* 2013;23(6):386-93. PMID: 23952185.

Kennel S, Taylor AG, Lyon D, et al. Pilot feasibility study of binaural auditory beats for reducing symptoms of inattention in children and adolescents with attention-deficit/hyperactivity disorder. *J Pediatr Nurs* 2010;25(1):3-11. PMID: 20117669.

Keshavarzi Z, Bajoghli H, Mohamadi MR, et al. In a randomized case-control trial with 10-years olds suffering from attention deficit/hyperactivity disorder (ADHD) sleep and psychological functioning improved during a 12-week sleep-training program. *World J Biol Psychiatry* 2014;15(8):609-19. PMID: 24957753.

Khanna D, Shaw J, Dolan M, et al. Does diagnosis affect the predictive accuracy of risk assessment tools for juvenile offenders: Conduct Disorder and Attention Deficit Hyperactivity Disorder. *J Adolesc* 2014;37(7):1171-9. PMID: 25173178.

Kim BN, Kim YN, Cheong US, et al. Switching from methylphenidate-immediate release (MPH-IR) to methylphenidate-OROS (OROS-MPH): A multi-center, open-label study in Korea. *Clinical Psychopharmacology and Neuroscience* 2011;9(1):29-35.

Kim JW, Park S, Kim BN, et al. Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves. *Pharmacopsychiatry* 2013;46(4):137-46. PMID: 23364873.

Kim JW, Sharma V and Ryan ND. Predicting Methylphenidate Response in ADHD Using Machine Learning Approaches. *Int J Neuropsychopharmacol* 2015;18(11). PMID: 25964505.

Klein RG, Mannuzza S, Olazagasti MAR, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. *JAMA Psychiatry* 2012;69(12):1295-1303.

Knebel W, Rogers J, Polhamus D, et al. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD. *J Pharmacokinet Pharmacodyn* 2015;42(1):45-65. PMID: 25373474.

Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. *Pediatrics* 2011;127(6):e1406-13. PMID: 21555501.

Kollins SH, Lopez FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(2):111-20. PMID: 21476931.

Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. *Pediatrics* 2011;127(4):e862-8. PMID: 21422081.

Kratz O, Studer P, Baack J, et al. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the

Attention Network Test. *Prog Neuropsychopharmacol Biol Psychiatry* 2012;37(1):81-9. PMID: 22227291.

Kray J, Karbach J, Haenig S, et al. Can task-switching training enhance executive control functioning in children with attention deficit/-hyperactivity disorder?. *Front Hum Neurosci* 2011;5:180. PMID: 22291628.

Kubas HA, Backenson EM, Wilcox G, et al. The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. *Postgrad Med* 2012;124(5):33-48. PMID: 23095424.

Lachaine J, Beauchemin C, Sasane R, et al. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. *Postgrad Med* 2012;124(3):139-48. PMID: 22691908.

Lamberti M, Italiano D, Guerriero L, et al. Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder. *Neuropsychiatric Disease and Treatment* 2015;11:1169-1174.

Langberg JM, Epstein JN, Becker SP, et al. Evaluation of the Homework, Organization, and Planning Skills (HOPS) Intervention for Middle School Students with ADHD as Implemented by School Mental Health Providers. *School Psych Rev* 2012;41(3):342-364. PMID: 25355991.

Langberg JM, Vaughn AJ, Williamson P, et al. Refinement of an Organizational Skills Intervention for Adolescents with ADHD for Implementation by School Mental Health Providers. *School Ment Health* 2011;3(3):143-155. PMID: 23599833.

Larranaga-Fragoso P, Noval S, Rivero JC, et al. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. *J aapos* 2015;19(4):322-6. PMID: 26235791.

Larson T, Kerekes N, Selinus EN, et al. Reliability of Autism-Tics, AD/HD, and other Comorbidities (A-TAC) inventory in a test-retest design. *Psychol Rep* 2014;114(1):93-103. PMID: 24765712.

Lecendreux M, Konofal E, Cortese S, et al. A 4-year follow-up of attention-deficit/hyperactivity disorder in a population sample. *J Clin Psychiatry* 2015;76(6):712-9. PMID: 26132672.

Lee J, Grizenko N, Bhat V, et al. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. *BMC Psychiatry* 2011;11:70. PMID: 21510895.

Lee MS, Lee SI, Hong SD, et al. Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12-week multicenter, open-label study. *J Child Adolesc Psychopharmacol* 2013;23(1):22-7. PMID: 23347125.

Lee SH, Seo WS, Sung HM, et al. Effect of methylphenidate on sleep parameters in children with ADHD. *Psychiatry Investig* 2012;9(4):384-90. PMID: 23251204.

- Lee SH, Seox WS, Sung HM, et al. Effect of methylphenidate on sleep parameters in children with ADHD. *Psychiatry Investigation* 2013;10(1):384-390.
- Lee SH, Song DH, Kim BN, et al. Variability of response time as a predictor of methylphenidate treatment response in Korean children with attention deficit hyperactivity disorder. *Yonsei Med J* 2009;50(5):650-5. PMID: 19881968.
- Levy S, Katusic SK, Colligan RC, et al. Childhood ADHD and risk for substance dependence in adulthood: a longitudinal, population-based study. *PLoS One* 2014;9(8):e105640. PMID: 25162629.
- Li L, Yang L, Zhuo CJ, et al. A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD. *Swiss Med Wkly* 2013;143:w13838. PMID: 23986461.
- Liddle EB, Hollis C, Batty MJ, et al. Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. *J Child Psychol Psychiatry* 2011;52(7):761-71. PMID: 21073458.
- Liechti MD, Maurizio S, Heinrich H, et al. First clinical trial of tomographic neurofeedback in attention-deficit/hyperactivity disorder: evaluation of voluntary cortical control. *Clin Neurophysiol* 2012;123(10):1989-2005. PMID: 22608481.
- Lloyd A, Brett D and Wesnes K. Coherence training in children with attention-deficit hyperactivity disorder: cognitive functions and behavioral changes. *Altern Ther Health Med* 2010;16(4):34-42. PMID: 20653294.
- Loh PR, Piek JP and Barrett NC. Comorbid ADHD and DCD: examining cognitive functions using the WISC-IV. *Res Dev Disabil* 2011;32(4):1260-9. PMID: 21377321.
- Looyeh MY, Kamali K and Shafieian R. An exploratory study of the effectiveness of group narrative therapy on the school behavior of girls with attention-deficit/hyperactivity symptoms. *Arch Psychiatr Nurs* 2012;26(5):404-10. PMID: 22999036.
- Lopez FA, Childress A, Adeyi B, et al. ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. *J Atten Disord* 2013. PMID: 23407278.
- Lopez FA, Scheckner B and Childress AC. Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study. *Neuropsychiatr Dis Treat* 2011;7:267-73. PMID: 21654872.
- Luman M, Goos V and Oosterlaan J. Instrumental learning in ADHD in a context of reward: intact learning curves and performance improvement with methylphenidate. *J Abnorm Child Psychol* 2015;43(4):681-91. PMID: 25212229.

- Luman M, Papanikolaou A and Oosterlaan J. The Unique and Combined Effects of Reinforcement and Methylphenidate on Temporal Information Processing in Attention-Deficit/Hyperactivity Disorder. *J Clin Psychopharmacol* 2015;35(4):414-21. PMID: 26075486.
- Lyon GJ, Samar SM, Conelea C, et al. Testing tic suppression: comparing the effects of dexamethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. *J Child Adolesc Psychopharmacol* 2010;20(4):283-9. PMID: 20807066.
- Maeir A, Fisher O, Bar-Ilan RT, et al. Effectiveness of Cognitive-Functional (Cog-Fun) occupational therapy intervention for young children with attention deficit hyperactivity disorder: a controlled study. *Am J Occup Ther* 2014;68(3):260-7. PMID: 24797189.
- Manos MJ, Caserta DA, Short EJ, et al. Evaluation of the duration of action and comparative effectiveness of lisdexamfetamine dimesylate and behavioral treatment in youth with ADHD in a quasi-naturalistic setting. *Journal of Attention Disorders* 2015;19(7):578-590.
- Maric M, van Steensel FJ and Bogels SM. Parental Involvement in CBT for Anxiety-Disordered Youth Revisited: Family CBT Outperforms Child CBT in the Long Term for Children With Comorbid ADHD Symptoms. *J Atten Disord* 2015. PMID: 25755259.
- Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. *Eur Child Adolesc Psychiatry* 2010;19(1):57-66. PMID: 19568826.
- Marx AM, Ehlis AC, Furdea A, et al. Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study. *Front Hum Neurosci* 2014;8:1038. PMID: 25610390.
- Matos M, Bauermeister JJ and Bernal G. Parent-child interaction therapy for Puerto Rican preschool children with ADHD and behavior problems: a pilot efficacy study. *Fam Process* 2009;48(2):232-52. PMID: 19579907.
- Matsuura N, Ishitobi M, Arai S, et al. Distinguishing between autism spectrum disorder and attention deficit hyperactivity disorder by using behavioral checklists, cognitive assessments, and neuropsychological test battery. *Asian Journal of Psychiatry* 2014;12:50-57.
- Matsuura N, Ishitobi M, Arai S, et al. Effects of methylphenidate in children with attention deficit hyperactivity disorder: A near-infrared spectroscopy study with CANTAB®. *Child and Adolescent Psychiatry and Mental Health* 2014;8.
- Maurizio S, Liechti MD, Heinrich H, et al. Comparing tomographic EEG neurofeedback and EMG biofeedback in children with attention-deficit/hyperactivity disorder. *Biol Psychol* 2014;95:31-44. PMID: 24211870.
- Mazaheri A, Fassbender C, Coffey-Corina S, et al. Differential oscillatory electroencephalogram between attention-deficit/hyperactivity disorder subtypes and typically developing adolescents. *Biological Psychiatry* 2014;76(5):422-429.

- Mazzone L, Postorino V, Reale L, et al. Self-esteem evaluation in children and adolescents suffering from ADHD. *Clin Pract Epidemiol Ment Health* 2013;9:96-102. PMID: 23878614.
- McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. *Pharmacoepidemiol Drug Saf* 2013;22(4):386-93. PMID: 23280590.
- McCracken JT, Badashova KK, Posey DJ, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. *Pharmacogenomics J* 2014;14(3):295-302. PMID: 23856854.
- McGough JJ, Greenbaum M, Adeyi B, et al. Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. *Journal of Clinical Psychopharmacology* 2012;32(1):138-140. PMID: 2012-02030-029.
- McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. *Brain Stimul* 2015;8(2):299-304. PMID: 25533244.
- Medina JA, Netto TL, Muszkat M, et al. Exercise impact on sustained attention of ADHD children, methylphenidate effects. *Atten Defic Hyperact Disord* 2010;2(1):49-58. PMID: 21432590.
- Meisel V, Servera M, Garcia-Banda G, et al. Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up. *Biol Psychol* 2013;94(1):12-21. PMID: 23665196.
- Meisel V, Servera M, Garcia-Banda G, et al. Reprint of "Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up". *Biol Psychol* 2014;95:116-25. PMID: 24055220.
- Menezes A, Dias NM, Trevisan BT, et al. Intervention for executive functions in attention deficit and hyperactivity disorder. *Arq Neuropsiquiatr* 2015;73(3):227-36. PMID: 25807129.
- Mikami AY, Cox DJ, Davis MT, et al. Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder. *J Clin Psychol Med Settings* 2009;16(3):233-42. PMID: 19418208.
- Mikami AY, Griggs MS, Lerner MD, et al. A randomized trial of a classroom intervention to increase peers' social inclusion of children with attention-deficit/hyperactivity disorder. *J Consult Clin Psychol* 2013;81(1):100-12. PMID: 22866680.
- Miranda A, Presentacion MJ, Siegenthaler R, et al. Effects of a psychosocial intervention on the executive functioning in children with ADHD. *J Learn Disabil* 2013;46(4):363-76. PMID: 22064952.

- Miyahara M, Healey DM and Halperin JM. One-week temporal stability of hyperactivity in preschoolers with ADHD during psychometric assessment. *Psychiatry Clin Neurosci* 2014;68(2):120-6. PMID: 24552632.
- Mohammadi MR, Hafezi P, Galeiha A, et al. Buspirone versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. *Acta Med Iran* 2012;50(11):723-8. PMID: 23292622.
- Mohammadi MR, Kazemi MR, Zia E, et al. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. *Hum Psychopharmacol* 2010;25(7-8):560-5. PMID: 21312290.
- Mohammadi MR, Mohammadzadeh S and Akhondzadeh S. Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: A double-blind, randomized clinical trial. *Iranian Journal of Psychiatry* 2015;10(2):106-114.
- Mohammadi MR, Soleimani AA, Farahmand Z, et al. A comparison of effectiveness of regulation of working memory function and methylphenidate on remediation of attention deficit hyperactivity disorder (ADHD). *Iran J Psychiatry* 2014;9(1):25-30. PMID: 25561945.
- Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. *Curr Med Res Opin* 2009;25(11):2745-54. PMID: 19785510.
- Moreno A, Duno L, Hoekzema E, et al. Striatal volume deficits in children with ADHD who present a poor response to methylphenidate. *Eur Child Adolesc Psychiatry* 2014;23(9):805-12. PMID: 24395136.
- Morgan PL, Li H, Cook M, et al. Which Kindergarten Children Are at Greatest Risk for Attention-Deficit/Hyperactivity and Conduct Disorder Symptomatology as Adolescents?. *Sch Psychol Q* 2015. PMID: 26192391.
- Moshe K, Karni A and Tirosh E. Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. *Atten Defic Hyperact Disord* 2012;4(3):153-8. PMID: 22622628.
- Munkvold LH, Manger T and Lundervold AJ. Conners' continuous performance test (CCPT-II) in children with ADHD, ODD, or a combined ADHD/ODD diagnosis. *Child Neuropsychol* 2014;20(1):106-26. PMID: 23244393.
- Munz MT, Prehn-Kristensen A, Thielking F, et al. Slow oscillating transcranial direct current stimulation during non-rapid eye movement sleep improves behavioral inhibition in attention-deficit/hyperactivity disorder. *Front Cell Neurosci* 2015;9:307. PMID: 26321911.
- Murray DW, Childress A, Giblin J, et al. Effects of OROS methylphenidate on academic, behavioral, and cognitive tasks in children 9 to 12 years of age with attention-deficit/hyperactivity disorder. *Clin Pediatr (Phila)* 2011;50(4):308-20. PMID: 21436147.

Murrell AR, Steinberg DS, Connally ML, et al. Acting out to ACTing on: A preliminary investigation in youth with ADHD and co-morbid disorders. *Journal of Child and Family Studies* 2015;24(7):2174-2181.

Nagashima M, Monden Y, Dan I, et al. Neuropharmacological effect of atomoxetine on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy. *Neurophotonics* 2014;1(2):025007. PMID: 26157979.

Nagashima M, Monden Y, Dan I, et al. Neuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy. *Neurophotonics* 2014;1(1):015001. PMID: 26157971.

Nagy P, Hage A, Coghill DR, et al. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. *Eur Child Adolesc Psychiatry* 2015. PMID: 25999292.

Newcorn JH and Donnelly C. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder. *Mt Sinai J Med* 2009;76(2):198-203. PMID: 19306385.

Newcorn JH, Sutton VK, Weiss MD, et al. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. *J Am Acad Child Adolesc Psychiatry* 2009;48(5):511-8. PMID: 19318988.

Newcorn JH, Stein MA and Cooper KM. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. *J Child Adolesc Psychopharmacol* 2010;20(3):187-96. PMID: 20578931.

Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. *J Am Acad Child Adolesc Psychiatry* 2013;52(9):921-30. PMID: 23972694.

Niederhofer H. Agomelatine treatment with adolescents with ADHD. *J Atten Disord* 2012;16(6):530-2. PMID: 22668524.

Niederhofer H. Treating ADHD with agomelatine. *J Atten Disord* 2012;16(4):346-8. PMID: 22491963.

Ogrim G and Hestad KA. Effects of neurofeedback versus stimulant medication in attention-deficit/hyperactivity disorder: a randomized pilot study. *J Child Adolesc Psychopharmacol* 2013;23(7):448-57. PMID: 23808786.

Ogrim G, Hestad KA, Brunner JF, et al. Predicting acute side effects of stimulant medication in pediatric attention deficit/hyperactivity disorder: data from quantitative electroencephalography,

- event-related potentials, and a continuous-performance test. *Neuropsychiatr Dis Treat* 2013;9:1301-9. PMID: 24043939.
- O'Mahony N, Florentino-Liano B, Carballo JJ, et al. Objective diagnosis of ADHD using IMUs. *Med Eng Phys* 2014;36(7):922-6. PMID: 24657100.
- O'Neill S, Schneiderman RL, Rajendran K, et al. Reliable ratings or reading tea leaves: can parent, teacher, and clinician behavioral ratings of preschoolers predict ADHD at age six?. *J Abnorm Child Psychol* 2014;42(4):623-34. PMID: 24085388.
- Park P, Caballero J and Omidian H. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics. *Ann Pharmacother* 2014;48(1):86-92. PMID: 24259607.
- Park S, Kim BN, Cho SC, et al. Baseline severity of parent-perceived inattentiveness is predictive of the difference between subjective and objective methylphenidate responses in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2013;23(6):410-4. PMID: 23952188.
- Park S, Kim BN, Cho SC, et al. The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(4):223-7. PMID: 24815731.
- Park S, Kim B-N, Kim J-W, et al. Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder. *Journal of Psychopharmacology* 2014;28(3):220-226. PMID: 2014-10977-004.
- Park S, Kim JW, Kim BN, et al. Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea. *J Psychopharmacol* 2014;28(7):671-676. PMID: 24763183.
- Pelham WE, Burrows-MacLean L, Gnagy EM, et al. A dose-ranging study of behavioral and pharmacological treatment in social settings for children with ADHD. *J Abnorm Child Psychol* 2014;42(6):1019-31. PMID: 24429997.
- Pelham WE, Jr., Gnagy EM, Sibley MH, et al. Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD. *J Atten Disord* 2013. PMID: 23893533.
- Pelsser LM, Frankena K, Toorman J, et al. A randomised controlled trial into the effects of food on ADHD. *Eur Child Adolesc Psychiatry* 2009;18(1):12-9. PMID: 18431534.
- Pelsser LM, van Steijn DJ, Frankena K, et al. A randomized controlled pilot study into the effects of a restricted elimination diet on family structure in families with ADHD and ODD. *Child and Adolescent Mental Health* 2013;18(1):39-45.

Percinel I, Yazici KU and Ustundag B. Iron Deficiency Parameters in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. *Child Psychiatry Hum Dev* 2015. PMID: 26092605.

Perreau-Linck E, Lessard N, Lévesque J, et al. Effects of neurofeed back training on inhibitory capacities in ADHD children: A single-blind, randomized, placebo-controlled study. *Journal of Neurotherapy* 2010;14(3):229-242.

Peyre H, Speranza M, Cortese S, et al. Do ADHD children with and without Child Behavior Checklist–Dysregulation Profile have different clinical characteristics, cognitive features, and treatment outcomes?. *Journal of Attention Disorders* 2015;19(1):63-71.

Pierce D, Katic A, Buckwalter M, et al. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. *J Clin Psychopharmacol* 2010;30(5):554-64. PMID: 20814325.

Pontifex MB, Saliba BJ, Raine LB, et al. Exercise improves behavioral, neurocognitive, and scholastic performance in children with attention-deficit/hyperactivity disorder. *J Pediatr* 2013;162(3):543-51. PMID: 23084704.

Posner J, Siciliano F, Wang Z, et al. A multimodal MRI study of the hippocampus in medication-naive children with ADHD: what connects ADHD and depression?. *Psychiatry Res* 2014;224(2):112-8. PMID: 25220159.

Posserud MB, Ullebø AK, Plessen KJ, et al. Influence of assessment instrument on ADHD diagnosis. *European Child and Adolescent Psychiatry* 2014;23(4):197-205.

Power TJ, Mautone JA, Marshall SA, et al. Feasibility and potential effectiveness of integrated services for children with ADHD in urban primary care practices. *Clinical Practice in Pediatric Psychology* 2014;2(4):412-426.

Prehn-Kristensen A, Krauel K, Hinrichs H, et al. Methylphenidate does not improve interference control during a working memory task in young patients with attention-deficit hyperactivity disorder. *Brain Research* 2011;1388:56-68.

Prehn-Kristensen A, Munz M, Goder R, et al. Transcranial oscillatory direct current stimulation during sleep improves declarative memory consolidation in children with attention-deficit/hyperactivity disorder to a level comparable to healthy controls. *Brain Stimul* 2014;7(6):793-9. PMID: 25153776.

Quantitative electroencephalography as a diagnostic aid for attention-deficit/hyperactivity disorder in children. *Technol Eval Cent Assess Program Exec Summ* 2014;29(1):1-6. PMID: 25577822.

Rajender G, Malhotra S, Bhatia MS, et al. Efficacy of cognitive retraining techniques in children with attention deficit hyperactivity disorder. *German Journal of Psychiatry* 2011;14(2):55-60.

Raman SR, Marshall SW, Haynes K, et al. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. *Inj Prev* 2013;19(3):164-70. PMID: 23143347.

Ramtvedt BE, Aabech HS and Sundet K. Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. *J Child Adolesc Psychopharmacol* 2014;24(3):130-9. PMID: 24666268.

Ramtvedt BE, Roinas E, Aabech HS, et al. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. *J Child Adolesc Psychopharmacol* 2013;23(9):597-604. PMID: 23659360.

Richardson M, Moore DA, Gwernan-Jones R, et al. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. *Health Technol Assess* 2015;19(45):1-470. PMID: 26129788.

Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. *J Am Acad Child Adolesc Psychiatry* 2011;50(9):903-14. PMID: 21871372.

Rimvall MK, Elberling H, Rask CU, et al. Predicting ADHD in school age when using the Strengths and Difficulties Questionnaire in preschool age: a longitudinal general population study, CCC2000. *Eur Child Adolesc Psychiatry* 2014;23(11):1051-60. PMID: 24737124.

Robb AS, Findling RL, Childress AC, et al. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD. *J Atten Disord* 2014. PMID: 24874348.

Rommel AS, Lichtenstein P, Rydell M, et al. Is Physical Activity Causally Associated With Symptoms of Attention-Deficit/Hyperactivity Disorder?. *J Am Acad Child Adolesc Psychiatry* 2015;54(7):565-70. PMID: 26088661.

Rosch KS, Fosco WD, Pelham WE, Jr., et al. Reinforcement and Stimulant Medication Ameliorate Deficient Response Inhibition in Children with Attention-Deficit/Hyperactivity Disorder. *J Abnorm Child Psychol* 2015. PMID: 25985978.

Rosenberg L, Maeir A, Yochman A, et al. Effectiveness of a cognitive-functional group intervention among preschoolers with attention deficit hyperactivity disorder: A pilot study. *American Journal of Occupational Therapy* 2015;69(3):p1-p8.

Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. *Neuropharmacology* 2009;57(7-8):640-52. PMID: 19715709.

Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. *Neuropsychopharmacology* 2011;36(8):1575-86. PMID: 21451498.

Ruggiero S, Rafaniello C, Bravaccio C, et al. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. *J Child Adolesc Psychopharmacol* 2012;22(6):415-22. PMID: 23234585.

Rugino TA. Effect on Primary Sleep Disorders When Children With ADHD Are Administered Guanfacine Extended Release. *J Atten Disord* 2014. PMID: 25376194.

Sallee FR, Kollins SH and Wigal TL. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2012;22(3):206-14. PMID: 22612526.

Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2009;48(2):155-65. PMID: 19106767.

Sander C, Arns M, Olbrich S, et al. EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder. *Clin Neurophysiol* 2010;121(9):1511-8. PMID: 20382071.

Sanefuji M, Yamashita H, Torisu H, et al. Altered strategy in short-term memory for pictures in children with attention-deficit/hyperactivity disorder: a near-infrared spectroscopy study. *Psychiatry Res* 2014;223(1):37-42. PMID: 24840133.

Santisteban JA, Stein MA, Bergmame L, et al. Effect of extended-release dexamethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder. *CNS Drugs* 2014;28(9):825-33. PMID: 25056567.

Sasaki T, Hashimoto K, Tachibana M, et al. Tlpepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. *Neuropsychiatr Dis Treat* 2014;10:147-51. PMID: 24493927.

Schawo S, van der Kolk A, Bouwmans C, et al. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?. *Pharmacoeconomics* 2015;33(5):489-509. PMID: 25715975.

Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. *Pediatrics* 2011;127(6):1102-10. PMID: 21576311.

Schlochtermeyer L, Stoy M, Schlagenhaut F, et al. Childhood methylphenidate treatment of ADHD and response to affective stimuli. *Eur Neuropsychopharmacol* 2011;21(8):646-54. PMID: 20570115.

Schuck SE, Emmerson NA, Fine AH, et al. Canine-assisted therapy for children with ADHD: preliminary findings from the positive assertive cooperative kids study. *J Atten Disord* 2015;19(2):125-37. PMID: 24062278.

Schulz E, Fleischhaker C, Hennighausen K, et al. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin (R) LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. *J Child Adolesc Psychopharmacol* 2010;20(5):377-85. PMID: 20973708.

Schulz E, Fleischhaker C, Hennighausen K, et al. A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin((R)) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks. *Atten Defic Hyperact Disord* 2010;2(3):133-8. PMID: 21432599.

Schwartz BS, Bailey-Davis L, Bandeen-Roche K, et al. Attention deficit disorder, stimulant use, and childhood body mass index trajectory. *Pediatrics* 2014;133(4):668-76. PMID: 24639278.

Schwenck C and Freitag CM. Differentiation between attention-deficit/hyperactivity disorder and autism spectrum disorder by the social communication questionnaire. *Atten Defic Hyperact Disord* 2014;6(3):221-9. PMID: 24966019.

Sciberras E, Lycett K, Efron D, et al. Anxiety in children with attention-deficit/hyperactivity disorder. *Pediatrics* 2014;133(5):801-8. PMID: 24753534.

Sciberras E, Mulraney M, Anderson V, et al. Managing Anxiety in Children With ADHD Using Cognitive-Behavioral Therapy: A Pilot Randomized Controlled Trial. *J Atten Disord* 2015. PMID: 25939582.

Seeley JR, Small JW, Walker HM, et al. Efficacy of the First Step to Success intervention for students with attention-deficit/hyperactivity disorder. *School Mental Health* 2009;1(1):37-48.

Seida JC, Schouten JR, Mousavi SS, et al. AHRQ Comparative Effectiveness Reviews. 2012. PMID: 22439156.

Setyawan J, Yang H, Cheng D, et al. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. *Value Health* 2015;18(6):824-31. PMID: 26409610.

Shahani SA, Evans WN, Mayman GA, et al. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective. *Pediatr Cardiol* 2014;35(3):485-9. PMID: 24141829.

Shang CY and Gau SS. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2012;22(5):353-63. PMID: 23083022.

Shang CY, Pan YL, Lin HY, et al. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 2015;25(7):566-73. PMID: 26222447.

Shemmassian SK and Lee SS. Comparing four methods of integrating parent and teacher symptom ratings of attention-deficit/hyperactivity disorder (ADHD). *Journal of Psychopathology and Behavioral Assessment* 2012;34(1):1-10.

Sibley MH, Altszuler AR, Morrow AS, et al. Mapping the academic problem behaviors of adolescents with ADHD. *Sch Psychol Q* 2014;29(4):422-37. PMID: 24933215.

Sibley MH, Pelham Jr WE, Derefinko KJ, et al. A pilot trial of supporting teens' academic needs daily (STAND): A parent-adolescent collaborative intervention for ADHD. *Journal of Psychopathology and Behavioral Assessment* 2013;35(4):436-449.

Sibley MH, Pelham WE, Evans SW, et al. An Evaluation of a Summer Treatment Program for Adolescents With ADHD. *Cognitive and Behavioral Practice* 2011;18(4):530-544.

Sigi Hale T, Wiley JF, Smalley SL, et al. A parietal biomarker for ADHD liability: As predicted by the distributed effects perspective model of ADHD. *Frontiers in Psychiatry* 2015;6(MAY).

Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. *Pharmacoepidemiol Drug Saf* 2012;21(Suppl 2):130-7. PMID: 22552988.

Sikirica V, Haim Erder M, Xie J, et al. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. *Pharmacoeconomics* 2012;30(8):e1-15. PMID: 22788263.

Sikirica V, Findling RL, Signorovitch J, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. *CNS Drugs* 2013;27(11):943-53. PMID: 23975660.

Silk TJ, Newman DP, Eramudugolla R, et al. Influence of methylphenidate on spatial attention asymmetry in adolescents with attention deficit hyperactivity disorder (ADHD): preliminary findings. *Neuropsychologia* 2014;56:178-83. PMID: 24486422.

Silva RR, Brams M, McCague K, et al. Extended-release dexamethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder. *Clin Neuropharmacol* 2013;36(4):117-21. PMID: 23860345.

Simonoff E, Taylor E, Baird G, et al. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. *J Child Psychol Psychiatry* 2013;54(5):527-35. PMID: 22676856.

Siu AFY and Zhou Y. Behavioral Assessment of the Dysexecutive Syndrome for Children: An examination of clinical utility for children with attention-deficit hyperactivity disorder (ADHD). *Journal of Child Neurology* 2014;29(5):608-616.

Sjowall D, Bohlin G, Rydell AM, et al. Neuropsychological deficits in preschool as predictors of ADHD symptoms and academic achievement in late adolescence. *Child Neuropsychol* 2015;1-18. PMID: 26212755.

Skogan AH, Zeiner P, Egeland J, et al. Parent ratings of executive function in young preschool children with symptoms of attention-deficit/-hyperactivity disorder. *Behav Brain Funct* 2015;11:16. PMID: 25889243.

Slama H, Fery P, Verheulpen D, et al. Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate. *J Child Neurol* 2015;30(8):1000-9. PMID: 25296928.

Smith A, Cubillo A, Barrett N, et al. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination. *Biol Psychiatry* 2013;74(8):615-22. PMID: 23731741.

Snircova E, Hrtanek I, Kulhan T, et al. Atomoxetine and methylphenidate treatment in ADHD. *Acta Medica Martiniana* 2015;15(1):20-26.

Socanski D, Aurlien D, Herigstad A, et al. Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?. *Seizure* 2015;25:80-3. PMID: 25645642.

Solanto M, Newcorn J, Vail L, et al. Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(6):663-71. PMID: 20035584.

Song DH, Choi S, Joung YS, et al. Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study. *Psychiatry Investig* 2012;9(3):257-62. PMID: 22993525.

Sonnby K, Skordas K, Olofsdotter S, et al. Validation of the World Health Organization Adult ADHD Self-Report Scale for adolescents. *Nord J Psychiatry* 2015;69(3):216-23. PMID: 25348323.

Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. *CNS Drugs* 2013;27(9):743-51. PMID: 23801529.

Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-

deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(5):501-10. PMID: 19877974.

Sprich SE, Burbridge J, Lerner JA, et al. Cognitive-behavioral therapy for ADHD in adolescents: Clinical considerations and a case series. *Cognitive and Behavioral Practice* 2015;22(2):116-126.

Steenhuis MP, Serra M, Minderaa RB, et al. An Internet version of the Diagnostic Interview Schedule for Children (DISC-IV): correspondence of the ADHD section with the paper-and-pencil version. *Psychol Assess* 2009;21(2):231-4. PMID: 19485678.

Stein MA, Sikirica V, Weiss MD, et al. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. *CNS Drugs* 2015. PMID: 26547425.

Stein MA, Waldman I, Newcorn J, et al. Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(5):238-44. PMID: 24813374.

Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexamethylphenidate and mixed amphetamine salts. *J Child Adolesc Psychopharmacol* 2011;21(6):581-8. PMID: 22136094.

Steiner NJ, Sheldrick RC, Gotthelf D, et al. Computer-based attention training in the schools for children with attention deficit/hyperactivity disorder: a preliminary trial. *Clin Pediatr (Phila)* 2011;50(7):615-22. PMID: 21561933.

Steinhausen HC and Bisgaard C. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. *Eur Neuropsychopharmacol* 2014;24(2):232-41. PMID: 24314850.

Storebo OJ, Skoog M, Rasmussen PD, et al. Attachment Competences in Children With ADHD During the Social-Skills Training and Attachment (SOSTRA) Randomized Clinical Trial. *J Atten Disord* 2015;19(10):865-71. PMID: 24532801.

Strand MT, Hawk LW, Jr., Bubnik M, et al. Improving working memory in children with attention-deficit/hyperactivity disorder: the separate and combined effects of incentives and stimulant medication. *J Abnorm Child Psychol* 2012;40(7):1193-207. PMID: 22477205.

Svanborg P, Thernlund G, Gustafsson PA, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. *Eur Child Adolesc Psychiatry* 2009;18(12):725-35. PMID: 19466476.

Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. *Eur Child Adolesc Psychiatry* 2009;18(4):240-9. PMID: 19156355.

Symmes A, Winters KC, Fahnhorst T, et al. The Association Between Attention-Deficit Hyperactivity Disorder and Nicotine Use Among Adolescents and Young Adults. *J Child Adolesc Subst Abuse* 2015;24(1):37-45. PMID: 25632218.

Takahashi J, Yasumura A, Nakagawa E, et al. Changes in negative and positive EEG shifts during slow cortical potential training in children with attention-deficit/hyperactivity disorder: A preliminary investigation. *NeuroReport: For Rapid Communication of Neuroscience Research* 2014;25(8):618-624. PMID: 2014-17071-013.

Takahashi M, Takita Y, Yamazaki K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(4):341-50. PMID: 19702486.

Ter-Stepanian M, Grizenko N, Zappitelli M, et al. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. *Can J Psychiatry* 2010;55(5):305-12. PMID: 20482957.

Teuscher NS, Adjei A, Findling RL, et al. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. *Drug Des Devel Ther* 2015;9:2767-75. PMID: 26060393.

Thompson MJ, Laver-Bradbury C, Ayres M, et al. A small-scale randomized controlled trial of the revised new forest parenting programme for preschoolers with attention deficit hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2009;18(10):605-16. PMID: 19404717.

Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. *J Am Acad Child Adolesc Psychiatry* 2010;49(6):573-82. PMID: 20494267.

Timler GR. Use of the Children's Communication Checklist-2 for classification of language impairment risk in young school-age children with attention-deficit/hyperactivity disorder. *Am J Speech Lang Pathol* 2014;23(1):73-83. PMID: 24018696.

Toufic Seblany H, Ștefania Dinu I, Safer M, et al. Pharmacological treatment in stabilizing the symptoms in children with ADHD symptoms. *Farmacia* 2013;61(5):1000-1008.

Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. *J Clin Psychiatry* 2009;70(5):756-64. PMID: 19389329.

Tse YJ, McCarty CA, Stoep AV, et al. Teletherapy delivery of caregiver behavior training for children with attention-deficit hyperactivity disorder. *Telemed J E Health* 2015;21(6):451-8. PMID: 25719609.

Tsheringla S, Simon A, Russell PS, et al. ADD-H-Comprehensive Teacher's Rating Scale (ACTeRS): a measure for attention deficit hyperactivity disorder among children with intellectual disability in India. *Indian J Pediatr* 2014;81(Suppl 2):S161-4. PMID: 25265891.

Tucha O, Tucha L, Kaumann G, et al. Training of attention functions in children with attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord* 2011;3(3):271-83. PMID: 21597880.

Umar MU, Obindo JT and Omigbodun OO. Prevalence and Correlates of ADHD Among Adolescent Students in Nigeria. *J Atten Disord* 2015. PMID: 26220786.

Upadhyaya H, Kratochvil C, Ghuman J, et al. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol* 2014. PMID: 25265343.

van de Weijer-Bergsma E, Formsma AR, Bruin EI, et al. The effectiveness of mindfulness training on behavioral problems and attentional functioning in adolescents with ADHD. *Journal of Child and Family Studies* 2012;21(5):775-787.

van den Ban EF, Souverein PC, van Engeland H, et al. Differences in ADHD medication usage patterns in children and adolescents from different cultural backgrounds in the Netherlands. *Soc Psychiatry Psychiatr Epidemiol* 2015;50(7):1153-62. PMID: 26017546.

van den Hoofdakker BJ, Hoekstra PJ, van der Veen-Mulders L, et al. Paternal influences on treatment outcome of behavioral parent training in children with attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry* 2014;23(11):1071-9. PMID: 24878676.

van der Donk ML, Hiemstra-Beernink AC, Tjeenk-Kalff AC, et al. Interventions to improve executive functioning and working memory in school-aged children with AD(H)D: a randomised controlled trial and stepped-care approach. *BMC Psychiatry* 2013;13:23. PMID: 23311304.

van der Kolk A, Bouwmans CA, Schawo SJ, et al. Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents. *J Ment Health Policy Econ* 2014;17(3):119-29. PMID: 25543115.

van der Oord S, Ponsioen AJ, Geurts HM, et al. A pilot study of the efficacy of a computerized executive functioning remediation training with game elements for children with ADHD in an outpatient setting: outcome on parent- and teacher-rated executive functioning and ADHD behavior. *J Atten Disord* 2014;18(8):699-712. PMID: 22879577.

van der Oord S, Prins PJ, Oosterlaan J, et al. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study. *Clin Psychol Psychother* 2012;19(3):270-8. PMID: 21404369.

Van Der Schans J, Kotsopoulos N, Hoekstra PJ, et al. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. *PLoS ONE* 2015;10(5).

van Dongen-Boomsma M, Vollebregt MA, Slaats-Willems D, et al. A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder. *J Clin Psychiatry* 2013;74(8):821-7. PMID: 24021501.

van Rooij D, Hoekstra PJ, Mennes M, et al. Distinguishing Adolescents With ADHD From Their Unaffected Siblings and Healthy Comparison Subjects by Neural Activation Patterns During Response Inhibition. *Am J Psychiatry* 2015;172(7):674-83. PMID: 25615565.

Vander Stoep A and Myers K. Methodology for conducting the children's attention-deficit hyperactivity disorder telemental health treatment study in multiple underserved communities. *Clin Trials* 2013;10(6):949-58. PMID: 23897950.

Vaughn AJ and Hoza B. The incremental utility of behavioral rating scales and a structured diagnostic interview in the assessment of attention-deficit/hyperactivity disorder. *Journal of Emotional and Behavioral Disorders* 2013;21(4):227-239. PMID: 2013-38804-001.

Verkuijl N, Perkins M and Fazel M. Childhood attention-deficit/hyperactivity disorder. *Bmj* 2015;350:h2168. PMID: 25994532.

Villemonteix T, De Brito SA, Kavec M, et al. Grey matter volumes in treatment naive vs. chronically treated children with attention deficit/hyperactivity disorder: a combined approach. *Eur Neuropsychopharmacol* 2015;25(8):1118-27. PMID: 25934396.

Vogt C and Shameli A. Assessments for attention-deficit hyperactivity disorder: Use of objective measurements. *Psychiatrist* 2011;35(10):380-383.

Vollebregt MA, van Dongen-Boomsma M, Buitelaar JK, et al. Does EEG-neurofeedback improve neurocognitive functioning in children with attention-deficit/hyperactivity disorder? A systematic review and a double-blind placebo-controlled study. *J Child Psychol Psychiatry* 2014;55(5):460-72. PMID: 24168522.

Wagner DJ, Vallerand IA and McLennan JD. Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project. *J Child Adolesc Psychopharmacol* 2014;24(9):472-80. PMID: 25329880.

Wang LJ, Hsiao CC, Huang YS, et al. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate. *Psychoneuroendocrinology* 2011;36(8):1209-16. PMID: 21411231.

Waxmonsky JG, Waschbusch DA, Akinnusi O, et al. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(1):21-32. PMID: 21288121.

Waxmonsky JG, Waschbusch DA, Pelham WE, et al. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. *J Clin Psychiatry* 2010;71(11):1535-51. PMID: 20673557.

Waxmonsky JG, Wymbs FA, Pariseau ME, et al. A novel group therapy for children with ADHD and severe mood dysregulation. *J Atten Disord* 2013;17(6):527-41. PMID: 22373865.

Weaver L, Rostain AL, Mace W, et al. Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study. *J ect* 2012;28(2):98-103. PMID: 22551775.

Wehmeier PM, Dittmann RW, Banaschewski T, et al. Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology?. *J Atten Disord* 2014;18(2):105-16. PMID: 22617861.

Wehmeier PM, Kipp L, Banaschewski T, et al. Does comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device?. *Journal of Attention Disorders* 2015;19(7):591-602. PMID: 2015-29687-004.

Wehmeier PM, Schacht A, Escobar R, et al. Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials. *Atten Defic Hyperact Disord* 2012;4(1):25-35. PMID: 22271466.

Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. *Qual Life Res* 2011;20(5):691-702. PMID: 21136299.

Wehmeier PM, Schacht A, Ulberstad F, et al. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology. *J Clin Psychopharmacol* 2012;32(5):653-60. PMID: 22926599.

Wehmeier PM, Schacht A, Wolff C, et al. Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. *J Child Adolesc Psychopharmacol* 2011;21(5):433-44. PMID: 22040189.

Weisler RH, Adler LA, Kollins SH, et al. Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate. *Neuropsychiatr Dis Treat* 2014;10:1-12. PMID: 24363557.

Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. *J Child Adolesc Psychopharmacol* 2009;19(5):575-82. PMID: 19877982.

Wentz E, Nyden A and Krevers B. Development of an internet-based support and coaching model for adolescents and young adults with ADHD and autism spectrum disorders: a pilot study. *Eur Child Adolesc Psychiatry* 2012;21(11):611-22. PMID: 22736195.

Whalen CK, Henker B, Ishikawa SS, et al. Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study. *J Atten Disord* 2010;13(4):391-400. PMID: 19474461.

Wiesner M, Windle M, Kanouse DE, et al. DISC Predictive Scales (DPS): Factor Structure and Uniform Differential Item Functioning Across Gender and Three Racial/Ethnic Groups for ADHD, Conduct Disorder, and Oppositional Defiant Disorder Symptoms. *Psychol Assess* 2015. PMID: 25774639.

Wietecha L, Williams D, Shaywitz S, et al. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. *J Child Adolesc Psychopharmacol* 2013;23(9):605-13. PMID: 24206099.

Wietecha LA, Ruff DD, Allen AJ, et al. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. *J Clin Psychiatry* 2013;74(12):1217-23. PMID: 24434090.

Wigal SB, Childress AC, Belden HW, et al. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. *J Child Adolesc Psychopharmacol* 2013;23(1):3-10. PMID: 23289899.

Wigal SB, Greenhill LL, Nordbrock E, et al. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(10):562-9. PMID: 25470572.

Wigal SB, Jun A, Wong AA, et al. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?. *Postgrad Med* 2010;122(5):27-34. PMID: 20861585.

Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. *Child Adolesc Psychiatry Ment Health* 2009;3(1):17. PMID: 19508731.

Wigal SB, Kollins SH, Childress AC, et al. Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. *Child Adolesc Psychiatry Ment Health* 2010;4:32. PMID: 21156071.

Wigal SB, Nordbrock E, Adjei AL, et al. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. *CNS Drugs* 2015;29(4):331-40. PMID: 25877989.

Wigal SB, Wigal T, Schuck S, et al. Academic, behavioral, and cognitive effects of OROS(R) methylphenidate on older children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(2):121-31. PMID: 21488750.

Wigal SB, Wong AA, Jun A, et al. Adverse events in medication treatment-naive children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate. *J Child Adolesc Psychopharmacol* 2012;22(2):149-56. PMID: 22372513.

Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2012;51(1):74-85.e2. PMID: 22176941.

Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. *J Am Acad Child Adolesc Psychiatry* 2011;50(1):73-84.e1. PMID: 21156272.

Wilens TE, Hammerness P, Martelon M, et al. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. *J Clin Psychiatry* 2010;71(5):548-56. PMID: 20492851.

Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. *J Child Adolesc Psychopharmacol* 2009;19(5):485-92. PMID: 19877972.

Wilens TE, McBurnett K, Turnbow J, et al. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD: Results From a Phase III Multicenter Trial. *J Atten Disord* 2013. PMID: 24071772.

Wilens TE, Robertson B, Sikirica V, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry* 2015;54(11):916-925.e2. PMID: 26506582.

Wilkes S, Cordier R, Bundy A, et al. A play-based intervention for children with ADHD: a pilot study. *Aust Occup Ther J* 2011;58(4):231-40. PMID: 21770958.

Wilkes-Gillan S, Bundy A, Cordier R, et al. Eighteen-month follow-up of a play-based intervention to improve the social play skills of children with attention deficit hyperactivity disorder. *Aust Occup Ther J* 2014;61(5):299-307. PMID: 24762264.

Williamson D, Murray DW, Damaraju CV, et al. Methylphenidate in children with ADHD with or without learning disability. *J Atten Disord* 2014;18(2):95-104. PMID: 22628142.

Wills HP and Mason BA. Implementation of a self-monitoring application to improve on-task behavior: A high-school pilot study. *Journal of Behavioral Education* 2014;23(4):421-434.

Winter W and Sheridan M. Previous reward decreases errors of commission on later 'No-Go' trials in children 4 to 12 years of age: Evidence for a context monitoring account. *Developmental Science* 2014;17(5):797-807.

Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. *Bmj* 2012;345:e4627. PMID: 22809800.

Wolraich ML, Bard DE, Neas B, et al. The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic teacher rating scale in a community population. *J Dev Behav Pediatr* 2013;34(2):83-93. PMID: 23363973.

Wong CG and Stevens MC. The effects of stimulant medication on working memory functional connectivity in attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2012;71(5):458-66. PMID: 22209640.

Woodruff DB, El-Mallakh RS and Thiruvengadam AP. A potential diagnostic blood test for attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord* 2011;3(3):265-9. PMID: 21523444.

Wrońska N, Garcia-Zapirain B and Mendez-Zorrilla A. An iPad-based tool for improving the skills of children with attention deficit disorder. *International Journal of Environmental Research and Public Health* 2015;12(6):6261-6280.

Xiaoli Y, Chao J, Wen P, et al. Prevalence of psychiatric disorders among children and adolescents in northeast China. *PLoS One* 2014;9(10):e111223. PMID: 25360718.

Xie Y, Dixon JF, Yee OM, et al. A study on the effectiveness of videoconferencing on teaching parent training skills to parents of children with ADHD. *Telemed J E Health* 2013;19(3):192-9. PMID: 23405952.

Yang L, Cao Q, Shuai L, et al. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. *Int J Neuropsychopharmacol* 2012;15(1):15-26. PMID: 22017969.

Yang R, Gao W, Li R, et al. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study. *Int J Neuropsychopharmacol* 2015;18(8). PMID: 25896257.

Yazd SN, Ayatizadeh F, Dehghan F, et al. Comparing the effects of drug therapy, perceptual motor training, and both combined on the motor skills of school-aged attention deficit hyperactivity disorder children. *CNS Neurol Disord Drug Targets* 2015. PMID: 26556079.

Yildiz O, Sismanlar SG, Memik NC, et al. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. *Child Psychiatry Hum Dev* 2011;42(3):257-69. PMID: 21165694.

## **Does not report data for a study population of interest**

Adler LA, Shaw DM, Spencer TJ, et al. Preliminary reliability and validity of a new time-sensitive ADHD symptom scale in adolescents with ADHD. *Postgrad Med* 2011;123(5):7-13. PMID: 21904082.

Aghebati A, Gharraee B, Hakim Shoshtari M, et al. Triple p-positive parenting program for mothers of ADHD children. *Iran J Psychiatry Behav Sci* 2014;8(1):59-65. PMID: 24995031.

Alqaryouti IA, Abu Hilar MM and Ibrahim MM. Validity and reliability of an attention deficit and hyperactivity disorder measure among a sample of Omani children. *Electronic Journal of Research in Educational Psychology* 2011;9(2):911-930.

Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?. *J Am Acad Child Adolesc Psychiatry* 2014;53(1):47-60.e1. PMID: 24342385.

Anastopoulos AD and King KA. A Cognitive-Behavior Therapy and Mentoring Program for College Students With ADHD. *Cognitive and Behavioral Practice* 2015;22(2):141-151.

Arnold LE, Gadow KD, Farmer CA, et al. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. *J Child Adolesc Psychopharmacol* 2015;25(3):203-12. PMID: 25885010.

Azevedo AF, Seabra-Santos MJ, Gaspar MF, et al. The Incredible Years Basic Parent Training for Portuguese preschoolers with AD/HD behaviors: Does it make a difference?. *Child & Youth Care Forum* 2013;42(5):403-424..

Barnard-Brak L, To YM and Fearon DD. Protopathic stimulant use among children with symptoms of ADHD. *Atten Defic Hyperact Disord* 2011;3(3):245-51. PMID: 21452045.

Baskin BM, Dwoskin LP and Kantak KM. Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. *Pharmacol Biochem Behav* 2015;131:51-6. PMID: 25643872.

Batzle CS, Weyandt LL, Janusis GM, et al. Potential impact of ADHD with stimulant medication label on teacher expectations. *Journal of Attention Disorders* 2010;14(2):157-166. PMID: 2010-17294-008.

Breda V, Rovaris DL, Vitola ES, et al. Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample. *Aust N Z J Psychiatry* 2015. PMID: 26460329.

Brown TE, Brams M, Gasior M, et al. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. *Curr Med Res Opin* 2011;27(Suppl 2):23-33. PMID: 21973229.

Burns GL, Walsh JA, Servera M, et al. Construct validity of ADHD/ODD rating scales: recommendations for the evaluation of forthcoming DSM-V ADHD/ODD scales. *J Abnorm Child Psychol* 2013;41(1):15-26. PMID: 22773361.

Burton B, Grant M, Feigenbaum A, et al. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. *Molecular Genetics and Metabolism* 2015;114(3):415-424.

Calarge CA, Schlechte JA, Burns TL, et al. The effect of psychostimulants on skeletal health in boys co-treated with risperidone. *Journal of Pediatrics* 2015;166(6):1449-1454.e1.

Camporeale A, Day KA, Ruff D, et al. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. *Drug Saf* 2013;36(8):663-71. PMID: 23775507.

Canivez GL and Gaboury AR. Construct Validity and Diagnostic Utility of the Cognitive Assessment System for ADHD. *J Atten Disord* 2013. PMID: 23757332.

Canu WH and Bearman SK. Community-clinic-based parent intervention addressing noncompliance in children with attention-deficit/hyperactivity disorder. *Cognitive and Behavioral Practice* 2011;18(4):491-501.

Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. *Journal of Child Psychology and Psychiatry* 2014;55(8):878-885. PMID: 2014-28246-005.

Charach A, Lin E and To T. Evaluating the Hyperactivity/Inattention Subscale of the National Longitudinal Survey of Children and Youth. *Health Rep* 2010;21(2):43-50. PMID: 20632524.

Chen CY, Yeh HH, Chen KH, et al. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(3):265-73. PMID: 21663429.

Chen Q, Sjolander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. *Bmj* 2014;348:g3769. PMID: 24942388.

Coben R and Myers TE. Sensitivity and specificity of long wave infrared imaging for attention-deficit/hyperactivity disorder. *J Atten Disord* 2009;13(1):56-65. PMID: 19429882.

Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med* 2011;365(20):1896-904. PMID: 22043968.

Corkum P, Elik N, Blotnicky-Gallant PA, et al. Web-Based Intervention for Teachers of Elementary Students With ADHD: Randomized Controlled Trial. *J Atten Disord* 2015. PMID: 26362259.

Croft S, Stride C, Maughan B, et al. Validity of the strengths and difficulties questionnaire in preschool-aged children. *Pediatrics* 2015;135(5):e1210-9. PMID: 25847804.

Dalsgaard S, Leckman JF, Mortensen PB, et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. *Lancet Psychiatry* 2015;2(8):702-9. PMID: 26249301.

Dalsgaard S, Nielsen HS and Simonsen M. Consequences of ADHD medication use for children's outcomes. *Journal of Health Economics* 2014;37(1):137-151.

de la Osa N, Granero R, Penelo E, et al. The short and very short forms of the Children's Behavior Questionnaire in a community sample of preschoolers. *Assessment* 2014;21(4):463-76. PMID: 24235176.

Delavarian M, Towhidkhan F, Dibajnia P, et al. Designing a decision support system for distinguishing ADHD from similar children behavioral disorders. *J Med Syst* 2012;36(3):1335-43. PMID: 20878211.

Delavarian M, Towhidkhan F, Gharibzadeh S, et al. Automatic classification of hyperactive children: comparing multiple artificial intelligence approaches. *Neurosci Lett* 2011;498(3):190-3. PMID: 21396979.

Doerfler LA, Connor DF and Toscano PF, Jr.. Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD. *J Affect Disord* 2011;131(1-3):312-9. PMID: 21168917.

Durell TM, Adler LA, Williams DW, et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. *J Clin Psychopharmacol* 2013;33(1):45-54. PMID: 23277268.

Efstratopoulou M, Simons J and Janssen R. Concordance among physical educators', teachers', and parents' perceptions of attention problems in children. *J Atten Disord* 2013;17(5):437-43. PMID: 22323118.

Elkins RM, Carpenter AL, Pincus DB, et al. Inattention symptoms and the diagnosis of comorbid attention-deficit/hyperactivity disorder among youth with generalized anxiety disorder. *J Anxiety Disord* 2014;28(8):754-60. PMID: 25260213.

Epstein JN, Langberg JM, Lichtenstein PK, et al. Use of an Internet portal to improve community-based pediatric ADHD care: a cluster randomized trial. *Pediatrics* 2011;128(5):e1201-8. PMID: 22007005.

Evans WN, Morrill MS and Parente ST. Measuring inappropriate medical diagnosis and treatment in survey data: The case of ADHD among school-age children. *J Health Econ* 2010;29(5):657-73. PMID: 20739076.

Follan M, Anderson S, Huline-Dickens S, et al. Discrimination between attention deficit hyperactivity disorder and reactive attachment disorder in school aged children. *Res Dev Disabil* 2011;32(2):520-6. PMID: 21257287.

Fowler PJ, Henry DB, Schoeny M, et al. Effects of the SAFE Children preventive intervention on developmental trajectories of attention-deficit/hyperactivity disorder symptoms. *Dev Psychopathol* 2014;26(4 Pt 1):1161-79. PMID: 24713426.

Freeman NC, Gray KM, Taffe JR, et al. Development of a new attention rating scale for children with intellectual disability: The Scale of Attention in Intellectual Disability (SAID). *American*

Journal on Intellectual and Developmental Disabilities 2015;120(2):91-109. PMID: 2015-11802-001.

Frindik JP, Morales A, Fowlkes J, et al. Stimulant medication use and response to growth hormone therapy: an NCGS database analysis. *Horm Res* 2009;72(3):160-6. PMID: 19729947.

Fujibayashi H, Kitayama S and Matsuo M. Score of inattention subscale of ADHD rating scale-IV is significantly higher for AD/HD than PDD. *Kobe J Med Sci* 2010;56(1):E12-7. PMID: 21063141.

Gadow KD, Arnold LE, Molina BS, et al. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. *J Am Acad Child Adolesc Psychiatry* 2014;53(9):948-959.e1. PMID: 25151418.

Garcia Fernandez T, Gonzalez-Pienda JA, Rodriguez Perez C, et al. Psychometric characteristics of the BRIEF scale for the assessment of executive functions in Spanish clinical population. *Psicothema* 2014;26(1):47-52. PMID: 24444729.

Ghanizadeh A. Psychometric analysis of the new ADHD DSM-V derived symptoms. *BMC Psychiatry* 2012;12:21. PMID: 22433111.

Gjevik E, Sandstad B, Andreassen OA, et al. Exploring the agreement between questionnaire information and DSM-IV diagnoses of comorbid psychopathology in children with autism spectrum disorders. *Autism* 2015;19(4):433-42. PMID: 24637430.

Gonzalez-Heydrich J, Hsin O, Gumlak S, et al. Comparing stimulant effects in youth with ADHD symptoms and epilepsy. *Epilepsy Behav* 2014;36:102-7. PMID: 24907495.

Goodman D, Faraone SV, Adler LA, et al. Interpreting ADHD rating scale scores: Linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. *Primary Psychiatry* 2010;17(3):44-52.

Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry* 2015;54(11):905-15. PMID: 26506581.

Harfterkamp M, van der Meer D, van der Loo-Neus G, et al. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder. *Journal of Child and Adolescent Psychopharmacology* 2015;25(4):372-375.

Herbert SD, Harvey EA, Roberts JL, et al. A randomized controlled trial of a parent training and emotion socialization program for families of hyperactive preschool-aged children. *Behav Ther* 2013;44(2):302-16. PMID: 23611079.

- Hodgkins P, Sasane R, Christensen L, et al. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. *Curr Med Res Opin* 2011;27(Suppl 2):53-62. PMID: 21973231.
- Holmberg K, Sundelin C and Hjern A. Screening for attention-deficit/hyperactivity disorder (ADHD): can high-risk children be identified in first grade?. *Child Care Health Dev* 2013;39(2):268-76. PMID: 22515618.
- Hondebrink L, Rietjens SJ, Hunault CC, et al. Methylphenidate intoxications in children and adults: exposure circumstances and evidence-based dose threshold for pre-hospital triage. *Clin Toxicol (Phila)* 2015;53(3):168-77. PMID: 25650984.
- Hoza B, Smith AL, Shoulberg EK, et al. A randomized trial examining the effects of aerobic physical activity on attention-deficit/hyperactivity disorder symptoms in young children. *J Abnorm Child Psychol* 2015;43(4):655-67. PMID: 25201345.
- Hult N, Kadesjo J, Kadesjo B, et al. ADHD and the QbTest: Diagnostic Validity of QbTest. *J Atten Disord* 2015. PMID: 26224575.
- Huss M, Ginsberg Y, Arnglim T, et al. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial. *Clin Drug Investig* 2014;34(9):639-49. PMID: 25015027.
- Hwang JW, Kim B, Kim Y, et al. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder. *Hum Psychopharmacol* 2013;28(6):600-7. PMID: 24519694.
- Ise E, Kierfeld F and Dopfner M. One-year follow-up of guided self-help for parents of preschool children with externalizing behavior. *J Prim Prev* 2015;36(1):33-40. PMID: 25331981.
- Johnson S, Hollis C, Marlow N, et al. Screening for childhood mental health disorders using the Strengths and Difficulties Questionnaire: the validity of multi-informant reports. *Dev Med Child Neurol* 2014;56(5):453-9. PMID: 24410039.
- Kim J, Kim G and Seo S. Validation of the FSA as screening tool for children with ADHD. *Arts in Psychotherapy* 2014;41(4):413-423.
- Ko HJ, Kim I, Kim JB, et al. Effects of Korean red ginseng extract on behavior in children with symptoms of inattention and hyperactivity/impulsivity: a double-blind randomized placebo-controlled trial. *J Child Adolesc Psychopharmacol* 2014;24(9):501-8. PMID: 25369174.
- Kolko DJ, Campo J, Kilbourne AM, et al. Collaborative care outcomes for pediatric behavioral health problems: a cluster randomized trial. *Pediatrics* 2014;133(4):e981-92. PMID: 24664093.
- Korsch F and Petermann F. Agreement between parents and teachers on preschool children's behavior in a clinical sample with externalizing behavioral problems. *Child Psychiatry Hum Dev* 2014;45(5):617-27. PMID: 24363143.

Kratochvil CJ, May DE, Silva SG, et al. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. *J Child Adolesc Psychopharmacol* 2009;19(5):519-27. PMID: 19877976.

Kraut AA, Langner I, Lindemann C, et al. Comorbidities in ADHD children treated with methylphenidate: a database study. *BMC Psychiatry* 2013;13:11. PMID: 23294623.

Kudo M, Altamirano W, Mearns J, et al. SWAN Preschool Rating Scale (SWAN-P): Validity evidence for English and Spanish versions. *The International Journal of Educational and Psychological Assessment* 2012;10(1):139-157.

Laezer KL. Effectiveness of psychoanalytic psychotherapy and behavioral therapy treatment in children with attention deficit hyperactivity disorder and oppositional defiant disorder. *Journal of Infant, Child & Adolescent Psychotherapy* 2015;14(2):111-128.

Landaas ET, Halmoy A, Oedegaard KJ, et al. The impact of cyclothymic temperament in adult ADHD. *J Affect Disord* 2012;142(1-3):241-7. PMID: 22840630.

Larson T, Lundstrom S, Nilsson T, et al. Predictive properties of the A-TAC inventory when screening for childhood-onset neurodevelopmental problems in a population-based sample. *BMC Psychiatry* 2013;13:233. PMID: 24066834.

Lecavalier L, Gadow KD, Devincent CJ, et al. Validity of DSM-IV syndromes in preschoolers with autism spectrum disorders. *Autism* 2011;15(5):527-43. PMID: 21454388.

Leuchter AF, McGough JJ, Korb AS, et al. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. *J Psychiatr Res* 2014;54:11-8. PMID: 24726639.

Limbers CA, Ripperger-Suhler J, Heffer RW, et al. Patient-reported Pediatric Quality of Life Inventory 4.0 Generic Core Scales in pediatric patients with attention-deficit/hyperactivity disorder and comorbid psychiatric disorders: feasibility, reliability, and validity. *Value Health* 2011;14(4):521-30. PMID: 21315637.

Loutfi KS, Carvalho AM, Lamounier JA, et al. ADHD and epilepsy: contributions from the use of behavioral rating scales to investigate psychiatric comorbidities. *Epilepsy Behav* 2011;20(3):484-9. PMID: 21300573.

Lufi D and Fichman N. Development and use of a computerized test, MATH-CPT, to assess attention. *Percept Mot Skills* 2012;114(1):59-74. PMID: 22582676.

Makransky G and Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating Scale (ADHD-RS): measurement invariance across gender, age, and informant. *Assessment* 2014;21(6):694-705. PMID: 24852496.

Man KKC, Chan EW, Coghill D, et al. Methylphenidate and the risk of trauma. *Pediatrics* 2015;135(1):40-48.

- Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. *Postgrad Med* 2013;125(4):181-90. PMID: 23933905.
- Marshall P, Schroeder R, O'Brien J, et al. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. *Clin Neuropsychol* 2010;24(7):1204-37. PMID: 20845231.
- Martel MM, Schimmack U, Nikolas M, et al. Integration of symptom ratings from multiple informants in ADHD diagnosis: A psychometric model with clinical utility. *Psychological Assessment* 2015;27(3):1060-1071.
- Martin P, Satin L, Kahn RS, et al. A thorough QT study of guanfacine. *Int J Clin Pharmacol Ther* 2015;53(4):301-16. PMID: 25109412.
- Masi G, Pisano S, Milone A, et al. Child behavior checklist dysregulation profile in children with disruptive behavior disorders: A longitudinal study. *J Affect Disord* 2015;186:249-53. PMID: 26254616.
- McCarthy S, Wilton L, Murray ML, et al. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. *BMC Psychiatry* 2012;12(1).
- McConaughy SH, Harder VS, Antshel KM, et al. Incremental validity of test session and classroom observations in a multimethod assessment of attention deficit/hyperactivity disorder. *J Clin Child Adolesc Psychol* 2010;39(5):650-66. PMID: 20706918.
- McConaughy SH, Ivanova MY, Antshel K, et al. Standardized Observational Assessment of Attention Deficit Hyperactivity Disorder Combined and Predominantly Inattentive Subtypes. II. Classroom Observations. *School Psych Rev* 2009;38(3):362-381. PMID: 20802813.
- Miller BS, Aydin F, Lundgren F, et al. Stimulant use and its impact on growth in children receiving growth hormone therapy: an analysis of the KIGS International Growth Database. *Horm Res Paediatr* 2014;82(1):31-7. PMID: 24924157.
- Miranda A, Colomer C, Mercader J, et al. Performance-based tests versus behavioral ratings in the assessment of executive functioning in preschoolers: associations with ADHD symptoms and reading achievement. *Front Psychol* 2015;6:545. PMID: 25972833.
- Miranda MC, Barbosa T, Muszkat M, et al. Performance patterns in Conners' CPT among children with attention deficit hyperactivity disorder and dyslexia. *Arq Neuropsiquiatr* 2012;70(2):91-6. PMID: 22311211.
- Missiuna C, Cairney J, Pollock N, et al. A staged approach for identifying children with developmental coordination disorder from the population. *Res Dev Disabil* 2011;32(2):549-59. PMID: 21216564.

Molife C, Bernauer MJ, Farr AM, et al. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. *Postgrad Med* 2012;124(5):7-22. PMID: 23095422.

Moore RM. Reliable ratings or reading tea leaves: Can parent, teacher, and clinician behavioral ratings of preschoolers predict ADHD at age six?. *Journal of Developmental and Behavioral Pediatrics* 2014;35(7):471-471.

Munkvold LH, Manger T and Lundervold AJ. Conners' continuous performance test (CCPT-II) in children with ADHD/ODD, or a combined ADHD/ODD diagnosis. *Child Neuropsychology* 2014;20(1):106-126.

Nazhvani AD, Boostani R, Afrasiabi S, et al. Classification of ADHD and BMD patients using visual evoked potential. *Clin Neurol Neurosurg* 2013;115(11):2329-35. PMID: 24050849.

Newman E and Reddy LA. Diagnostic Utility of the Pediatric Attention Disorders Diagnostic Screener. *J Atten Disord* 2014. PMID: 24639402.

Nielsen NP and Wiig EH. Validation of the AQT color-form additive model for screening and monitoring pharmacological treatment of ADHD. *J Atten Disord* 2013;17(3):187-93. PMID: 22210798.

Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 2012;51(2):147-56. PMID: 22265361.

Palli SR, Kamble PS, Chen H, et al. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2012;22(2):139-48. PMID: 22364400.

Park JH, Lee SI and Schachar RJ. Reliability and validity of the child and adolescent functioning impairment scale in children with attention-deficit/hyperactivity disorder. *Psychiatry Investig* 2011;8(2):113-22. PMID: 21852987.

Parker A and Corkum P. ADHD Diagnosis: As Simple As Administering a Questionnaire or a Complex Diagnostic Process?. *J Atten Disord* 2013. PMID: 23887860.

Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. *J Child Adolesc Psychopharmacol* 2013;23(5):337-51. PMID: 23782128.

Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. *J Child Adolesc Psychopharmacol* 2009;19(5):563-73. PMID: 19877981.

Prevatt F and Yelland S. An empirical evaluation of ADHD coaching in college students. *Journal of Attention Disorders* 2015;19(8):666-677.

Reddy LA, Newman E, Pedigo TK, et al. Concurrent validity of the pediatric attention disorders diagnostic screener for children with ADHD. *Child Neuropsychol* 2010;16(5):478-93. PMID: 20485995.

Redmond SM, Thompson HL and Goldstein S. Psycholinguistic profiling differentiates specific language impairment from typical development and from attention-deficit/hyperactivity disorder. *J Speech Lang Hear Res* 2011;54(1):99-117. PMID: 20719871.

Reimherr FW, Marchant BK, Olsen JL, et al. Oppositional defiant disorder in adults with ADHD. *J Atten Disord* 2013;17(2):102-13. PMID: 22100691.

Reyes JS, de Ridder MA, Breukhoven PE, et al. Methylphenidate and the response to growth hormone treatment in short children born small for gestational age. *PLoS One* 2012;7(12):e53164. PMID: 23300884.

Richa S, Rohayem J, Chammai R, et al. ADHD prevalence in Lebanese school-age population. *J Atten Disord* 2014;18(3):242-6. PMID: 22628148.

Roberts G, Rane S, Fall A-M, et al. The impact of intensive reading intervention on level of attention in middle school students. *Journal of Clinical Child and Adolescent Psychology* 2015;44(6):942-953.

Rogalin MT and Nencini A. Consequences of the 'Attention-Deficit/Hyperactivity Disorder' (ADHD) diagnosis. An investigation with education professionals. *Psychological Studies* 2015;60(1):41-49.

Rogińska N and Biegankowska K. Sick sinus syndrome: A family study. *Cardiology in the Young* 2014;24(1):136-139.

Rohatgi RK, Bos JM and Ackerman MJ. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?. *Heart Rhythm* 2015;12(8):1807-12. PMID: 25956966.

Rose SR, Reeves G, Gut R, et al. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study. *Journal of Pediatrics* 2015.

Rotger S, Richarte V, Nogueira M, et al. Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. *Eur Arch Psychiatry Clin Neurosci* 2014;264(8):719-27. PMID: 24710954.

Rubio B, Hernandez S, Verche E, et al. A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities. *Atten Defic Hyperact Disord* 2011;3(1):13-20. PMID: 21432614.

Rucklidge JJ, Frampton CM, Gorman B, et al. Vitamin–mineral treatment of attention-deficit hyperactivity disorder in adults: Double-blind randomised placebo-controlled trial. *The British Journal of Psychiatry* 2014;204(4):306-315.

Rucklidge JJ, Johnstone J, Gorman B, et al. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement. *Prog Neuropsychopharmacol Biol Psychiatry* 2014;50:163-71. PMID: 24374068.

Russ SA, Larson K and Halfon N. A national profile of childhood epilepsy and seizure disorder. *Pediatrics* 2012;129(2):256-64. PMID: 22271699.

Sable JJ, Kyle MR, Knopf KL, et al. The Sensory Gating Inventory as a potential diagnostic tool for attention-deficit hyperactivity disorder. *Atten Defic Hyperact Disord* 2012;4(3):141-4. PMID: 22644992.

Sasane R, Hodgkins P and Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. *Curr Med Res Opin* 2010;26(11):2565-74. PMID: 20863165.

Sayal K, Merrell C, Tymms P, et al. Academic Outcomes Following a School-Based RCT for ADHD: 6-Year Follow-Up. *J Atten Disord* 2015. PMID: 25555626.

Scahill L, McCracken JT, King BH, et al. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. *Am J Psychiatry* 2015:appiajp201515010055. PMID: 26315981.

Scheithauer MC and Kelley ML. Self-Monitoring by College Students With ADHD: The Impact on Academic Performance. *J Atten Disord* 2014. PMID: 25319163.

Schneider H, Thornton JF, Freeman MA, et al. Conventional SPECT versus 3D thresholded SPECT imaging in the diagnosis of ADHD: A retrospective study. *Journal of Neuropsychiatry and Clinical Neurosciences* 2014;26(4):335-343.

Setyawan J, Guerin A, Hodgkins P, et al. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. *J Med Econ* 2013;16(11):1275-89. PMID: 24004347.

Shata ZN, Abu-Nazel MW, Fahmy SI, et al. Efficacy of a psychosocial intervention for parents of children with attention deficit hyperactivity disorder, Alexandria, Egypt. *J Egypt Public Health Assoc* 2014;89(1):9-15. PMID: 24717395.

Shyu YC, Yuan SS, Lee SY, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. *Schizophr Res* 2015;168(1-2):161-7. PMID: 26363968.

Sikirica V, Xie J, He TL, et al. Immediate-release versus extended-release guanfacine for treatment of attention-deficit/hyperactivity disorder. *American Journal of Pharmacy Benefits* 2013;5(4):e85-e94.

Silverstein M, Hironaka LK, Feinberg E, et al. Using Clinical Data to Predict Accurate ADHD Diagnoses Among Urban Children. *Clin Pediatr (Phila)* 2015. PMID: 26130393.

Silverstein M, Hironaka LK, Walter HJ, et al. Collaborative care for children with ADHD symptoms: a randomized comparative effectiveness trial. *Pediatrics* 2015;135(4):e858-67. PMID: 25802346.

Sirois PA, Montepiedra G, Kapetanovic S, et al. Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. *J Dev Behav Pediatr* 2009;30(5):403-12. PMID: 19827220.

Snyder SM, Rugino TA, Hornig M, et al. Integration of an EEG biomarker with a clinician's ADHD evaluation. *Brain Behav* 2015;5(4):e00330. PMID: 25798338.

Soderstrom S, Pettersson R and Nilsson KW. Quantitative and subjective behavioural aspects in the assessment of attention-deficit hyperactivity disorder (ADHD) in adults. *Nord J Psychiatry* 2014;68(1):30-7. PMID: 23527787.

Stattin H, Enebrink P, Ozdemir M, et al. A National Evaluation of Parenting Programs in Sweden: The Short-Term Effects Using an RCT Effectiveness Design. *J Consult Clin Psychol* 2015. PMID: 26009784.

Steiner NJ, Frenette E, Hynes C, et al. A pilot feasibility study of neurofeedback for children with autism. *Applied Psychophysiology and Biofeedback* 2014;39(2):99-107. PMID: 2014-14168-001.

Thakur GA, Grizenko N, Sengupta SM, et al. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. *BMC Psychiatry* 2010;10:50. PMID: 20569447.

Toomey SL, Chan E, Ratner JA, et al. The patient-centered medical home, practice patterns, and functional outcomes for children with attention deficit/hyperactivity disorder. *Acad Pediatr* 2011;11(6):500-7. PMID: 21967721.

Trillingsgaard T, Trillingsgaard A and Webster-Stratton C. Assessing the effectiveness of the 'Incredible Years((R)) parent training' to parents of young children with ADHD symptoms - a preliminary report. *Scand J Psychol* 2014;55(6):538-45. PMID: 25130208.

Ullebo AK, Posserud MB, Heiervang E, et al. Screening for the attention deficit hyperactivity disorder phenotype using the strength and difficulties questionnaire. *Eur Child Adolesc Psychiatry* 2011;20(9):451-8. PMID: 21833627.

Valo S and Tannock R. Diagnostic instability of DSM-IV ADHD subtypes: effects of informant source, instrumentation, and methods for combining symptom reports. *J Clin Child Adolesc Psychol* 2010;39(6):749-60. PMID: 21058123.

Villodas MT, McBurnett K, Kaiser N, et al. Additive effects of parent adherence on social and behavioral outcomes of a collaborative school–home behavioral intervention for ADHD. *Child Psychiatry and Human Development* 2014;45(3):348-360. PMID: 2013-33475-001.

Wakschlag LS, Estabrook R, Petittlerc A, et al. Clinical Implications of a Dimensional Approach: The Normal:Abnormal Spectrum of Early Irritability. *J Am Acad Child Adolesc Psychiatry* 2015;54(8):626-34. PMID: 26210331.

Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. *Nutr Neurosci* 2010;13(2):87-100. PMID: 20406576.

Williamson KD, Combs HL, Berry DT, et al. Discriminating among ADHD alone, ADHD with a comorbid psychological disorder, and feigned ADHD in a college sample. *Clin Neuropsychol* 2014;28(7):1182-96. PMID: 25225947.

Yang HN, Tai YM, Yang LK, et al. Prediction of childhood ADHD symptoms to quality of life in young adults: adult ADHD and anxiety/depression as mediators. *Res Dev Disabil* 2013;34(10):3168-81. PMID: 23886759.

Young JC and Gross AM. Detection of response bias and noncredible performance in adult attention-deficit/hyperactivity disorder. *Arch Clin Neuropsychol* 2011;26(3):165-75. PMID: 21441258.

Zambrano-Sanchez E, Martinez-Cortes JA, Del Rio-Carlos Y, et al. Identification of attention-deficit-hyperactivity disorder and conduct disorder in Mexican children by the scale for evaluation of deficit of attention and hyperactivity. *Psychiatry Res* 2011;187(3):437-40. PMID: 20934222.

Zentall SS and Lee J. A Reading Motivation Intervention With Differential Outcomes for Students At Risk for Reading Disabilities, ADHD, and Typical Comparisons: “Clever Is and Clever Does”. *Learning Disability Quarterly* 2012;35(4):248-259.

Zhang C, Kutuyifa V, Moss AJ, et al. Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. *Journal of Cardiovascular Electrophysiology* 2015;26(10):1039-1044.

Zoega H, Rothman KJ, Huybrechts KF, et al. A population-based study of stimulant drug treatment of ADHD and academic progress in children. *Pediatrics* 2012;130(1):e53-62. PMID: 22732167.

Zoega H, Valdimarsdottir UA and Hernandez-Diaz S. Age, academic performance, and stimulant prescribing for ADHD: a nationwide cohort study. *Pediatrics* 2012;130(6):1012-8. PMID: 23166340.

Zuvekas SH and Vitiello B. Stimulant medication use in children: a 12-year perspective. *Am J Psychiatry* 2012;169(2):160-6. PMID: 22420039.

## Does not include an intervention of interest

Bachmann M, Bachmann CJ, John K, et al. The effectiveness of child and adolescent psychiatric treatments in a naturalistic outpatient setting. *World Psychiatry* 2010;9(2):111-7. PMID: 20671900.

Barnard-Brak L, Schmidt M and Sulak T. ADHD medication vacations and parent-child interactions by gender. *J Atten Disord* 2013;17(6):506-9. PMID: 22366239.

Bart O, Raz S and Dan O. Reliability and validity of the Continuous Performance Test among children. *Assessment* 2014;21(5):637-643. PMID: 2014-39289-010.

Bauer NS, Szczepaniak D, Sullivan PD, et al. Group Visits to Improve Pediatric Attention-Deficit Hyperactivity Disorder Chronic Care Management. *J Dev Behav Pediatr* 2015;36(8):553-61. PMID: 26414089.

Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. *Pediatrics* 2009;124(1):71-8. PMID: 19564285.

Biederman J, Petty CR, Fried R, et al. Is the diagnosis of ADHD influenced by time of entry to school? An examination of clinical, familial, and functional correlates in children at early and late entry points. *J Atten Disord* 2014;18(3):179-85. PMID: 22628145.

Brocki KC, Eninger L, Thorell LB, et al. Interrelations between executive function and symptoms of hyperactivity/impulsivity and inattention in preschoolers: a two year longitudinal study. *J Abnorm Child Psychol* 2010;38(2):163-71. PMID: 19763816.

Carroll AE, Bauer NS, Dugan TM, et al. Use of a computerized decision aid for ADHD diagnosis: a randomized controlled trial. *Pediatrics* 2013;132(3):e623-9. PMID: 23958768.

Casagrande M, Martella D, Ruggiero MC, et al. Assessing attentional systems in children with Attention Deficit Hyperactivity Disorder. *Arch Clin Neuropsychol* 2012;27(1):30-44. PMID: 22071484.

Casaseca-de-la-Higuera P, Martin-Martinez D, Alberola-Lopez S, et al. Automatic diagnosis of ADHD based on multichannel nonlinear analysis of actimetry registries. *Conf Proc IEEE Eng Med Biol Soc* 2012;2012:4204-7. PMID: 23366855.

Catale C, Geurten M, Lejeune C, et al. The Conners Parent Rating Scale: Psychometric properties in typically developing 4- to 12-year-old Belgian French-speaking children. *European Review of Applied Psychology / Revue Européenne de Psychologie Appliquée* 2014;64(5):221-227. PMID: 2014-42090-003.

Chilakamarri JK, Filkowski MM and Ghaemi SN. Misdiagnosis of bipolar disorder in children and adolescents: a comparison with ADHD and major depressive disorder. *Ann Clin Psychiatry* 2011;23(1):25-9. PMID: 21318193.

Cordier R, Bundy A, Hocking C, et al. Comparison of the play of children with attention deficit hyperactivity disorder by subtypes. *Aust Occup Ther J* 2010;57(2):137-45. PMID: 20854579.

de Luis-Garcia R, Cabus-Pinol G, Imaz-Roncero C, et al. Attention deficit/hyperactivity disorder and medication with stimulants in young children: a DTI study. *Prog Neuropsychopharmacol Biol Psychiatry* 2015;57:176-84. PMID: 25445066.

Demidovich M, Kolko DJ, Bukstein OG, et al. Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. *J Child Adolesc Psychopharmacol* 2011;21(1):57-66. PMID: 21288119.

Denis I, Guay MC, Foldes-Busque G, et al. Effect of Treating Anxiety Disorders on Cognitive Deficits and Behaviors Associated with Attention Deficit Hyperactivity Disorder: A Preliminary Study. *Child Psychiatry Hum Dev* 2015. PMID: 26323585.

Dyck MJ and Piek JP. Developmental delays in children with ADHD. *J Atten Disord* 2014;18(5):466-78. PMID: 22508756.

Efron D and Sciberras E. The diagnostic outcomes of children with suspected attention deficit hyperactivity disorder following multidisciplinary assessment. *J Paediatr Child Health* 2010;46(7-8):392-7. PMID: 20546102.

England SJ, Picchietti DL, Couvadelli BV, et al. L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. *Sleep Med* 2011;12(5):471-7. PMID: 21463967.

Fergusson DM, Boden JM and Horwood LJ. Classification of behavior disorders in adolescence: scaling methods, predictive validity, and gender differences. *J Abnorm Psychol* 2010;119(4):699-712. PMID: 20853914.

Fiks AG, Mayne S, Hughes CC, et al. Development of an instrument to measure parents' preferences and goals for the treatment of attention deficit-hyperactivity disorder. *Acad Pediatr* 2012;12(5):445-55. PMID: 22748759.

Foreman DM and Morton S. Nurse-delivered and doctor-delivered care in an attention deficit hyperactivity disorder follow-up clinic: a comparative study using propensity score matching. *J Adv Nurs* 2011;67(6):1341-8. PMID: 21375572.

Fortes D, Serra-Pinheiro MA, Coutinho G, et al. Quantitative measurement of impairment in ADHD: Perspectives for research and clinical practice. *Revista de Psiquiatria Clinica* 2014;41(5):124-130.

Goetz M, Yeh CB, Ondrejka I, et al. A 12-month prospective, observational study of treatment regimen and quality of life associated with ADHD in central and eastern europe and eastern Asia. *J Atten Disord* 2012;16(1):44-59. PMID: 20858785.

Groenman AP, Oosterlaan J, Rommelse NN, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. *Br J Psychiatry* 2013;203(2):112-9. PMID: 23846996.

Haynes V, Lopez-Romero P and Anand E. Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects. *Atten Defic Hyperact Disord* 2015;7(4):295-311. PMID: 26115621.

Hinshaw SP, Owens EB, Zalecki C, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. *J Consult Clin Psychol* 2012;80(6):1041-51. PMID: 22889337.

Jans T, Jacob C, Warnke A, et al. Does intensive multimodal treatment for maternal ADHD improve the efficacy of parent training for children with ADHD? A randomized controlled multicenter trial. *J Child Psychol Psychiatry* 2015. PMID: 26123832.

Kim HW, Cho SC, Kim BN, et al. Does oppositional defiant disorder have temperament and psychopathological profiles independent of attention deficit/hyperactivity disorder?. *Compr Psychiatry* 2010;51(4):412-8. PMID: 20579516.

Kolko DJ and Pardini DA. ODD dimensions, ADHD, and callous-unemotional traits as predictors of treatment response in children with disruptive behavior disorders. *J Abnorm Psychol* 2010;119(4):713-25. PMID: 21090875.

Kurth L and Haussmann R. Perinatal Pitocin as an early ADHD biomarker: neurodevelopmental risk?. *J Atten Disord* 2011;15(5):423-31. PMID: 21527574.

Lahey BB and Willcutt EG. Predictive validity of a continuous alternative to nominal subtypes of attention-deficit/hyperactivity disorder for DSM-V. *J Clin Child Adolesc Psychol* 2010;39(6):761-75. PMID: 21058124.

Lambek R and Trillingsgaard A. Elaboration, validation and standardization of the five to fifteen (FTF) questionnaire in a Danish population sample. *Research in Developmental Disabilities* 2015;38:161-170.

Lavigne JV, Dulcan MK, LeBailly SA, et al. Computer-assisted management of attention-deficit/hyperactivity disorder. *Pediatrics* 2011;128(1):e46-53. PMID: 21669891.

Lin DY, Kratochvil CJ, Xu W, et al. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(4):190-200. PMID: 24840045.

Mattis S, Papolos D, Luck D, et al. Neuropsychological factors differentiating treated children with pediatric bipolar disorder from those with attention-deficit/hyperactivity disorder. *J Clin Exp Neuropsychol* 2011;33(1):74-84. PMID: 20603740.

- Monden Y, Dan I, Nagashima M, et al. Individual classification of ADHD children by right prefrontal hemodynamic responses during a go/no-go task as assessed by fNIRS. *Neuroimage Clin* 2015;9:1-12. PMID: 26266096.
- Montoya A, Escobar R, Garcia-Polavieja MJ, et al. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. *J Child Neurol* 2011;26(1):31-6. PMID: 20525942.
- Montoya A, Hervas A, Fuentes J, et al. Cluster-randomized, controlled 12-month trial to evaluate the effect of a parental psychoeducation program on medication persistence in children with attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat* 2014;10:1081-92. PMID: 24966679.
- Morrow RL, Garland EJ, Wright JM, et al. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. *Cmaj* 2012;184(7):755-62. PMID: 22392937.
- Mukherjee S, Aneja S, Russell PS, et al. INCLIN diagnostic tool for attention deficit hyperactivity disorder (INDT-ADHD): development and validation. *Indian Pediatr* 2014;51(6):457-62. PMID: 24986281.
- O'Connor B, Garner AA, Peugh JL, et al. Improved but still impaired: Symptom-impairment correspondence among youth with attention-deficit hyperactivity disorder receiving community-based care. *Journal of Developmental and Behavioral Pediatrics* 2015;36(2):106-114.
- Park JI, Shim SH, Lee M, et al. The validities and efficiencies of korean ADHD rating scale and korean child behavior checklist for screening children with ADHD in the community. *Psychiatry Investig* 2014;11(3):258-65. PMID: 25110498.
- Paul-Jordanov I, Bechtold M and Gawrilow C. Methylphenidate and if-then plans are comparable in modulating the P300 and increasing response inhibition in children with ADHD. *Atten Defic Hyperact Disord* 2010;2(3):115-26. PMID: 21432597.
- Peterson BS, Potenza MN, Wang Z, et al. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. *Am J Psychiatry* 2009;166(11):1286-94. PMID: 19755575.
- Powell SG, Thomsen PH, Frydenberg M, et al. Long-term treatment of ADHD with stimulants: a large observational study of real-life patients. *J Atten Disord* 2011;15(6):439-51. PMID: 20631198.
- Riddle MA, Yershova K, Lazzaretto D, et al. The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. *J Am Acad Child Adolesc Psychiatry* 2013;52(3):264-278.e2. PMID: 23452683.
- Sallee FR. Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers. *Journal of Child and Adolescent Psychopharmacology* 2015;25(7):558-565.

- Sandler AD, Glesne CE and Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. *J Dev Behav Pediatr* 2010;31(5):369-75. PMID: 20495473.
- Sangal RB, Blumer JL, Lankford DA, et al. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. *Pediatrics* 2014;134(4):e1095-103. PMID: 25266438.
- Serrano E, Ezpeleta L, Alda JA, et al. Psychometric properties of the Young Mania Rating Scale for the identification of mania symptoms in Spanish children and adolescents with attention deficit/hyperactivity disorder. *Psychopathology* 2011;44(2):125-32. PMID: 21228617.
- Sibley MH, Pelham WE, Jr., Molina BS, et al. Diagnosing ADHD in adolescence. *J Consult Clin Psychol* 2012;80(1):139-50. PMID: 22148878.
- Sims DM and Lonigan CJ. Multi-method assessment of ADHD characteristics in preschool children: Relations between measures. *Early Childhood Research Quarterly* 2012;27(2):329-337.
- Solanto MV and Alvir J. Reliability of DSM-IV Symptom Ratings of ADHD: implications for DSM-V. *J Atten Disord* 2009;13(2):107-16. PMID: 19372494.
- Sonuga-Barke EJ, Coghill D, DeBacker M, et al. Measuring methylphenidate response in attention-deficit/hyperactivity disorder: how are laboratory classroom-based measures related to parent ratings?. *J Child Adolesc Psychopharmacol* 2009;19(6):691-8. PMID: 20035587.
- Srebnicki T, Kolakowski A and Wolanczyk T. Adolescent outcome of child ADHD in primary care setting: stability of diagnosis. *J Atten Disord* 2013;17(8):655-9. PMID: 22408135.
- Staikova E, Marks DJ, Miller CJ, et al. Childhood stimulant treatment and teen depression: is there a relationship?. *J Child Adolesc Psychopharmacol* 2010;20(5):387-93. PMID: 20973709.
- Stocks JD, Taneja BK, Baroldi P, et al. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. *J Child Adolesc Psychopharmacol* 2012;22(2):102-11. PMID: 22372512.
- Szomlajski N, Dyrborg J, Rasmussen H, et al. Validity and clinical feasibility of the ADHD rating scale (ADHD-RS) A Danish Nationwide Multicenter Study. *Acta Paediatr* 2009;98(2):397-402. PMID: 18775056.
- Telford C, Green C, Logan S, et al. Estimating the costs of ongoing care for adolescents with attention-deficit hyperactivity disorder. *Soc Psychiatry Psychiatr Epidemiol* 2013;48(2):337-44. PMID: 22699685.
- Vitiello B, Lazzaretto D, Yershova K, et al. Pharmacotherapy of the Preschool ADHD Treatment Study (PATs) Children Growing Up. *J Am Acad Child Adolesc Psychiatry* 2015;54(7):550-6. PMID: 26088659.

Vollebregt MA, Van Dongen-Boomsma M, Slaats-Willems D, et al. How the Individual Alpha Peak Frequency Helps Unravel the Neurophysiologic Underpinnings of Behavioral Functioning in Children With Attention-Deficit/Hyperactivity Disorder. *Clinical EEG and Neuroscience* 2015;46(4):285-291.

Volpe RJ, DuPaul GJ, Jitendra AK, et al. Consultation-based academic interventions for children with attention deficit hyperactivity disorder: Effects on reading and mathematics outcomes at 1-year follow-up. *School Psychology Review* 2009;38(1):5-13.

Volpe RJ, Gadow KD, Blom-Hoffman J, et al. Factor-analytic and individualized approaches to constructing brief measures of ADHD behaviors. *Journal of Emotional and Behavioral Disorders* 2009;17(2):118-128.

Wan Salwina WI, Baharudin A, Nik Ruzyanei NJ, et al. Attention deficit hyperactivity disorder symptoms reporting in Malaysian adolescents: do adolescents, parents and teachers agree with each other?. *Asian J Psychiatr* 2013;6(6):483-7. PMID: 24309858.

Wehmeier PM, Schacht A, Dittmann RW, et al. Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder. *Atten Defic Hyperact Disord* 2010;2(2):73-85. PMID: 21432592.

Westerlund J, Ek U, Holmberg K, et al. The Conners' 10-item scale: findings in a total population of Swedish 10-11-year-old children. *Acta Paediatr* 2009;98(5):828-33. PMID: 19154524.

Winters KC, Lee S, Botzet A, et al. A Prospective Examination of the Association of Stimulant Medication History and Drug Use Outcomes among Community Samples of ADHD Youths. *J Child Adolesc Subst Abuse* 2011;20(4):314-329. PMID: 22582022.

Zima BT, Bussing R, Tang L, et al. Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care medicaid program. *J Am Acad Child Adolesc Psychiatry* 2010;49(12):1225-37, 1237.e1-11. PMID: 21093772.

## **Does not include a comparator of interest**

Adler LA, Shaw DM, Spencer TJ, et al. Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents. *J Child Adolesc Psychopharmacol* 2012;22(3):238-44. PMID: 22537184.

al Ansari A and Asiri MM. The impact of multimodal psychosocial intervention among children with attention deficit hyperactivity disorder. *Bahrain Medical Bulletin* 2012;34(1):1-6.

Alloway TP, Gathercole SE, Holmes J, et al. The diagnostic utility of behavioral checklists in identifying children with ADHD and children with working memory deficits. *Child Psychiatry Hum Dev* 2009;40(3):353-66. PMID: 19280339.

Amonn F, Frölich J, Breuer D, et al. Evaluation of a computer-based neuropsychological training in children with Attention-Deficit Hyperactivity Disorder (ADHD). *NeuroRehabilitation* 2013;32(3):555-562.

An L, Cao XH, Cao QJ, et al. Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. *Neuropsychopharmacology* 2013;38(7):1287-95. PMID: 23340519.

Araki A, Ikegami M, Okayama A, et al. Improved prefrontal activity in AD/HD children treated with atomoxetine: a NIRS study. *Brain Dev* 2015;37(1):76-87. PMID: 24767548.

Arnold LE, Bozzolo DR, Hodgkins P, et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. *Curr Med Res Opin* 2010;26(1):129-37. PMID: 19916704.

Arns M, Drinkenburg W and Leon Kenemans J. The effects of QEEG-informed neurofeedback in ADHD: an open-label pilot study. *Appl Psychophysiol Biofeedback* 2012;37(3):171-80. PMID: 22446998.

Atzori P, Usala T, Carucci S, et al. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. *J Child Adolesc Psychopharmacol* 2009;19(6):673-81. PMID: 20035585.

Babinski DE, Pelham WE, Jr., Molina BS, et al. Late adolescent and young adult outcomes of girls diagnosed with ADHD in childhood: an exploratory investigation. *J Atten Disord* 2011;15(3):204-14. PMID: 20562386.

Balazs J, Dallos G, Keresztesy A, et al. Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2011;21(2):133-8. PMID: 21486166.

Bos DJ, Oranje B, Veerhoek ES, et al. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder. *Neuropsychopharmacology* 2015;40(10):2298-306. PMID: 25790022.

Breuer D, Gortz-Dorten A, Rothenberger A, et al. Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. *Eur Child Adolesc Psychiatry* 2011;20 (Suppl 2):S289-96. PMID: 21901413.

Brossard-Racine M, Shevell M, Snider L, et al. Persistent handwriting difficulties in children with ADHD after treatment with stimulant medication. *Journal of Attention Disorders* 2015;19(7):620-629.

Brule D, Sule L, Landau-Halpern B, et al. An open-label pilot study of homeopathic treatment of attention deficit hyperactivity disorder in children and youth. *Forsch Komplementmed* 2014;21(5):302-9. PMID: 25427521.

Buyck I and Wiersema JR. Resting electroencephalogram in attention deficit hyperactivity disorder: developmental course and diagnostic value. *Psychiatry Res* 2014;216(3):391-7. PMID: 24656956.

Childress AC, Cutler AJ, Saylor K, et al. Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2014;24(4):210-7. PMID: 24815910.

Chou WJ, Chen SJ, Chen YS, et al. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. *J Child Adolesc Psychopharmacol* 2012;22(3):215-25. PMID: 22537358.

Ciesielski HA, Tamm L, Vaughn AJ, et al. Academic Skills Groups for Middle School Children With ADHD in the Outpatient Mental Health Setting: An Open Trial. *J Atten Disord* 2015. PMID: 25926629.

Cronin SD, Gottschlich MM, Gose LM, et al. Zolpidem and Sleep in Pediatric Burn Patients with Attention Deficit/Hyperactivity Disorder. *Pediatr Nurs* 2015;41(3):132-4, 140. PMID: 26201171.

Dalsgaard S, Mortensen PB, Frydenberg M, et al. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. *Addict Behav* 2014;39(1):325-8. PMID: 24090624.

Dave UP, Dingankar SR, Saxena VS, et al. An open-label study to elucidate the effects of standardized *Bacopa monnieri* extract in the management of symptoms of attention-deficit hyperactivity disorder in children. *Adv Mind Body Med* 2014;28(2):10-5. PMID: 24682000.

Davis C, Cohen A, Davids M, et al. Attention- deficit/hyperactivity disorder in relation to addictive behaviors: A moderated-mediation analysis of personality risk factors and sex. *Frontiers in Psychiatry* 2015;6(MAR).

Diaz-Orueta U, Garcia-Lopez C, Crespo-Eguilaz N, et al. AULA virtual reality test as an attention measure: convergent validity with Conners' Continuous Performance Test. *Child Neuropsychol* 2014;20(3):328-42. PMID: 23638628.

Dittmann RW, Banaschewski T, Schacht A, et al. Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment. *Atten Defic Hyperact Disord* 2014;6(4):291-302. PMID: 24705867.

Dittmann RW, Wehmeier PM, Schacht A, et al. Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians. *Child Adolesc Psychiatry Ment Health* 2009;3(1):21. PMID: 19703299.

Dittmann RW, Wehmeier PM, Schacht A, et al. Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings. *Atten Defic Hyperact Disord* 2009;1(2):187-200. PMID: 20234829.

Döpfner M, Breuer D, Walter D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes. *Eur Child Adolesc Psychiatry* 2011;20(Suppl 2):S277-88. PMID: 21901414.

Döpfner M, Görtz-Dorten A, Breuer D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: Effectiveness on symptoms and impairment, and safety. *European Child & Adolescent Psychiatry* 2011;20(Suppl 2):S243-S255.

Dupuy FE, Clarke AR, Barry RJ, et al. EEG differences between the Combined and Inattentive types of attention-deficit/hyperactivity disorder in girls: A further investigation. *Clinical EEG and Neuroscience* 2014;45(4):231-237.

Dura-Trave T and Gallinas-Victoriano F. Caloric and nutrient intake in children with attention deficit hyperactivity disorder treated with extended-release methylphenidate: analysis of a cross-sectional nutrition survey. *JRSM Open* 2014;5(2):2042533313517690. PMID: 25057372.

Dura-Trave T, Yoldi-Petri ME, Gallinas-Victoriano F, et al. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment. *J Child Neurol* 2012;27(5):604-9. PMID: 22190507.

Efron D, Lycett K and Sciberras E. Use of sleep medication in children with ADHD. *Sleep Med* 2014;15(4):472-5. PMID: 24684977.

Epstein JN, Langberg JM, Lichtenstein PK, et al. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. *Arch Pediatr Adolesc Med* 2010;164(2):160-5. PMID: 20124145.

Ercan ES, Akyol Ardic U, Kabukcu Basay B, et al. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review. *Atten Defic Hyperact Disord* 2013;5(4):377-85. PMID: 23737214.

Escolano C, Navarro-Gil M, Garcia-Campayo J, et al. The effects of individual upper alpha neurofeedback in ADHD: an open-label pilot study. *Appl Psychophysiol Biofeedback* 2014;39(3-4):193-202. PMID: 25199660.

Faraone SV, Hammerness PG and Wilens TE. Reliability and Validity of the Before-School Functioning Scale in Children With ADHD. *J Atten Disord* 2015. PMID: 25575616.

Faraone SV, Spencer TJ, Kollins SH, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. *J Am Acad Child Adolesc Psychiatry* 2010;49(1):24-32. PMID: 20215923.

Fernandez-Jaen A, Fernandez-Mayoralas DM, Calleja Perez B, et al. Atomoxetine for attention deficit hyperactivity disorder in mental retardation. *Pediatr Neurol* 2010;43(5):341-7. PMID: 20933178.

Fernandez-Jaen A, Fernandez-Mayoralas DM, Calleja-Perez B, et al. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study. *J Atten Disord* 2013;17(6):497-505. PMID: 22366240.

Fernandez-Jaen A, Fernandez-Mayoralas DM, Pardos A, et al. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation. *Adv Ther* 2009;26(12):1097-110. PMID: 20082241.

Findling RL, Cutler AJ, Saylor K, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2013;23(1):11-21. PMID: 23410138.

Findling RL, Ginsberg LD, Jain R, et al. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. *J Child Adolesc Psychopharmacol* 2009;19(6):649-62. PMID: 20035583.

Findling RL, Katic A, Rubin R, et al. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2010;20(5):365-75. PMID: 20973707.

Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. *Clin Ther* 2009;31(8):1844-55. PMID: 19808143.

Ford-Jones PC. Misdiagnosis of attention deficit hyperactivity disorder: 'Normal behaviour' and relative maturity. *Paediatr Child Health* 2015;20(4):200-2. PMID: 26038639.

Frazier TW, Weiss M, Hodgkins P, et al. Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. *J Child Adolesc Psychopharmacol* 2010;20(5):355-64. PMID: 20973706.

Froehlich TE, Antonini TN, Brinkman WB, et al. Mediators of methylphenidate effects on math performance in children with attention-deficit hyperactivity disorder. *J Dev Behav Pediatr* 2014;35(2):100-7. PMID: 24509055.

Frölich J, Breuer D, Görtz-Dorten A, et al. Effects of switching to once-daily modified-release methylphenidate from previous treatment with other psychostimulants in children and adolescents with ADHD: An observational study with clinician, parent, and teacher evaluations. *Journal of Clinical Psychopharmacology* 2014;34(1):168-171. PMID: 2014-03584-032.

Fuentes J, Danckaerts M, Cardo E, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol* 2013;33(6):766-74. PMID: 23963057.

Gerwe M, Stollhoff K, Mossakowski J, et al. Tolerability and effects of OROS(R) MPH (Concerta (R)) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial. *Atten Defic Hyperact Disord* 2009;1(2):175-86. PMID: 21432582.

Golubchik P, Golubchik L, Sever JM, et al. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety. *Int Clin Psychopharmacol* 2014;29(5):274-8. PMID: 24743562.

Golubchik P, Sever J and Weizman A. Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia. *International Clinical Psychopharmacology* 2014;29(4):212-215.

Gormez V, Avery B and Mann H. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder. *Eur Rev Med Pharmacol Sci* 2013;17(17):2345-9. PMID: 24065228.

Grizenko N, Rodrigues Pereira RM and Joobar R. Sensitivity of scales to evaluate change in symptomatology with psychostimulants in different ADHD subtypes. *J Can Acad Child Adolesc Psychiatry* 2013;22(2):153-8. PMID: 23667362.

Guderjahn L, Gold A, Stadler G, et al. Self-regulation strategies support children with ADHD to overcome symptom-related behavior in the classroom. *Atten Defic Hyperact Disord* 2013;5(4):397-407. PMID: 24062181.

Halperin JM, Marks DJ, Bedard AC, et al. Training executive, attention, and motor skills: a proof-of-concept study in preschool children With ADHD. *J Atten Disord* 2013;17(8):711-21. PMID: 22392551.

Hammer R, Tennekoon M, Cooke GE, et al. Feedback associated with expectation for larger-reward improves visuospatial working memory performances in children with ADHD. *Dev Cogn Neurosci* 2015;14:38-49. PMID: 26142072.

Hammerness P, Doyle R, Kotarski M, et al. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. *Eur Child Adolesc Psychiatry* 2009;18(8):493-8. PMID: 19377865.

Hammerness P, Fried R, Petty C, et al. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. *Child Neuropsychol* 2014;20(3):319-27. PMID: 23639146.

Hammerness P, Joshi G, Doyle R, et al. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. *J Pediatr* 2013;162(1):22-7.e2. PMID: 22878114.

Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. *J Pediatr* 2009;155(1):84-9, 89.e1. PMID: 19394037.

Hansen MV, Darling L and Holst H. Safety and Tolerability of Lisdexamfetamine: A Retrospective Cohort Study. *CNS Drugs* 2015;29(5):415-23. PMID: 25920467.

Harfterkamp M, Buitelaar JK, Minderaa RB, et al. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. *J Child Adolesc Psychopharmacol* 2013;23(3):194-9. PMID: 23578015.

Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. *Pediatrics* 2014;134(4):e935-44. PMID: 25180281.

Helseth SA, Waschbusch DA, Gnagy EM, et al. Effects of behavioral and pharmacological therapies on peer reinforcement of deviancy in children with ADHD-only, ADHD and conduct problems, and controls. *J Consult Clin Psychol* 2015;83(2):280-92. PMID: 25495357.

Hinz M, Stein A, Neff R, et al. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation. *Neuropsychiatric Disease and Treatment* 2011;7(1):31-38.

Howard AL, Molina BS, Swanson JM, et al. Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. *Addiction* 2015;110(5):784-95. PMID: 25664657.

Ishii-Takahashi A, Takizawa R, Nishimura Y, et al. Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial. *Neuropsychopharmacology* 2015;40(12):2676-85. PMID: 25936640.

Jang B, Song J, Kim J, et al. Equine-Assisted Activities and Therapy for Treating Children with Attention-Deficit/Hyperactivity Disorder. *J Altern Complement Med* 2015;21(9):546-53. PMID: 26167851.

Javelot H, Glay-Ribau C, Ligier F, et al. Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases. *Ann Pharm Fr* 2014;72(3):164-77. PMID: 24780832.

Jin L, Xu W, Krefetz D, et al. Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2013;23(3):200-7. PMID: 23607409.

Johnston BA, Coghill D, Matthews K, et al. Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study. *J Psychopharmacol* 2015;29(1):24-30. PMID: 25237119.

Kądziela-Olech H. The measurement of the symptoms of ADHD in the NICHQ vanderbilt assessment scale for parent (VADPRS) and for teacher (VADTRS). *Psychiatria i Psychologia Kliniczna* 2014;14(4):277-283.

Katic A, Ginsberg L, Jain R, et al. Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate. *J Atten Disord* 2012;16(5):384-97. PMID: 21173426.

Kelly AS, Rudser KD, Dengel DR, et al. Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants. *J Pediatr* 2014;165(4):755-9. PMID: 25015574.

Khajehpiri Z, Mahmoudi-Gharaei J, Faghihi T, et al. Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center. *Journal of Research in Pharmacy Practice* 2014;3(4):130-136.

Khodadust N, Jalali AH, Ahmadzad-Asl M, et al. Comparison of Two brands of Methylphenidate (Stimdate((R)) vs. Ritalin((R))) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. *Iran J Psychiatry Behav Sci* 2012;6(1):26-32. PMID: 24644466.

Kim E, Cheon KA, Joung YS, et al. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate. *Clin Neuropharmacol* 2015;38(1):30-5. PMID: 25580917.

Kim HJ, Yang J and Lee MS. Changes of Heart Rate Variability during Methylphenidate Treatment in Attention-Deficit Hyperactivity Disorder Children: A 12-Week Prospective Study. *Yonsei Med J* 2015;56(5):1365-71. PMID: 26256981.

Kim HW, Kim SO, Shon S, et al. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review. *J Child Adolesc Psychopharmacol* 2014;24(8):448-53. PMID: 25285915.

Kim HW, Yoon IY, Cho SC, et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. *Int Clin Psychopharmacol* 2010;25(2):107-15. PMID: 20093941.

Kim SH, Han DH, Lee YS, et al. Baduk (the game of go) improved cognitive function and brain activity in children with attention deficit hyperactivity disorder. *Psychiatry Investigation* 2014;11(2):143-151.

Kobel M, Bechtel N, Weber P, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. *Eur J Paediatr Neurol* 2009;13(6):516-23. PMID: 19056305.

Kordon A, Stollhoff K, Niederkirchner K, et al. Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with

ADHD transitioning from immediate-release MPH. *Postgrad Med* 2011;123(5):27-38. PMID: 21904084.

Lambert MC, Reid R, Prosser B, et al. A Survival Analysis of Psychostimulant Prescriptions in New South Wales from 1990 to 2010. *J Child Adolesc Psychopharmacol* 2015;25(6):475-81. PMID: 26218772.

Leisman G, Melillo R, Thum S, et al. The effect of hemisphere specific remediation strategies on the academic performance outcome of children with ADD/ADHD. *Int J Adolesc Med Health* 2010;22(2):275-83. PMID: 21061929.

Liao YC, Guo NW, Lei SH, et al. Electroencephalogram valid rate in simple reaction time task as an easy index of children's attention functions. *Pediatr Int* 2015;57(5):930-5. PMID: 25925420.

Lim CG, Lee TS, Guan C, et al. A brain-computer interface based attention training program for treating attention deficit hyperactivity disorder. *PLoS One* 2012;7(10):e46692. PMID: 23115630.

Loren RE, Vaughn AJ, Langberg JM, et al. Effects of an 8-session behavioral parent training group for parents of children with ADHD on child impairment and parenting confidence. *J Atten Disord* 2015;19(2):158-66. PMID: 23599209.

Lufi D, Bassin-Savion S and Rubel L. The effect of methylphenidate on sustained attention among adolescents with attention-deficit hyperactivity disorder. *Neurocase* 2015;21(6):802-808.

Mahon AD, Woodruff ME, Horn MP, et al. Effect of stimulant medication use by children with ADHD on heart rate and perceived exertion. *Adapt Phys Activ Q* 2012;29(2):151-60. PMID: 22467834.

Malik TA and Tariq N. Parent training in reduction of attention-deficit/hyperactivity disorder and oppositional defiant disorder symptoms in children. *Pakistan Journal of Psychological Research* 2014;29(1):151-169.

Manos M, Frazier TW, Landgraf JM, et al. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. *Curr Med Res Opin* 2009;25(12):3001-10. PMID: 19849639.

Masi G, Gagliano A, Siracusano R, et al. Aripirazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: A 12-week, open-label, preliminary study. *Journal of Child and Adolescent Psychopharmacology* 2012;22(2):120-125.

McCarthy A, Asghar S, Wilens T, et al. Using a Brief Parent-Report Measure to Track Outcomes for Children and Teens with ADHD. *Child Psychiatry Hum Dev* 2015. PMID: 26271346.

Mikolajczyk R, Horn J, Schmedt N, et al. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. *JAMA Pediatr* 2015;169(4):391-5. PMID: 25686215.

Moungnoi P and Maipang P. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. *J Med Assoc Thai* 2011;94(Suppl 3):S158-63. PMID: 22043770.

Na KS, Lee SI, Hong SD, et al. Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study. *Int Clin Psychopharmacol* 2013;28(4):184-92. PMID: 23587983.

Nagashima M, Monden Y, Dan I, et al. Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study. *Neuroimage Clin* 2014;6:192-201. PMID: 25379431.

Nair V and Mahadevan S. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. *J Trop Pediatr* 2009;55(2):116-21. PMID: 19203986.

Niederkirchner K, Slawik L, Wermelskirchen D, et al. Transitioning to OROS((R)) methylphenidate from atomoxetine is effective in children and adolescents with ADHD. *Expert Rev Neurother* 2011;11(4):499-508. PMID: 21469923.

Park SY, Kim EJ and Cheon KA. Association between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. *Journal of Child and Adolescent Psychopharmacology* 2015;25(8):633-640.

Paton K, Hammond P, Barry E, et al. Methylphenidate improves some but not all measures of attention, as measured by the TEA-Ch in medication-naive children with ADHD. *Child Neuropsychol* 2014;20(3):303-18. PMID: 23639119.

Pfiffner LJ, Villodas M, Kaiser N, et al. Educational outcomes of a collaborative school-home behavioral intervention for ADHD. *Sch Psychol Q* 2013;28(1):25-36. PMID: 23506023.

Piepmeier AT, Shih CH, Whedon M, et al. The effect of acute exercise on cognitive performance in children with and without ADHD. *Journal of Sport and Health Science* 2015;4(1):97-104.

Poil SS, Bollmann S, Ghisleni C, et al. Age dependent electroencephalographic changes in attention-deficit/hyperactivity disorder (ADHD). *Clin Neurophysiol* 2014;125(8):1626-38. PMID: 24582383.

Pollak Y, Shomaly HB, Weiss PL, et al. Methylphenidate effect in children with ADHD can be measured by an ecologically valid continuous performance test embedded in virtual reality. *CNS Spectr* 2010;15(2):125-30. PMID: 20414157.

Poulton AS, Bui Q, Melzer E, et al. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. *Int Clin Psychopharmacol* 2015. PMID: 26544899.

Poulton AS, Melzer E, Tait PR, et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. *Med J Aust* 2013;198(1):29-32. PMID: 23330767.

Powell SG, Frydenberg M and Thomsen PH. The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients. *Child Adolesc Psychiatry Ment Health* 2015;9:50. PMID: 26516345.

Radziuk AL, Kieling RR, Santos K, et al. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. *Epilepsy Behav* 2015;46:215-20. PMID: 25940104.

Ramtvedt BE and Sundet K. Relationships between computer-based testing and behavioral ratings in the assessment of attention and activity in a pediatric ADHD stimulant crossover trial. *Clin Neuropsychol* 2014;28(7):1146-61. PMID: 25249305.

Rockhill CM, Tse YJ, Fesinmeyer MD, et al. Telepsychiatrists' Medication Treatment Strategies in the Children's Attention-Deficit/Hyperactivity Disorder Telemental Health Treatment Study. *J Child Adolesc Psychopharmacol* 2015. PMID: 26258927.

Rothenberger A, Becker A, Breuer D, et al. An observational study of once-daily modified-release methylphenidate in ADHD: Quality of life, satisfaction with treatment and adherence. *European Child & Adolescent Psychiatry* 2011;20(Suppl 2):S257-S265.

Sahin S, Yuce M, Alacam H, et al. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. *Int J Psychiatry Clin Pract* 2014;18(4):280-7. PMID: 24994482.

Sangal RB and Sangal JM. Use of EEG Beta-1 Power and Theta/Beta Ratio Over Broca's Area to confirm Diagnosis of Attention Deficit/Hyperactivity Disorder in Children. *Clin EEG Neurosci* 2015;46(3):177-82. PMID: 24973230.

Saylor K, Williams DW, Schuh KJ, et al. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. *Curr Med Res Opin* 2010;26(9):2087-95. PMID: 20642391.

Schreiber JM, Lanham DC, Trescher WH, et al. Variations in EEG discharges predict ADHD severity within individual Smith-Lemli-Opitz patients. *Neurology* 2014;83(2):151-9. PMID: 24920862.

Scott NG, Ripperger-Suhler J, Rajab MH, et al. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. *J Child Adolesc Psychopharmacol* 2010;20(3):197-203. PMID: 20578932.

Shaywitz BA, Williams DW, Fox BK, et al. Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment. *J Child Adolesc Psychopharmacol* 2014;24(8):419-25. PMID: 25299355.

Shemmassian SK and Lee SS. Predictive Utility of Four Methods of Incorporating Parent and Teacher Symptom Ratings of ADHD for Longitudinal Outcomes. *J Clin Child Adolesc Psychol* 2015:1-12. PMID: 25643854.

Sibley MH, Pelham WE, Molina BS, et al. The role of early childhood ADHD and subsequent CD in the initiation and escalation of adolescent cigarette, alcohol, and marijuana use. *J Abnorm Psychol* 2014;123(2):362-74. PMID: 24886010.

Sibley MH, Smith BH, Evans SW, et al. Treatment response to an intensive summer treatment program for adolescents with ADHD. *Journal of Attention Disorders* 2012;16(6):443-448.

Song J, Kim SW, Hong HJ, et al. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. *Clin Neuropharmacol* 2014;37(5):136-41. PMID: 25229170.

Sprafkin J, Mattison RE, Gadow KD, et al. A brief DSM-IV-referenced teacher rating scale for monitoring behavioral improvement in ADHD and co-occurring symptoms. *J Atten Disord* 2011;15(3):235-45. PMID: 20228218.

Su Y, Li H, Chen Y, et al. Remission Rate and Functional Outcomes during a 6-Month Treatment with Osmotic-Release Oral-System Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder. *Journal of Clinical Psychopharmacology* 2015;35(5):525-534.

Sumner CR, Gathercole S, Greenbaum M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia. *Child Adolesc Psychiatry Ment Health* 2009;3:40. PMID: 20003507.

Sumner CR, Haynes VS, Teicher MH, et al. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?. *Postgrad Med* 2010;122(5):52-61. PMID: 20861588.

Tamm L, Nakonezny PA and Hughes CW. An open trial of a metacognitive executive function training for young children with ADHD. *J Atten Disord* 2014;18(6):551-9. PMID: 22647287.

Tanidir IC, Tanidir C, Ozturk E, et al. Effects of atomoxetine on heart rhythm in children and adolescents. *Pediatr Int* 2015. PMID: 26096186.

Topczewski A. Attention deficit and hyperactivity disorder: a therapeutic option. *Einstein (Sao Paulo)* 2014;12(3):310-3. PMID: 25295451.

Torres A, Whitney J, Rao S, et al. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. *Epilepsy Behav* 2011;20(1):95-102. PMID: 21146461.

Treuer T, Feng Q, Desaiyah D, et al. Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. *Int J Clin Pract* 2014;68(9):1152-60. PMID: 24703228.

Tsai CS, Huang YS, Wu CL, et al. Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder. *BMC Psychiatry* 2013;13:330. PMID: 24305033.

- Turgay A, Ginsberg L, Sarkis E, et al. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. *J Child Adolesc Psychopharmacol* 2010;20(6):503-11. PMID: 21186969.
- Tzang RF, Wang YC, Yeh CB, et al. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. *Psychiatry Clin Neurosci* 2012;66(1):53-63. PMID: 22250610.
- Uebel-von Sandersleben H, Rothenberger A, Albrecht B, et al. Ginkgo biloba extract EGb 761(R) in children with ADHD. *Z Kinder Jugendpsychiatr Psychother* 2014;42(5):337-47. PMID: 25163996.
- Uebel-von Sandersleben H, Rothenberger A, Albrecht B, et al. Ginkgo biloba Extract EGb 761® in Children with ADHD: Preliminary Findings of an Open Multilevel Dose-Finding Study. *Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie* 2014;42(5):337-347.
- Vakula IN, Vasyanina YS, Gorbunova ZK, et al. Efficacy of Strattera in children and adolescents with attention deficit hyperactivity disorder. *Neuroscience and Behavioral Physiology* 2010;40(9):1034-1037.
- Valdizan-Uson JR, Canovas-Martinez A, De Lucas-Taracena MT, et al. Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. *Neuropsychiatr Dis Treat* 2013;9:211-8. PMID: 23430373.
- van der Oord S, Bögels SM and Peijnenburg D. The effectiveness of mindfulness training for children with ADHD and mindful parenting for their parents. *Journal of Child and Family Studies* 2012;21(1):139-147.
- Vaughn AJ, Epstein JN, Rausch J, et al. Relation between outcomes on a continuous performance test and ADHD symptoms over time. *J Abnorm Child Psychol* 2011;39(6):853-64. PMID: 21476025.
- Visser SN, Bitsko RH, Danielson ML, et al. Treatment of Attention Deficit/Hyperactivity Disorder among Children with Special Health Care Needs. *J Pediatr* 2015;166(6):1423-30.e1-2. PMID: 25841538.
- Walitza S, Kampf K, Artamonov N, et al. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. *Toxicol Lett* 2009;184(1):38-43. PMID: 19015014.
- Wang LJ, Chen CK and Huang YS. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study. *J Child Adolesc Psychopharmacol* 2015;25(6):501-8. PMID: 26262904.

Wang LJ, Chen CK and Huang YS. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate. *J Child Adolesc Psychopharmacol* 2015;25(3):246-53. PMID: 25574708.

Wang LJ, Huang YS, Chiang YL, et al. Clinical symptoms and performance on the Continuous Performance Test in children with attention deficit hyperactivity disorder between subtypes: a natural follow-up study for 6 months. *BMC Psychiatry* 2011;11:65. PMID: 21504587.

Wang LJ, Wu CC, Lee SY, et al. Salivary neurosteroid levels and behavioural profiles of children with attention-deficit/hyperactivity disorder during six months of methylphenidate treatment. *J Child Adolesc Psychopharmacol* 2014;24(6):336-40. PMID: 24956271.

Warshaw EM, Squires L, Li Y, et al. Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. *Prim Care Companion J Clin Psychiatry* 2010;12(6). PMID: 21494336.

Webster-Stratton C, Reid MJ and Beauchaine TP. One-year follow-up of combined parent and child intervention for young children with ADHD. *J Clin Child Adolesc Psychol* 2013;42(2):251-61. PMID: 23020199.

Wehmeier PM, Dittmann RW and Banaschewski T. Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study. *Atten Defic Hyperact Disord* 2015;7(2):165-74. PMID: 25416667.

Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies. *Child and Adolescent Psychiatry and Mental Health* 2009;3.

Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(6):719-30. PMID: 20035590.

Wigal SB, Maltas S, Crinella F, et al. Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children diagnosed with ADHD. *J Atten Disord* 2012;16(1):23-33. PMID: 20978273.

Yilmaz A, Gokcen C, Fettahoglu EC, et al. The effect of methylphenidate on executive functions in children with Attention-Deficit Hyperactivity Disorder. *Klinik Psikofarmakoloji Bulteni* 2013;23(2):162-170.

Zelnik N and Terkel-Dawer R. The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations. *Atten Defic Hyperact Disord* 2015;7(4):313-8. PMID: 25838111.

**Does not include outcomes of interest**

- Adisetiyo V, Jensen JH, Tabesh A, et al. Multimodal MR imaging of brain iron in attention deficit hyperactivity disorder: a noninvasive biomarker that responds to psychostimulant treatment?. *Radiology* 2014;272(2):524-32. PMID: 24937545.
- Adriaanse M, van Domburgh L, Zwirs B, et al. School-based screening for psychiatric disorders in Moroccan-Dutch youth. *Child and Adolescent Psychiatry and Mental Health* 2015;9(1).
- Alba-Sanchez F, Yanez-Suarez O and Brust-Carmona H. Assisted diagnosis of attention-deficit hyperactivity disorder through EEG bandpower clustering with self-organizing maps. *Conf Proc IEEE Eng Med Biol Soc* 2010:2447-50. PMID: 21095960.
- Amer DA, Rakhawy MY and El Kholly SH. Quantitative EEG in children with attention deficit hyperactivity disorder. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery* 2010;47(3):399-406.
- Anjana Y, Khaliq F and Vaney N. Event-related potentials study in attention deficit hyperactivity disorder. *Funct Neurol* 2010;25(2):87-92. PMID: 20923606.
- Bailey UL, Derefinko KJ, Milich R, et al. The effects of stimulant medication on free recall of story events among children with ADHD. *Journal of Psychopathology and Behavioral Assessment* 2011;33(4):409-419.
- Bakhtadze S, Beridze M, Geladze N, et al. Effect of EEG Biofeedback on Cognitive Flexibility in Children with Attention Deficit Hyperactivity Disorder With and Without Epilepsy. *Appl Psychophysiol Biofeedback* 2015. PMID: 26346570.
- Barry RJ, Clarke AR, Hajos M, et al. Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder. *Neuropharmacology* 2009;57(7-8):702-707.
- Becker A, Rothenberger A and Sohn A. Six years ahead: a longitudinal analysis regarding course and predictive value of the Strengths and Difficulties Questionnaire (SDQ) in children and adolescents. *European Child and Adolescent Psychiatry* 2015;24(6):715-725.
- Beyer Von Morgenstern S, Becker I and Sinzig J. Improvement of facial affect recognition in children and adolescents with attention-deficit/hyperactivity disorder under methylphenidate. *Acta Neuropsychiatrica* 2013;26(4):202-208.
- Bink M, van Nieuwenhuizen C, Popma A, et al. Neurocognitive effects of neurofeedback in adolescents with ADHD: a randomized controlled trial. *J Clin Psychiatry* 2014;75(5):535-42. PMID: 24922488.
- Cassuto H, Ben-Simon A and Berger I. Using environmental distractors in the diagnosis of ADHD. *Frontiers in Human Neuroscience* 2013(NOV).
- Chelonis JJ, Johnson TA, Ferguson SA, et al. Effect of methylphenidate on motivation in children with attention-deficit/hyperactivity disorder. *Experimental and Clinical Psychopharmacology* 2011;19(2):145-153.

Chuang LY, Tsai YJ, Chang YK, et al. Effects of acute aerobic exercise on response preparation in a Go/No Go Task in children with ADHD: An ERP study. *Journal of Sport and Health Science* 2015;4(1):82-88.

Chutko LS, Surushkina SY, Nikishena IS, et al. Use of Adaptol in the treatment of attention deficit hyperactivity disorder in children. *Neuroscience and Behavioral Physiology* 2010;40(9):1038-1041.

Co JP, Johnson SA, Poon EG, et al. Electronic health record decision support and quality of care for children with ADHD. *Pediatrics* 2010;126(2):239-46. PMID: 20643719.

Dalsgaard S, Mortensen PB, Frydenberg M, et al. Association between Attention-Deficit Hyperactivity Disorder in childhood and schizophrenia later in adulthood. *Eur Psychiatry* 2014;29(4):259-63. PMID: 24016863.

de Jong CG, Van De Voorde S, Roeyers H, et al. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder. *J Child Adolesc Psychopharmacol* 2009;19(6):699-707. PMID: 20035588.

DeVito EE, Blackwell AD, Clark L, et al. Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). *Psychopharmacology (Berl)* 2009;202(1-3):531-9. PMID: 18818905.

Diamond G, Badir M, Sevilla P, et al. Comparison between neurological examination and computerized test of attention for suspected ADHD: Implications for assessment of a common childhood disability. *International Journal on Disability and Human Development* 2013;12(3):289-295.

Diomšina B, Rasmussen PD and Danilevičiute V. Clinical experience of long-term treatment with aripiprazole (abilify) in children and adolescents at the child and adolescent psychiatric clinic 1 in Roskilde, Denmark. *Acta Poloniae Pharmaceutica - Drug Research* 2015;72(3):597-606.

Fabiano GA, Pelham WE, Cunningham CE, et al. A waitlist-controlled trial of behavioral parent training for fathers of children with ADHD. *J Clin Child Adolesc Psychol* 2012;41(3):337-45. PMID: 22397639.

Fernandez de la Cruz L, Simonoff E, McGough JJ, et al. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). *J Am Acad Child Adolesc Psychiatry* 2015;54(1):62-70.e3. PMID: 25524791.

Fried R, Hirshfeld-Becker D, Petty C, et al. How Informative Is the CANTAB to Assess Executive Functioning in Children With ADHD? A Controlled Study. *J Atten Disord* 2015;19(6):468-75. PMID: 22923781.

Gevensleben H, Holl B, Albrecht B, et al. Distinct EEG effects related to neurofeedback training in children with ADHD: a randomized controlled trial. *Int J Psychophysiol* 2009;74(2):149-57. PMID: 19712709.

Ghanizadeh A and Haddad B. The effect of dietary education on ADHD, a randomized controlled clinical trial. *Ann Gen Psychiatry* 2015;14:12. PMID: 25767556.

Gonzalez MA, Campbell D and Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(3):227-32. PMID: 19519257.

Görtz-Dorten A, Breuer D, Hautmann C, et al. What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. *European Child & Adolescent Psychiatry* 2011;20(Suppl 2):S297-S307. PMID: 2011-22383-007.

Gow RV, Hibbeln JR and Parletta N. Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder. *Curr Opin Clin Nutr Metab Care* 2015;18(2):133-8. PMID: 25581035.

Gray SA, Chaban P, Martinussen R, et al. Effects of a computerized working memory training program on working memory, attention, and academics in adolescents with severe LD and comorbid ADHD: a randomized controlled trial. *J Child Psychol Psychiatry* 2012;53(12):1277-84. PMID: 22978357.

Greenfield B, Hechtman L, Stehli A, et al. Sexual maturation among youth with ADHD and the impact of stimulant medication. *Eur Child Adolesc Psychiatry* 2014;23(9):835-9. PMID: 24488239.

Groen Y, Mulder LJ, Wijers AA, et al. Methylphenidate improves diminished error and feedback sensitivity in ADHD: An evoked heart rate analysis. *Biol Psychol* 2009;82(1):45-53. PMID: 19464338.

Guney E, Cetin FH, Alisik M, et al. Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study. *Psychiatry Research* 2015;229(1-2):310-317.

Halldorsdottir T, Ollendick TH, Ginsburg G, et al. Treatment Outcomes in Anxious Youth with and without Comorbid ADHD in the CAMS. *J Clin Child Adolesc Psychol* 2015;44(6):985-91. PMID: 25310142.

Hareendran A, Setyawan J, Pokrzywinski R, et al. Evaluating functional outcomes in adolescents with attention-deficit/hyperactivity disorder: Development and initial testing of a self-report instrument. *Health and Quality of Life Outcomes* 2015;13(1).

Hidas A, Birman N, Noy AF, et al. Salivary bacteria and oral health status in medicated and non-medicated children and adolescents with attention deficit hyperactivity disorder (ADHD). *Clin Oral Investig* 2013;17(8):1863-7. PMID: 23135427.

Holmes J, Gathercole SE, Place M, et al. Working memory deficits can be overcome: Impacts of training and medication on working memory in children with ADHD. *Applied Cognitive Psychology* 2010;24(6):827-836.

Holtmann M, Pniewski B, Wachtlin D, et al. Neurofeedback in children with attention-deficit/hyperactivity disorder (ADHD)--a controlled multicenter study of a non-pharmacological treatment approach. *BMC Pediatr* 2014;14:202. PMID: 25123917.

Huang YS, Wang LJ and Chen CK. Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status. *BMC Psychiatry* 2012;12:194. PMID: 23140464.

Hwang-Gu SL and Gau SSF. Interval timing deficits assessed by time reproduction dual tasks as cognitive endophenotypes for attention-deficit/hyperactivity disorder. *PLoS ONE* 2015;10(5).

Jacobi-Polishook T, Shorer Z and Melzer I. The effect of methylphenidate on postural stability under single and dual task conditions in children with attention deficit hyperactivity disorder - a double blind randomized control trial. *J Neurol Sci* 2009;280(1-2):15-21. PMID: 19217632.

Jans T, Graf E, Jacob C, et al. A randomized controlled multicentre trial on the treatment for ADHD in mothers and children: enrolment and basic characteristics of the study sample. *Atten Defic Hyperact Disord* 2013;5(1):29-40. PMID: 23070786.

Johnstone SJ, Roodenrys S, Blackman R, et al. Neurocognitive training for children with and without AD/HD. *Atten Defic Hyperact Disord* 2012;4(1):11-23. PMID: 22179720.

Jurbergs N, Palcic JL and Kelley ML. Daily Behavior Report Cards with and without Home-Based Consequences: Improving Classroom Behavior in Low Income, African American Children with ADHD. *Child & Family Behavior Therapy* 2010;32(3):177-195.

Kielbasa W, Quinlan T, Jin L, et al. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2012;22(4):269-76. PMID: 22849510.

Kwon HJ, Lim MH, Ha M, et al. Transferrin in Korean children with attention deficit hyperactivity disorder. *Psychiatry Investigation* 2011;8(4):366-371.

Lakes KD, Swanson JM and Riggs M. The reliability and validity of the English and Spanish Strengths and Weaknesses of ADHD and Normal behavior rating scales in a preschool sample: continuum measures of hyperactivity and inattention. *J Atten Disord* 2012;16(6):510-6. PMID: 21807955.

Langberg JM, Vaughn AJ, Brinkman WB, et al. Clinical utility of the Vanderbilt ADHD Rating Scale for ruling out comorbid learning disorders. *Pediatrics* 2010;126(5):e1033-8. PMID: 20937653.

- Li S, Yu B, Lin Z, et al. Randomized-controlled study of treating attention deficit hyperactivity disorder of preschool children with combined electro-acupuncture and behavior therapy. *Complement Ther Med* 2010;18(5):175-83. PMID: 21056840.
- Lin HY, Lee P, Chang WD, et al. Effects of weighted vests on attention, impulse control, and on-task behavior in children with attention deficit hyperactivity disorder. *Am J Occup Ther* 2014;68(2):149-58. PMID: 24581401.
- Maoz H, Tsviban L, Gvirts HZ, et al. Stimulants improve theory of mind in children with attention deficit/hyperactivity disorder. *Journal of Psychopharmacology* 2014;28(3):212-219. PMID: 2014-10977-003.
- McCarty CA, Stoep AV, Violette H, et al. Interventions developed for psychiatric and behavioral treatment in the children's ADHD Telemental Health Treatment Study. *Journal of Child and Family Studies* 2015;24(6):1735-1743. PMID: 2014-20776-001.
- Meftagh SD, Najimi A, Mohammadi N, et al. The most effective intervention for attention deficit-hyperactivity disorder: using continuous performance test. *Psychiatr Danub* 2014;26(2):165-71. PMID: 24909254.
- O'Connor BC, Fabiano GA, Waschbusch DA, et al. Effects of a summer treatment program on functional sports outcomes in young children with ADHD. *J Abnorm Child Psychol* 2014;42(6):1005-17. PMID: 24362766.
- Ota T, Iida J, Nakanishi Y, et al. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy. *Psychiatry and Clinical Neurosciences* 2015;69(3):161-170.
- Perera H, Jeewandara KC, Seneviratne S, et al. Combined  $\omega_3$  and  $\omega_6$  supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: A double-blind, placebo-controlled study. *Journal of Child Neurology* 2012;27(6):747-753.
- Prins PJ, Dosis S, Ponsioen A, et al. Does computerized working memory training with game elements enhance motivation and training efficacy in children with ADHD?. *Cyberpsychol Behav Soc Netw* 2011;14(3):115-22. PMID: 20649448.
- Pritchard AE, Koriakin T, Jacobson LA, et al. Incremental validity of neuropsychological assessment in the identification and treatment of youth with ADHD. *Clin Neuropsychol* 2014;28(1):26-48. PMID: 24345262.
- Rajwan E, Chacko A, Wymbs BT, et al. Evaluating clinically significant change in mother and child functioning: comparison of traditional and enhanced behavioral parent training. *J Abnorm Child Psychol* 2014;42(8):1407-12. PMID: 24740438.
- Ramtvedt BE, Sandvik L and Sundet K. Correspondence between children's and adults' ratings of stimulant-induced changes in ADHD behaviours in a crossover trial with medication-naive

children. *European Journal of Developmental Psychology* 2014;11(6):687-700. PMID: 2014-33449-005.

Rivera-Flores GW. Self-instructional cognitive training to reduce impulsive cognitive style in children with attention deficit with hyperactivity disorder. *Electronic Journal of Research in Educational Psychology* 2015;13(1):27-46.

Rubia K, Alegria AA, Cubillo AI, et al. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *Biol Psychiatry* 2014;76(8):616-28. PMID: 24314347.

Rundberg-Rivera EV, Townsend LD, Schneider J, et al. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. *J Child Adolesc Psychopharmacol* 2015;25(3):225-33. PMID: 25885012.

Saadat F, Kosha M, Amiry A, et al. Brain-derived neurotrophic factor as a biomarker in children with attention deficit-hyperactivity disorder. *Journal of Krishna Institute of Medical Sciences University* 2015;4(4):10-17.

Sadatnezhad K, Boostani R and Ghanizadeh A. Proposing an adaptive mutation to improve XCSF performance to classify ADHD and BMD patients. *J Neural Eng* 2010;7(6):066006. PMID: 21048285.

Schacht A, Escobar R, Wagner T, et al. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. *Atten Defic Hyperact Disord* 2011;3(4):335-49. PMID: 21986814.

Schweren LJ, Hartman CA, Zwiwers MP, et al. Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study. *Eur Child Adolesc Psychiatry* 2015;24(8):959-68. PMID: 25395383.

Setyawan J, Hodgkins P, Guerin A, et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. *J Med Econ* 2013;16(7):962-75. PMID: 23621503.

Setyawan J, Hodgkins P, Guerin A, et al. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults. *J Med Econ* 2013;16(10):1203-15. PMID: 23937642.

Shaw P, Sharp WS, Morrison M, et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. *Am J Psychiatry* 2009;166(1):58-63. PMID: 18794206.

Shiels K, Hawk LW, Jr., Reynolds B, et al. Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. *Exp Clin Psychopharmacol* 2009;17(5):291-301. PMID: 19803628.

Sibley MH, Altszuler AR, Ross JM, et al. A Parent-Teen Collaborative Treatment Model for Academically Impaired High School Students With ADHD. *Cognitive and Behavioral Practice* 2014;21(1):32-42.

Sikirica V, Pliszka SR, Betts KA, et al. Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder. *Am J Manag Care* 2014;20(9):711-21. PMID: 25365746.

Silva D, Colvin L, Glauert R, et al. Contact with the juvenile justice system in children treated with stimulant medication for attention deficit hyperactivity disorder: a population study. *Lancet Psychiatry* 2014;1(4):278-85. PMID: 26360861.

Silva D, Houghton S, Hagemann E, et al. Child Attention Deficit Hyperactive Disorder co morbidities on family stress: Effect of medication. *Community Mental Health Journal* 2015;51(3):347-353.

Spencer SV, Hawk LW, Jr., Richards JB, et al. Stimulant treatment reduces lapses in attention among children with ADHD: the effects of methylphenidate on intra-individual response time distributions. *J Abnorm Child Psychol* 2009;37(6):805-16. PMID: 19291387.

Springer C and Reddy LA. Measuring parental treatment adherence in a multimodal treatment program for children with ADHD: A preliminary investigation. *Child & Family Behavior Therapy* 2010;32(4):272-290.

Steger CM, Gondoli DM, Gibson BS, et al. Combined cognitive and parent training interventions for adolescents with ADHD and their mothers: A randomized controlled trial. *Child Neuropsychol* 2015:1-26. PMID: 25731907.

Stray LL, Ellertsen B and Stray T. Motor function and methylphenidate effect in children with attention deficit hyperactivity disorder. *Acta Paediatr* 2010;99(8):1199-204. PMID: 20298494.

Sundquist J, Ohlsson H, Sundquist K, et al. Attention-deficit/hyperactivity disorder and risk for drug use disorder: A population-based follow-up and co-relative study. *Psychological Medicine* 2015;45(5):977-983.

Tamm L and Nakonezny PA. Metacognitive executive function training for young children with ADHD: a proof-of-concept study. *ADHD Attention Deficit and Hyperactivity Disorders* 2015;7(3):183-190.

Tarakçioğlu MC, Çakın Memik N, Olgun NN, et al. Turkish validity and reliability study of the Weiss Functional Impairment Rating Scale-Parent Report. *ADHD Attention Deficit and Hyperactivity Disorders* 2015;7(2):129-139.

Tucker JD, Suter W, Petibone DM, et al. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. *Mutat Res* 2009;677(1-2):53-8. PMID: 19465145.

van der Kolk A, Bouwmans CA, Schawo SJ, et al. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. *Springerplus* 2015;4:224. PMID: 26155437.

Wehrmann T and Müller JM. An objective measure of hyperactivity aspects with compressed webcam video. *Child and Adolescent Psychiatry and Mental Health* 2015;9(1).

Wu Q, Zhou T, Ma L, et al. Protective effects of dietary supplementation with natural omega-3 polyunsaturated fatty acids on the visual acuity of school-age children with lower IQ or attention-deficit hyperactivity disorder. *Nutrition* 2015;31(7-8):935-40. PMID: 26015389.

Yalcin O, Iseri E, Bukan N, et al. Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: An open label trial. *Klinik Psikofarmakoloji Bulteni* 2014;24(2):146-157.

Zarrabi M, Shahrivar Z, Tehrani Doost M, et al. Concurrent validity of the behavior rating inventory of executive function in children with attention deficit hyperactivity disorder. *Iranian Journal of Psychiatry and Behavioral Sciences* 2015;9(1).

Zhang L, Jin X and Zhang Y. Effect of methylphenidate on intelligence quotient scores in Chinese children with attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol* 2011;31(1):51-5. PMID: 21192143.

## **Timing or setting not applicable**

Williams LM, Hermens DF, Thein T, et al. Using brain-based cognitive measures to support clinical decisions in ADHD. *Pediatr Neurol* 2010;42(2):118-26. PMID: 20117748.

## Appendix E. Key to Included Primary and Companion Articles

\*Companion articles marked with an asterisk did not individually meet criteria for inclusion but were considered for supplemental information (e.g., methods data pertinent to an included study).

Study Designation	Primary Abstracted Article	Companion Articles
CATTS (Children's ADHD Telemental Health Treatment Study)	Myers, 2015 <sup>1</sup>	None
INCA (Impact of Nutrition on Children with ADHD)	Pelsser, 2011 <sup>2</sup>	None
MTA (Multimodal Treatment Study)	Molina, 2009 <sup>3</sup>	Vitiello, 2012 <sup>4</sup> *MTA Cooperative Group, 1999 <sup>5</sup>
SOSTRA (SOcial Skills TRaining Attachment)	Storebo, 2012 <sup>6</sup>	None
None	Boyer, 2015 <sup>7</sup>	Boyer, 2015 <sup>8</sup>
None	Bunte, 2013 <sup>9</sup>	Bunte, 2013 <sup>10</sup>
None	Duric, 2012 <sup>11</sup>	Duric, 2014 <sup>12</sup>
None	Egeland, 2013 <sup>13</sup>	Hovik, 2013 <sup>14</sup>
None	Gevensleben, 2009 <sup>15</sup>	Wangler, 2011 <sup>16</sup> Gevensleben, 2010 <sup>17</sup>
None	Hiscock, 2015 <sup>18</sup>	Papadopoulos, 2015 <sup>19</sup>
None	Johnson, 2009 <sup>20</sup>	Johnson, 2012 <sup>21</sup>
None	Manor, 2012 <sup>22</sup>	Manor, 2013 <sup>23</sup>
None	Milte, 2012 <sup>24</sup>	Milte, 2015 <sup>25</sup>
None	Mohammadi, 2012 <sup>26</sup>	Mostafavi, 2012 <sup>27</sup>
None	Steiner, 2014 <sup>28</sup>	Steiner, 2014 <sup>29</sup>
None	Abikoff, 2015 <sup>30</sup>	None
None	Abikoff, 2013 <sup>31</sup>	None
None	Arcieri, 2012 <sup>32</sup>	None
None	Arnold, 2011 <sup>33</sup>	None
None	Bai, 2015 <sup>34</sup>	None
None	Banaschewski, 2014 <sup>35</sup>	None
None	Barragan, 2014 <sup>36</sup>	None
None	Beck, 2010 <sup>37</sup>	None
None	Berger, 2010 <sup>38</sup>	None
None	Bink, 2015 <sup>39</sup>	*Bink, 2014 <sup>40</sup>
None	Bloch, 2012 <sup>41</sup>	None
None	Carballo, 2014 <sup>42</sup>	None
None	Castro-Cabrera, 2010 <sup>43</sup>	None
None	Caudal, 2011 <sup>44</sup>	None
None	Cetin, 2015 <sup>45</sup>	None
None	Chacko, 2014 <sup>46</sup>	None
None	Chacko, 2009 <sup>47</sup>	None
None	Clemow, 2015 <sup>48</sup>	None
None	Cortese, 2015 <sup>49</sup>	None
None	Didoni, 2011 <sup>50</sup>	None
None	dosReis, 2010 <sup>51</sup>	None
None	Dovis, 2015 <sup>52</sup>	None
None	Dutta, 2012 <sup>53</sup>	None

<b>Study Designation</b>	<b>Primary Abstracted Article</b>	<b>Companion Articles</b>
None	Ercan, 2014 <sup>54</sup>	None
None	Evans, 2015 <sup>55</sup>	None
None	Ferrin, 2014 <sup>56</sup>	None
None	Ferrin, 2012 <sup>57</sup>	None
None	Findling, 2010 <sup>58</sup>	*Findling, 2008 <sup>59</sup> *Biederman, 2007 <sup>60</sup>
None	Gonzalez, 2013 <sup>61</sup>	None
None	Gustafsson, 2010 <sup>62</sup>	None
None	Hammerness, 2012 <sup>63</sup>	None
None	Hariri, 2012 <sup>64</sup>	None
None	Huang, 2015 <sup>65</sup>	None
None	Katz, 2010 <sup>66</sup>	None
None	Kim, 2015 <sup>67</sup>	None
None	Kim, 2015 <sup>68</sup>	None
None	Klenberg, 2010 <sup>69</sup>	None
None	Li, 2011 <sup>70</sup>	None
None	Liechti, 2013 <sup>71</sup>	None
None	Martin-Martinez, 2012 <sup>72</sup>	None
None	Mautone, 2012 <sup>73</sup>	None
None	Moreno-Garcia, 2015 <sup>74</sup>	None
None	Oberai, 2013 <sup>75</sup>	None
None	Ogrim, 2012 <sup>76</sup>	None
None	Ohan, 2011 <sup>77</sup>	None
None	Ostberg, 2012 <sup>78</sup>	None
None	Pane, 2010 <sup>79</sup>	None
None	Perera, 2012 <sup>80</sup>	None
None	Pfiffner, 2014 <sup>81</sup>	None
None	Power, 2012 <sup>82</sup>	None
None	Raz, 2009 <sup>83</sup>	None
None	Salehi, 2010 <sup>84</sup>	None
None	Sallee, 2009 <sup>85</sup>	None
None	Shakibaei, 2015 <sup>86</sup>	None
None	Soliva, 2010 <sup>87</sup>	None
None	Tamm, 2013 <sup>88</sup>	None
None	Thorell, 2010 <sup>89</sup>	None
None	Tobaiqy, 2011 <sup>90</sup>	None
None	Trzepacz, 2011 <sup>91</sup>	None
None	van der Donk, 2015 <sup>92</sup>	None
None	van Dongen-Boomsma, 2014 <sup>93</sup>	None
None	Vidal, 2015 <sup>94</sup>	None
None	Webster-Stratton, 2011 <sup>95</sup>	None
None	Widenhorn-Muller, 2014 <sup>96</sup>	None
None	Winterstein, 2009 <sup>97</sup>	None
None	Zelnik, 2012 <sup>98</sup>	None
None	Zhang, 2010 <sup>99</sup>	None

## References to Appendix E:

1. Myers K, Vander Stoep A, Zhou C, et al. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2015 Apr;54(4):263-74. doi: 10.1016/j.jaac.2015.01.009. PMID: 25791143.
2. Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. *Lancet*. 2011 Feb 5;377(9764):494-503. doi: 10.1016/s0140-6736(10)62227-1. PMID: 21296237.
3. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. *J Am Acad Child Adolesc Psychiatry*. 2009 May;48(5):484-500. doi: 10.1097/CHI.0b013e31819c23d0. PMID: 19318991.
4. Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. *Am J Psychiatry*. 2012 Feb;169(2):167-77. doi: 10.1176/appi.ajp.2011.10111705. PMID: 21890793.
5. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. *Arch Gen Psychiatry*. 1999 Dec;56(12):1073-86. PMID: 10591283.
6. Storebo OJ, Gluud C, Winkel P, et al. Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial. *PLoS One*. 2012;7(6):e37280. doi: 10.1371/journal.pone.0037280. PMID: 22745657.
7. Boyer BE, Geurts HM, Prins PJ, et al. Two novel CBTs for adolescents with ADHD: the value of planning skills. *Eur Child Adolesc Psychiatry*. 2015 Sep;24(9):1075-90. doi: 10.1007/s00787-014-0661-5. PMID: 25549767.
8. Boyer BE, Geurts HM, Prins PJM, et al. One-year follow-up of two novel CBTs for adolescents with ADHD. *European Child and Adolescent Psychiatry*. 2015.
9. Bunte TL, Schoemaker K, Hessen DJ, et al. Clinical usefulness of the Kiddie-Disruptive Behavior Disorder Schedule in the diagnosis of DBD and ADHD in preschool children. *J Abnorm Child Psychol*. 2013 Jul;41(5):681-90. doi: 10.1007/s10802-013-9732-1. PMID: 23474833.
10. Bunte TL, Laschen S, Schoemaker K, et al. Clinical usefulness of observational assessment in the diagnosis of DBD and ADHD in preschoolers. *J Clin Child Adolesc Psychol*. 2013;42(6):749-61. doi: 10.1080/15374416.2013.773516. PMID: 23477379.
11. Duric NS, Assmus J, Gundersen D, et al. Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports. *BMC Psychiatry*. 2012;12:107. doi: 10.1186/1471-244x-12-107. PMID: 22877086.
12. Duric NS, Assmus J, Elgen IB. Self-reported efficacy of neurofeedback treatment in a clinical randomized controlled study of ADHD children and adolescents. *Neuropsychiatr Dis Treat*. 2014;10:1645-54. doi: 10.2147/ndt.s66466. PMID: 25214789.
13. Egeland J, Aarli AK, Saunes BK. Few effects of far transfer of working memory training in ADHD: a randomized controlled trial. *PLoS One*. 2013;8(10):e75660. doi: 10.1371/journal.pone.0075660. PMID: 24124503.

14. Hovik KT, Saunes BK, Aarlien AK, et al. RCT of working memory training in ADHD: long-term near-transfer effects. *PLoS One*. 2013;8(12):e80561. doi: 10.1371/journal.pone.0080561. PMID: 24352414.
15. Gevensleben H, Holl B, Albrecht B, et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. *J Child Psychol Psychiatry*. 2009 Jul;50(7):780-9. doi: 10.1111/j.1469-7610.2008.02033.x. PMID: 19207632.
16. Wangler S, Gevensleben H, Albrecht B, et al. Neurofeedback in children with ADHD: specific event-related potential findings of a randomized controlled trial. *Clin Neurophysiol*. 2011 May;122(5):942-50. doi: 10.1016/j.clinph.2010.06.036. PMID: 20843737.
17. Gevensleben H, Holl B, Albrecht B, et al. Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. *Eur Child Adolesc Psychiatry*. 2010 Sep;19(9):715-24. doi: 10.1007/s00787-010-0109-5. PMID: 20499120.
18. Hiscock H, Sciberras E, Mensah F, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. *Bmj*. 2015;350:h68. doi: 10.1136/bmj.h68. PMID: 25646809.
19. Papadopoulos N, Sciberras E, Hiscock H, et al. The Efficacy of a Brief Behavioral Sleep Intervention in School-Aged Children With ADHD and Comorbid Autism Spectrum Disorder. *J Atten Disord*. 2015 Feb 2doi: 10.1177/1087054714568565. PMID: 25646022.
20. Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. *J Atten Disord*. 2009 Mar;12(5):394-401. doi: 10.1177/1087054708316261. PMID: 18448859.
21. Johnson M, Mansson JE, Ostlund S, et al. Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. *Atten Defic Hyperact Disord*. 2012 Dec;4(4):199-204. doi: 10.1007/s12402-012-0084-4. PMID: 22753087.
22. Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. *Eur Psychiatry*. 2012 Jul;27(5):335-42. doi: 10.1016/j.eurpsy.2011.05.004. PMID: 21807480.
23. Manor I, Magen A, Keidar D, et al. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension. *Eur Psychiatry*. 2013 Aug;28(6):386-91. doi: 10.1016/j.eurpsy.2012.11.001. PMID: 23312676.
24. Milte CM, Parletta N, Buckley JD, et al. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. *Nutrition*. 2012 Jun;28(6):670-7. doi: 10.1016/j.nut.2011.12.009. PMID: 22541055.
25. Milte CM, Parletta N, Buckley JD, et al. Increased Erythrocyte Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated With Improved Attention and Behavior in Children With ADHD in a Randomized Controlled Three-Way Crossover Trial. *J Atten Disord*. 2015 Nov;19(11):954-64. doi: 10.1177/1087054713510562. PMID: 24214970.
26. Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. *Iran J Psychiatry*. 2012 Spring;7(2):87-92. PMID: 22952551.

27. Mostafavi SA, Mohammadi MR, Hosseinzadeh P, et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement? *Iran J Psychiatry*. 2012 Summer;7(3):114-9. PMID: 23139692.
28. Steiner NJ, Frenette EC, Rene KM, et al. Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. *J Dev Behav Pediatr*. 2014 Jan;35(1):18-27. doi: 10.1097/dbp.0000000000000009. PMID: 24399101.
29. Steiner NJ, Frenette EC, Rene KM, et al. In-school neurofeedback training for ADHD: sustained improvements from a randomized control trial. *Pediatrics*. 2014 Mar;133(3):483-92. doi: 10.1542/peds.2013-2059. PMID: 24534402.
30. Abikoff HB, Thompson M, Laver-Bradbury C, et al. Parent training for preschool ADHD: a randomized controlled trial of specialized and generic programs. *J Child Psychol Psychiatry*. 2015 Jun;56(6):618-31. doi: 10.1111/jcpp.12346. PMID: 25318650.
31. Abikoff H, Gallagher R, Wells KC, et al. Remediating organizational functioning in children with ADHD: immediate and long-term effects from a randomized controlled trial. *J Consult Clin Psychol*. 2013 Feb;81(1):113-28. doi: 10.1037/a0029648. PMID: 22889336.
32. Arcieri R, Germinario EA, Bonati M, et al. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. *J Child Adolesc Psychopharmacol*. 2012 Dec;22(6):423-31. PMID: 23362511.
33. Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. *J Child Adolesc Psychopharmacol*. 2011 Feb;21(1):1-19. doi: 10.1089/cap.2010.0073. PMID: 21309695.
34. Bai GN, Wang YF, Yang L, et al. Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: Improvement of medication adherence and symptoms. *Neuropsychiatric Disease and Treatment*. 2015;11:2721-35.
35. Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. *CNS Drugs*. 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z. PMID: 25139785.
36. Barragan E, Breuer D, Dopfner M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. *J Atten Disord*. 2014 Jan 24doi: 10.1177/1087054713518239. PMID: 24464327.
37. Beck SJ, Hanson CA, Puffenberger SS, et al. A controlled trial of working memory training for children and adolescents with ADHD. *J Clin Child Adolesc Psychol*. 2010;39(6):825-36. doi: 10.1080/15374416.2010.517162. PMID: 21058129.
38. Berger I, Goldzweig G. Objective measures of attention-deficit/hyperactivity disorder: a pilot study. *Isr Med Assoc J*. 2010 Sep;12(9):531-5. PMID: 21287795.
39. Bink M, van Nieuwenhuizen C, Popma A, et al. Behavioral effects of neurofeedback in adolescents with ADHD: a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2015 Sep;24(9):1035-48. doi: 10.1007/s00787-014-0655-3. PMID: 25477074.
40. Bink M, van Nieuwenhuizen C, Popma A, et al. Neurocognitive effects of neurofeedback in adolescents with ADHD: a randomized

- controlled trial. *J Clin Psychiatry*. 2014 May;75(5):535-42. doi: 10.4088/JCP.13m08590. PMID: 24922488.
41. Bloch Y, Fixman M, Maoz H, et al. Can computerized cognitive tests assist in the clinical diagnosis of attention-deficit hyperactivity disorder? *J Neuropsychiatry Clin Neurosci*. 2012 Winter;24(1):111-4. doi: 10.1176/appi.neuropsych.11010014. PMID: 22450621.
  42. Carballo JJ, Rodriguez-Blanco L, Garcia-Nieto R, et al. Screening for the ADHD Phenotype Using the Strengths and Difficulties Questionnaire in a Clinical Sample of Newly Referred Children and Adolescents. *J Atten Disord*. 2014 Dec 16;doi: 10.1177/1087054714561858. PMID: 25515677.
  43. Castro-Cabrera P, Gomez-Garcia J, Restrepo F, et al. Evaluation of feature extraction techniques on event-related potentials for detection of attention-deficit/hyperactivity disorder. *Conf Proc IEEE Eng Med Biol Soc*. 2010;2010:851-4. doi: 10.1109/iembs.2010.5626862. PMID: 21096317.
  44. Caudal F. New marker using bioimpedance technology in screening for attention deficit/hyperactivity disorder (ADHD) in children as an adjunct to conventional diagnostic methods. *Psychol Res Behav Manag*. 2011;4:113-7. doi: 10.2147/prbm.s22924. PMID: 22114541.
  45. Çetin FH, Taş Torun Y, Işık Taner Y. Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: A six-month follow up study for efficacy and adverse effects. *Türkiye Klinikleri Journal of Medical Sciences*. 2015;35(2):88-96.
  46. Chacko A, Bedard AC, Marks DJ, et al. A randomized clinical trial of Cogmed Working Memory Training in school-age children with ADHD: a replication in a diverse sample using a control condition. *J Child Psychol Psychiatry*. 2014 Mar;55(3):247-55. doi: 10.1111/jcpp.12146. PMID: 24117656.
  47. Chacko A, Wymbs BT, Wymbs FA, et al. Enhancing traditional behavioral parent training for single mothers of children with ADHD. *J Clin Child Adolesc Psychol*. 2009 Mar;38(2):206-18. doi: 10.1080/15374410802698388. PMID: 19283599.
  48. Clemow DB, Mason OW, Sarkis EH, et al. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. *Expert Rev Neurother*. 2015 Oct 21:1-14. doi: 10.1586/14737175.2015.1102060. PMID: 26488905.
  49. Cortese S, Panei P, Arcieri R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. *CNS Drugs*. 2015 Oct;29(10):865-77. doi: 10.1007/s40263-015-0266-7. PMID: 26293742.
  50. Didoni A, Sequi M, Panei P, et al. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. *Eur J Clin Pharmacol*. 2011 Oct;67(10):1061-7. doi: 10.1007/s00228-011-1050-3. PMID: 21538145.
  51. dosReis S, Barksdale CL, Sherman A, et al. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. *Psychiatric Services*. 2010;61(8):811-6. doi: 10.1176/appi.ps.61.8.811. PMID: 2010-16657-009.
  52. Dosis S, Van der Oord S, Wiers RW, et al. Improving executive functioning in children with ADHD: training multiple executive functions within the context of a computer game. a randomized double-blind placebo controlled trial. *PLoS One*. 2015;10(4):e0121651. doi: 10.1371/journal.pone.0121651. PMID: 25844638.
  53. Dutta B, Barua TK, Ray J, et al. A study of evaluation of safety and efficacy of memomet, a multi herbal formulation (memomet) in the treatment of behavioural disorder in children. *International Journal of*

- Research in Pharmaceutical Sciences. 2012;3(2):282-6.
54. Ercan ES, Ardic UA, Kutlu A, et al. No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. *J Atten Disord*. 2014 Feb;18(2):145-57. doi: 10.1177/1087054711432884. PMID: 22522574.
  55. Evans SW, Langberg JM, Schultz BK, et al. Evaluation of a School-Based Treatment Program for Young Adolescents With ADHD. *Journal of Consulting and Clinical Psychology*. 2015.
  56. Ferrin M, Moreno-Granados JM, Salcedo-Marin MD, et al. Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: immediate and long-term effects using a blind randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2014 Aug;23(8):637-47. doi: 10.1007/s00787-013-0494-7. PMID: 24292412.
  57. Ferrin M, Vance A. Examination of neurological subtle signs in ADHD as a clinical tool for the diagnosis and their relationship to spatial working memory. *J Child Psychol Psychiatry*. 2012 Apr;53(4):390-400. doi: 10.1111/j.1469-7610.2011.02496.x. PMID: 22141455.
  58. Findling RL, Adeyi B, Chen G, et al. Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit/hyperactivity disorder. *CNS Spectrums*. 2010;15(9):559-68.
  59. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. *CNS Spectr*. 2008 Jul;13(7):614-20. PMID: 18622366.
  60. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. *Clin Ther*. 2007 Mar;29(3):450-63. PMID: 17577466.
  61. Gonzalez JJ, Mendez LD, Manas S, et al. Performance analysis of univariate and multivariate EEG measurements in the diagnosis of ADHD. *Clin Neurophysiol*. 2013 Jun;124(6):1139-50. doi: 10.1016/j.clinph.2012.12.006. PMID: 23332776.
  62. Gustafsson PA, Birberg-Thornberg U, Duchon K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr*. 2010 Oct;99(10):1540-9. doi: 10.1111/j.1651-2227.2010.01871.x. PMID: 20491709.
  63. Hammerness P, Petty C, Faraone SV, et al. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. *J Atten Disord*. 2012 Dec 20doi: 10.1177/1087054712468051. PMID: 23264367.
  64. Hariri M, Djazayeri A, Djalali M, et al. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. *Malays J Nutr*. 2012 Dec;18(3):329-35. PMID: 24568073.
  65. Huang YH, Chung CY, Ou HY, et al. Treatment effects of combining social skill training and parent training in Taiwanese children with attention deficit hyperactivity disorder. *Journal of the Formosan Medical Association*. 2015;114(3):260-7.
  66. Katz M, Levine AA, Kol-Degani H, et al. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. *J Atten Disord*. 2010 Nov;14(3):281-91. doi: 10.1177/1087054709356388. PMID: 20228219.

67. Kim JW, Lee J, Kim BN, et al. Theta-phase gamma-amplitude coupling as a neurophysiological marker of attention deficit/hyperactivity disorder in children. *Neurosci Lett*. 2015 Aug 31;603:25-30. doi: 10.1016/j.neulet.2015.07.006. PMID: 26170246.
68. Kim J, Lee Y, Han D, et al. The utility of quantitative electroencephalography and Integrated Visual and Auditory Continuous Performance Test as auxiliary tools for the Attention Deficit Hyperactivity Disorder diagnosis. *Clin Neurophysiol*. 2015 Mar;126(3):532-40. doi: 10.1016/j.clinph.2014.06.034. PMID: 25088931.
69. Klenberg L, Jamsa S, Hayrinen T, et al. The Attention and Executive Function Rating Inventory (ATTEX): Psychometric properties and clinical utility in diagnosing ADHD subtypes. *Scand J Psychol*. 2010 Mar 19;51(5):439-48. doi: 10.1111/j.1467-9450.2010.00812.x. PMID: 20338019.
70. Li JJ, Li ZW, Wang SZ, et al. Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder. *Psychopharmacology (Berl)*. 2011 Aug;216(4):501-9. doi: 10.1007/s00213-011-2238-z. PMID: 21416235.
71. Liechti MD, Valko L, Muller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. *Brain Topogr*. 2013 Jan;26(1):135-51. doi: 10.1007/s10548-012-0258-6. PMID: 23053601.
72. Martin-Martinez D, Casaseca-de-la-Higuera P, Alberola-Lopez S, et al. Nonlinear analysis of actigraphic signals for the assessment of the attention-deficit/hyperactivity disorder (ADHD). *Med Eng Phys*. 2012 Nov;34(9):1317-29. doi: 10.1016/j.medengphy.2011.12.023. PMID: 22297088.
73. Mautone JA, Marshall SA, Sharman J, et al. Development of a Family-School Intervention for Young Children With Attention Deficit Hyperactivity Disorder. *School Psych Rev*. 2012;41(4):447-66. PMID: 24353368.
74. Moreno-García I, Delgado-Pardo G, de Reya CC-V, et al. Neurofeedback, pharmacological treatment and behavioral therapy in hyperactivity: Multilevel analysis of treatment effects on electroencephalography. *International Journal of Clinical and Health Psychology*. 2015;15(3):217-25. doi: 10.1016/j.ijchp.2015.04.003. PMID: 2015-48012-005.
75. Oberai P, Gopinadhan S, Varanasi R, et al. Homoeopathic management of attention deficit hyperactivity disorder: A randomised placebo-controlled pilot trial. *Indian Journal of Research in Homeopathy*. 2013;7(4):158-67.
76. Ogrim G, Kropotov J, Hestad K. The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: sensitivity, specificity, and behavioral correlates. *Psychiatry Res*. 2012 Aug 15;198(3):482-8. doi: 10.1016/j.psychres.2011.12.041. PMID: 22425468.
77. Ohan JL, Visser TAW, Strain MC, et al. Teachers' and education students' perceptions of and reactions to children with and without the diagnostic label 'ADHD'. *Journal of School Psychology*. 2011;49(1):81-105. doi: 10.1016/j.jsp.2010.10.001. PMID: 2011-00464-004.
78. Ostberg M, Rydell AM. An efficacy study of a combined parent and teacher management training programme for children with ADHD. *Nord J Psychiatry*. 2012 Apr;66(2):123-30. doi: 10.3109/08039488.2011.641587. PMID: 22150634.
79. Pane P, Arcieri R, Bonati M, et al. Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. *Adverse Drug Reaction Bulletin*. 2010(260):999-1002.

80. Perera H, Jeewandara KC, Seneviratne S, et al. Combined omega3 and omega6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. *J Child Neurol.* 2012 Jun;27(6):747-53. doi: 10.1177/0883073811435243. PMID: 22596014.
81. Pfiffner LJ, Hinshaw SP, Owens E, et al. A two-site randomized clinical trial of integrated psychosocial treatment for ADHD-inattentive type. *J Consult Clin Psychol.* 2014 Dec;82(6):1115-27. doi: 10.1037/a0036887. PMID: 24865871.
82. Power TJ, Mautone JA, Soffer SL, et al. A family-school intervention for children with ADHD: results of a randomized clinical trial. *J Consult Clin Psychol.* 2012 Aug;80(4):611-23. doi: 10.1037/a0028188. PMID: 22506793.
83. Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. *J Child Adolesc Psychopharmacol.* 2009 Apr;19(2):167-77. doi: 10.1089/cap.2008.070. PMID: 19364294.
84. Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry.* 2010 Feb 1;34(1):76-80. doi: 10.1016/j.pnpbp.2009.09.026. PMID: 19815048.
85. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol.* 2009 Jun;19(3):215-26. doi: 10.1089/cap.2008.0080. PMID: 19519256.
86. Shakibaei F, Radmanesh M, Salari E, et al. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. *Complement Ther Clin Pract.* 2015 May;21(2):61-7. doi: 10.1016/j.ctcp.2015.04.001. PMID: 25925875.
87. Soliva JC, Fauquet J, Bielsa A, et al. Quantitative MR analysis of caudate abnormalities in pediatric ADHD: proposal for a diagnostic test. *Psychiatry Res.* 2010 Jun 30;182(3):238-43. doi: 10.1016/j.psychres.2010.01.013. PMID: 20488672.
88. Tamm L, Epstein JN, Peugh JL, et al. Preliminary data suggesting the efficacy of attention training for school-aged children with ADHD. *Dev Cogn Neurosci.* 2013 Apr;4:16-28. doi: 10.1016/j.dcn.2012.11.004. PMID: 23219490.
89. Thorell LB, Eninger L, Brocki KC, et al. Childhood executive function inventory (CHEXI): a promising measure for identifying young children with ADHD? *J Clin Exp Neuropsychol.* 2010 Jan;32(1):38-43. doi: 10.1080/13803390902806527. PMID: 19381995.
90. Tobaiqy M, Stewart D, Helms PJ, et al. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK. *Drug Saf.* 2011 Mar 1;34(3):211-9. doi: 10.2165/11586050-000000000-00000. PMID: 21332245.
91. Trzepacz PT, Spencer TJ, Zhang S, et al. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. *Curr Med Res Opin.* 2011;27 Suppl 2:45-52. doi: 10.1185/03007995.2011.599372. PMID: 21973230.
92. van der Donk M, Hiemstra-Beernink AC, Tjeenk-Kalff A, et al. Cognitive training for children with ADHD: a randomized controlled trial of cogmed working memory training and 'paying attention in class'. *Front Psychol.* 2015;6:1081. doi:

- 10.3389/fpsyg.2015.01081. PMID: 26284005.
93. van Dongen-Boomsma M, Vollebregt MA, Buitelaar JK, et al. Working memory training in young children with ADHD: a randomized placebo-controlled trial. *J Child Psychol Psychiatry*. 2014 Aug;55(8):886-96. doi: 10.1111/jcpp.12218. PMID: 24628438.
94. Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2015 Apr;54(4):275-82. doi: 10.1016/j.jaac.2014.12.016. PMID: 25791144.
95. Webster-Stratton CH, Reid MJ, Beauchaine T. Combining parent and child training for young children with ADHD. *J Clin Child Adolesc Psychol*. 2011;40(2):191-203. doi: 10.1080/15374416.2011.546044. PMID: 21391017.
96. Widenhorn-Muller K, Schwanda S, Scholz E, et al. Effect of supplementation with long-chain omega-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. *Prostaglandins Leukot Essent Fatty Acids*. 2014 Jul-Aug;91(1-2):49-60. doi: 10.1016/j.plefa.2014.04.004. PMID: 24958525.
97. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. *Pediatrics*. 2009 Jul;124(1):e75-80. doi: 10.1542/peds.2008-3138. PMID: 19564272.
98. Zelnik N, Bennett-Back O, Miari W, et al. Is the test of variables of attention reliable for the diagnosis of attention-deficit hyperactivity disorder (ADHD)? *J Child Neurol*. 2012 Jun;27(6):703-7. doi: 10.1177/0883073811423821. PMID: 22378668.
99. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. *Neuropediatrics*. 2010 Aug;41(2):55-9. doi: 10.1055/s-0030-1261893. PMID: 20799150.

## Appendix F. Characteristics of Included Studies

**Appendix Table F-1. Characteristics of Included Studies for KQ 1**

Study	Study Design Geographic Location N Completed	Mean Age (Years unless specified)	Gold Standard	Diagnostic Tools	Outcomes (Subgroups analyzed)	Quality
Berger, 2010 <sup>1</sup>	Observational Middle East 58	ADHD: 9.86 (SD 1.89) Non-ADHD: 10.50 (SD 1.81)	A neurologic examination, the completion of DSM-based questionnaires by parents and teachers, and neuropsychologic evaluation confirmed the diagnosis.	Continuous Performance Functions Tests TOVA Conners CPT TOVA + Conner's CPT	Overall accuracy Sensitivity False negative	Fair
Bloch, 2012 <sup>2</sup>	Observational Middle East 34	Total pop.: 11.5, Min. age: 7 Max. age: 17	Consensus achieved on a structured interview by a psychologist using DSM-IV based assessment and a clinical interview by child and adolescent psychiatrist.	CANTAB TOVA (Test of Variable of Attention)	Sensitivity Specificity False positive False negative	Fair
Bunte, 2013 <sup>3</sup>	Observational UK/Europe 251	ADHD: 54.7 months (SD: 8.8) Non-ADHD: 53.1 months (SD: 8.4)	Clinical interview with psychiatrist and psychologist who agreed on diagnosis using K-DBDS semi-structured DSM-4 interview.	Disruptive Behavior Diagnostic Observation Schedule (DB-DOS) Kiddie-Disruptive Behavior Disorder Schedule (K-DBDS)-	Sensitivity Specificity AUC  (Comorbidity)	Fair
Carballo, 2014 <sup>4</sup>	Observational UK/Europe 523	Min. age: 3 Max. age: 17	Positive ADHD diagnosis based exclusively on the ADHD RS-IV which assesses DSM-IV-TR ADHD symptoms.	SDQ	Sensitivity Specificity  (ADHD presentation)	Poor
Castro-Cabrera, 2010 <sup>5</sup>	Observational Latin America 46	Min. age: 4 Max. age: 15	Medical diagnostic was determined by neurophysiological evaluation based on clinical criteria of DSM IV.	Event-Related Potentials (ERPs)	Overall accuracy Sensitivity Specificity AUC	Fair
Caudal, 2011 <sup>6</sup>	Observational UK/Europe 112	ADHD: 8.00 Non-ADHD: 8.70	Children diagnosed with ADHD according to the DSM-IV and further examinations.	Electro interstitial scans (EIS)	Sensitivity Specificity	Fair
dosReis, 2010 <sup>7</sup>	Observational U.S. 48	Total: 8.8 (SD 2.30)	Unclear/NR	Unclear/NR	Labeling/Stigma	Good

Study	Study Design Geographic Location N Completed	Mean Age (Years unless specified)	Gold Standard	Diagnostic Tools	Outcomes (Subgroups analyzed)	Quality
Ferrin, 2012 <sup>8</sup>	Observational Australia/N.Z. 1,185	ADHD: 131.44 months (SD 38.93 months) Non-ADHD: 133.16 months (SD 27.95 months)	ADHD status was categorically defined by the semistructured clinical interview of their parent's K-SADS-PL, and dimensionally by the Conners Global Index (CGI). The K-SADS-PL is a semi-structured diagnostic interview designed to assess current and past episodes of psychopathology in children and adolescents according to DSM-IV criteria.	Neurological subtle signs (NSS)	Overall accuracy AUC  (Age)	Fair
Gonzalez, 2013 <sup>9</sup>	Observational UK/Europe 43	Min. age: 4 Max. age: 15	Physical examination, clinical interview and a structured checklist covering DSM-IV and ICD-10 criteria.	EEG IM generalized EEG IM beta band	Overall accuracy Sensitivity Specificity	Fair
Kim, 2015 <sup>10</sup>	Observational Asia 157	ADHD: 10.16 (SD 1.90) Non-ADHD: 9.62 (SD 1.72)	ADHD Diagnosis was based on a Korean version of the Diagnostic Interview Schedule for Children Version IV (DISC-IV) and the diagnoses were confirmed by multiple child and adolescent psychiatrists. The DISC-IV uses diagnostic criteria as specified in DSM-IV.	EEG-TGC EEG Delta Wave EEG Theta/beta ratio IVA CPT commission error IVA CPT omission error	Overall accuracy Sensitivity Specificity	Fair
Kim, 2015 <sup>11</sup>	Observational Asia 97	ADHD: 9.25 (SD 1.63) Non-ADHD: 9.56 (SD 1.98)	ADHD Diagnosis was based on a Korean version of the Diagnostic Interview Schedule for Children Version IV (DISC-IV) and the diagnoses were confirmed by multiple child and adolescent psychiatrists. The DISC-IV uses diagnostic criteria as specified in DSM-IV.	EEG Theta Wave EEG Delta Wave EEG Theta/beta ratio IVA CPT commission error IVA CPT omission error	Overall accuracy Sensitivity Specificity	Fair
Klenberg, 2010 <sup>12</sup>	Observational UK/Europe 916	ADHD: 10.10 (SD 2.40) Non-ADHD: 10.70 (SD 2.50)	Diagnoses were based on structured interviews of parents and children and a parent rating scale (ADHD RS-IV: Home Version) and teacher reports from school.	Attention and Executive Function Rating Inventory (ATTEX)	Overall accuracy Sensitivity Specificity AUC	Good

Study	Study Design Geographic Location N Completed	Mean Age (Years unless specified)	Gold Standard	Diagnostic Tools	Outcomes (Subgroups analyzed)	Quality
Liechti, 2013 <sup>13</sup>	Observational UK/Europe 62	ADHD: 11.1 (SD 2.10) Non-ADHD: 11.2 (SD 2.10)	Children with ADHD combined subtype (DSM-IV), aged 8–16 years, were diagnosed using the semi-structured clinical diagnostic interview PACS (parental account of children's symptoms; plus Conners teacher rating scale—revised)	EEG + Event Related Potentials (ERPs)	Overall accuracy Sensitivity Specificity	Fair
Martin-Martinez, 2012 <sup>14</sup>	Observational UK/Europe 63	Total pop.: 6	Case group was diagnosed as having the combined kind of ADHD according to the DSM-IV criteria	Actigraphy - PCA1 [Px00(15 min, D) + Pz22(1 min, FR) + Py01(15 min, AA)]	Overall accuracy Sensitivity Specificity AUC	Poor
Ogrim, 2012 <sup>15</sup>	Observational UK/Europe 101	Total pop.: 11 (SD 3.00)	All diagnoses were according to DSM IV-TR and accepted clinical guidelines. A senior neuropsychologist (GO) was responsible for diagnostic conclusions after discussions in the team, which included a pediatrician and a clinical psychologist.	EEG Theta EEG Theta/beta ratio Visual CPT omission error	Overall accuracy	Fair
Ohan, 2011 <sup>16</sup>	Observational Canada 56	Not Reported	Not Applicable	Not Applicable	Labeling/Stigma	Good
Soliva, 2010 <sup>17</sup>	Observational UK/Europe 78	ADHD: 10.90 (SD 2.83) Non-ADHD: 11.46 (SD 2.86)	ADHD subjects were diagnosed by a team consisting of a psychologist and a psychiatrist. Scoring was based on parent and teacher rating scales, as well as a semi-structured clinical interview, which systematically reviewed DSM-IV-TR criteria for ADHD, oppositional-defiant disorder, conduct disorder, and depressive and anxiety disorders (DICA-IV).	MRI of Caudate Body Volume	Overall accuracy Sensitivity Specificity  (Sex and ADHD presentation)	Fair

<b>Study</b>	<b>Study Design Geographic Location N Completed</b>	<b>Mean Age (Years unless specified)</b>	<b>Gold Standard</b>	<b>Diagnostic Tools</b>	<b>Outcomes (Subgroups analyzed)</b>	<b>Quality</b>
Thorell, 2010 <sup>18</sup>	Observational UK/Europe 45	Unclear/NR	Children met the symptom criteria, the age of onset criterion (i.e., <7 years) the pervasiveness criterion (symptoms present in two settings), and the duration criterion (>6 months) for ADHD according to DSM-IV. Subjects saw a child psychologist and if deemed "at risk" they were given scales to confirm diagnosis.	Childhood Executive Function Inventory (CHEXI)- Parent rating inhibition subscale	Overall accuracy Sensitivity Specificity	Fair
Zelnik, 2012 <sup>19</sup>	Observational Middle East 230	Total pop.: 10 (SD 2.70)	Clinical diagnostic work-up included a family interview about the behavioral and neurodevelopmental history of the child, neurological evaluation and observation at the physician's office, utilization of the DSM-IV diagnostic criteria, and employment of the Conners Rating Scales.	TOVA (Test of Variable of Attention)	Sensitivity Specificity False positive False negative	Fair

**Appendix Table F-2. Characteristics of Included Studies for KQ 2**

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Abikoff, 2013 <sup>20</sup>	RCT U.S. 151	Inattentive: 49.4% Combined: 38.9%	Arm 1: 9.06 (SD: 0.91) Arm 2: 9.01 (SD: 0.79) Arm 3: 9.15 (SD: 0.76)	Organizational Skills Training (teaching children new organizational tools and routines) vs. Performance based intervention precluding skill without organizational skills training vs. Waitlist control	Academic performance	Good
Abikoff, 2015 <sup>21</sup>	RCT U.S. 164	Inattentive: 15.3% Hyperactive: 33.7% Combined: 50.9%	Total: 3.57 (SD: 0.5)	New Forest Parenting Package (home-based intervention) vs. Helping the noncompliant child (clinic-based parenting intervention) vs. Waitlist control	Behavior changes	Good
Arcieri, 2012 <sup>22</sup>	Observational UK/Europe 751	Inattentive: 6% Hyperactive: 4% Combined: 90%	Arm 1: 10.41 (SD: 2.62) Arm 2: 10.82 (SD: 2.81) Arm 3: 10.56 (SD: 2.55)	Registry with patients on methylphenidate vs. Registry with patients on strattera vs. In registry taking both methylphenidate and strattera	Cardiac arrhythmias; Elevated blood pressure	Poor
Arnold, 2011 <sup>23</sup>	RCT U.S. 52	Inattentive: 29.1%, 15%, 50% Combined: 70.8%, 85%	Arm 1: 10.24 (SD: 2.69) Arm 2: 9.61 (SD: 3.36) Arm 3: 8.89 (SD: 2.31)	Zinc 15mg once daily vs. Zinc 15mg twice daily vs. Placebo	Changes in standardized symptom scores; Behavior changes; Changes in appetite; Suicide ideation; Sleep disturbance; Tics or other movement disorders; Gastrointestinal symptoms	Fair

<b>Study</b>	<b>Study Design Geographic Location N Completed</b>	<b>Percent ADHD Subtype*</b>	<b>Mean Age (Years unless specified)</b>	<b>Interventions</b>	<b>Outcomes (Subgroups analyzed)</b>	<b>Quality</b>
Bai, 2015 <sup>24</sup>	RCT Asia 89	Unclear/NR	Arm 1: 9.3 (SD: 2.8) Arm 2: 9.6 (SD: 2.9)	Planned behavior psychoeducation program for parents vs. General clinical counseling for parents, without psychoeducation	Changes in standardized symptom scores; Acceptability of treatment	Good
Banaschewski, 2014 <sup>25</sup>	RCT U.S., UK/Europe 73	Unclear/NR	Total: 11.1 (SD: 2.59)	Randomized to Lisdexamfetamine dimesylate (LDX) after 52 weeks of being on the drug (vs. withdrawal on placebo--see below) vs. Randomized to placebo after 52 weeks of being on LDX.	Quality of peer relationships; Risk-taking behaviors	Poor
Barragan, 2014 <sup>26</sup>	RCT Latin America 69	Unclear/NR	Total: 8.27 (SD: 1.74)	Methylphenidate (maximum 1 mg/kg/day) vs. Methylphenidate (maximum 1 mg/kg/day and omega 3/6 fatty acid supplementation (6 capsules/day) vs. Omega-3/6 fatty acid supplementation (6 capsules/day)	Changes in appetite; Behavior changes; Sleep disturbance; Gastrointestinal symptoms; Changes in standardized symptom scores	Poor
Beck, 2010 <sup>27</sup>	Observational U.S. 51	Inattentive: 71% Hyperactive: 0% Combined: 29%	Total: 11.75	Computer-based working memory intervention vs. Waitlist control	Changes in standardized symptom scores	Fair
Bink, 2015 <sup>28</sup>	RCT UK/Europe 71	Unclear/NR	Arm 1: 16.1 (SD: 3.3) Arm 2: 16.2 (SD: 3.4)	Neurofeedback (NF) plus treatment as usual (TAU). NF training over about 25 wks, with 2-3 training sessions/wk. Participants offered 40 training sessions of 30 minutes. Mean # of sessions was 37 (minimum 19). Theta/sensorimotor rhythm training was applied. vs. Treatment as usual (TAU)	Changes in standardized symptom scores	Good
Boyer, 2015 <sup>29</sup>	RCT UK/Europe 136	Inattentive: 74.7%, 65.8% Hyperactive: 7.2%, 2.6% Combined: 18.1%, 31.6%	Arm 1: 14.4 (SD: 1.2) Arm 2: 14.4 (SD: 1.3)	CBT with an aim to improve planning skills vs. Solution-focused CBT without an aim to improve planning skills	Depression or anxiety; Changes in standardized symptom scores	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Çetin, 2015 <sup>30</sup>	RCT Middle East 120	Inattentive: 12.5% Combined: 87.5%	Arm 1: 9.55 (SD: 2.71) Arm 2: 9.95 (SD: 2.02)	Atomoxetine (ATX) vs. Osmotic release oral system methylphenidate (OROS-MPH)	Changes in standardized symptom scores	Fair
Chacko, 2014 <sup>31</sup>	RCT U.S. 73	Inattentive: 34%, 41% Combined: 66%, 59%	Arm 1: 8.4 (SD: 1.4) Arm 2: 8.4 (SD: 1.3)	Cogmed working memory training with difficulty titrated to a user's ability vs. "Placebo" Cogmed working memory training with difficulty <u>not</u> titrated to a user's ability	Changes in standardized symptom scores; Academic performance	Good
Chacko, 2009 <sup>32</sup>	RCT U.S. 118; 115 follow-up	Unclear/NR	Arm 1: 7.36 (SD: 1.86) Arm 2: 8.17 (SD: 2.42) Arm 3: 8.02 (SD: 2.15)	Strategies to Enhance Positive Parenting (STEPP) program (a manualized, behavioral parent training program for single mothers) with concurrent group social skills program for children vs. Behavioral parent training program with concurrent group social skills program for children vs. Waitlist control	Changes in standardized symptom scores; Acceptability of treatment	Good
Clemow, 2015 <sup>33</sup>	Observational U.S. 71	Inattentive: 48.1%, 51.9% Combined: 26%, 38.9%	Arm 1: 24.0 (SD: 15.3) Arm 2: 26.2 (SD: 15.2)	First prescribed atomoxetine (ATX) and not switched or the monotherapy portion of time spent by those prescribed ATX with another ADHD drug and then was switched to ATX only. vs. First prescribed ATX with another drug and did not switch or the combination portion of time spent by those who were first prescribed ATX and then had another ADHD prescribed.	Changes in standardized symptom scores	Poor
Cortese, 2015 <sup>34</sup>	Observational UK/Europe 2411	Inattentive: 11.5%, 11.9% Hyperactive: 2.4%, 5.2% Combined: 85.9%, 82.7%	Arm 1: 10.55 (SD: 2.75) Arm 2: 10.87 (SD: 2.84)	Methylphenidate immediate release, at a dosage of 0.3-0.6 mg/kg/dose/day, in 2-3 doses/day vs. Atomoxetine, starting with 0.5mg/kg daily for at least 7 days, then increasing up to 1.2mg/kg/day	Cardiac arrhythmias	Good

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Didoni, 2011 <sup>35</sup>	Observational UK/Europe 229	Inattentive: 11.7%, 14.5% Hyperactive: 8.8%, 6.2% Combined: 79.4%, 70.1%	Arm 1: 10.7 (SD: 2.7) Arm 2: 11 (SD: 2.7)	Methylphenidate vs. Strattera	Acceptability of treatment; Changes in appetite; Behavior changes; Sleep disturbance; Increased heart rate; Gastrointestinal symptoms; Tics or other movement disorders	Fair
Dovis, 2015 <sup>36</sup>	RCT UK/Europe 89	Combined: 0%, 100%, 100%	Arm 1: 10.6 (SD: 1.4) Arm 2: 10.3 (SD: 1.3) Arm 3: 10.5 (SD: 1.3)	"Braingame Brian" (computerized, home-based executive functioning training) vs. Braingame Brian in training mode and the working memory task in placebo mode vs. All tasks in training mode (overall easier)	Behavior changes	Good
Duric, 2012 <sup>37</sup>	RCT UK/Europe 91	Inattentive: 5.4% Hyperactive: 15.4% Combined: 79.1%	Arm 1: 10.9 (SD: 2.4) Arm 2: 11.2 (SD: 2.8) Arm 3: 11.4 (SD: 3.1)	MPH (dose not reported) vs. MPH + Neurofeedback vs. Neurofeedback	Changes in standardized symptom scores	Poor
Dutta, 2012 <sup>38</sup>	RCT Asia 86	Unclear/NR	Arm 1: 8 (SD: 1.12) Arm 2: 9.1 (SD: 1.1)	Memomet syrup (Bacopa monniera 125 mg, Convulvulus pleuricaulis 100 mg, Centella asiatica 100 mg) vs. Placebo	Changes in standardized symptom scores	Good
Egeland, 2013 <sup>39</sup>	RCT UK/Europe 67	Unclear/NR	Arm 1: 10.5 (SD: 0.7) Arm 2: 10.3 (SD: 0.8)	Cogmed robomemo program vs. Waitlist control	Changes in standardized symptom scores	Good
Ercan, 2014 <sup>40</sup>	Observational UK/Europe 45	Combined: 100%	Arm 1: 9.23 (SD: 2) Arm 2: 8.7 (SD: 1.7)	MPH+11 months of parent training vs. MPH (Usual care)	Changes in standardized symptom scores	Fair

<b>Study</b>	<b>Study Design Geographic Location N Completed</b>	<b>Percent ADHD Subtype*</b>	<b>Mean Age (Years unless specified)</b>	<b>Interventions</b>	<b>Outcomes (Subgroups analyzed)</b>	<b>Quality</b>
Evans, 2015 <sup>41</sup>	RCT U.S. 312	Combined: 49.1%, 50%, 47.1%	Arm 1: 12.1 (SD: 0.9) Arm 2: 12.1 (SD: 0.9) Arm 3: 12.2 (SD: 1.0)	Challenging Horizons Program-After School (CHP-AS) program (organization, social functioning, and academic study skills training) vs. Challenging Horizons Program Mentoring Version (students paired with a mentor who delivered a subset of the CHP-AS interventions during school) vs. Usual care	Functional impairment; Academic performance	Fair
Ferrin, 2014 <sup>42</sup>	RCT UK/Europe 76	Combined: 72.1%, 81.1%	Arm 1: 11.25 (SD: 2.96) Arm 2: 9.94 (SD: 3.04)	Psychoeducational program vs. Parent support group	Changes in standardized symptom scores	Good
Findling, 2010 <sup>43</sup>	RCT U.S. 230	Combined: 96%	Min. age: 8.7 Max. age: 9.4	Lisdexamfetamine dimeslyate (LDX) 30mg/day vs. Lisdexamfetamine dimeslyate (LDX) 50mg/day vs. Lisdexamfetamine dimeslyate (LDX) 70mg/day vs. Placebo	Changes in standardized symptom scores	Fair
Gevensleben, 2009 <sup>44</sup>	RCT UK/Europe 94	Inattentive: 33.8%, 22.8% Combined: 66.1%, 77.1%	Arm 1: 9.10 (SD: 1.3) Arm 2: 9.4 (SD: 1.2)	Neurofeedback vs. Attention skills training	Changes in standardized symptom scores; Acceptability of treatment	Good
Gustafsson, 2010 <sup>45</sup>	RCT UK/Europe 82	Unclear/NR	Min. age: 7 Max. age: 12	Omega-3 fatty acid supplementation (eicosapentaenoic acid 500 mg daily) vs. Placebo	Changes in standardized symptom scores	Good
Hammerness, 2012 <sup>46</sup>	Observational U.S. 115	Unclear/NR	Arm 1: 15.5 (SD: 1.7) Arm 2: 14.9 (SD: 3.4) Arm 3: 15.7 (SD: 2.7) Arm 4: 14.8 (SD: 2.9)	Clinical Trial Participant on MPH vs. Non-clinical trial participants on medication vs. Non-clinical trial participants not on medication vs. Non ADHD Group	Substance abuse	Fair

<b>Study</b>	<b>Study Design Geographic Location N Completed</b>	<b>Percent ADHD Subtype*</b>	<b>Mean Age (Years unless specified)</b>	<b>Interventions</b>	<b>Outcomes (Subgroups analyzed)</b>	<b>Quality</b>
Hariri, 2012 <sup>47</sup>	RCT Middle East 103	Unclear/NR	Arm 1: 7.9 (SD: 1.53) Arm 2: 7.9 (SD: 1.45)	Omega-3 fatty acid supplementation (900 mg daily) vs. Placebo	Changes in standardized symptom scores	Poor
Hiscock, 2015 <sup>48</sup>	RCT Australia/N.Z. 196	Unclear/NR	Arm 1: 10.3 (SD: 1.8) Arm 2: 9.9 (SD: 2.1) Arm 3: 10.3 (SD: 1.7) Arm 4: 9.8 (SD: 2.0)	Sleep hygiene vs. Usual care	Changes in standardized symptom scores; Depression or anxiety; Workforce participation; Sleep disturbance  (Comorbidity)	Good
Huang, 2015 <sup>49</sup>	RCT Asia 97	Inattentive: 13.3%, 25% Combined: 86.7%, 75%	Arm 1: 8.2 (SD: 0.9) Arm 2: 8.5 (SD: 0.9)	Behavioral based social skill training for patients and parallel parent group sessions vs. Group therapy for motivation and treatment per their usual care	Changes in standardized symptom scores	Fair
Johnson, 2009 <sup>50</sup>	RCT UK/Europe 59	Inattentive: 24%, 29% Hyperactive: 0%, 0% Combined: 25%, 21%	Arm 1: 11.8 (SD: 2.14) Arm 2: 12.2 (SD: 2.19)	Omega-3/6 fatty acid supplementation (792 mg daily) vs. Placebo	Changes in standardized symptom scores; Functional impairment	Good
Katz, 2010 <sup>51</sup>	RCT Middle East 92	Unclear/NR	Arm 1: 9.72 (SD: 1.58) Arm 2: 9.20 (SD: 1.82)	Patented herbal preparation vs. Placebo	Motor vehicle collisions; Changes in appetite; Gastrointestinal symptoms; Sleep disturbance; Mood disorders	Fair

<b>Study</b>	<b>Study Design Geographic Location N Completed</b>	<b>Percent ADHD Subtype*</b>	<b>Mean Age (Years unless specified)</b>	<b>Interventions</b>	<b>Outcomes (Subgroups analyzed)</b>	<b>Quality</b>
Li, 2011 <sup>52</sup>	RCT Asia 69	Unclear/NR	Arm 1: 9.3 (SD: 1.8) Arm 2: 9.2 (SD: 2.2)	Methylphenidate 1 mg/kg/day vs. Ningdong granule (a traditional Chinese medicine preparation)	Chemical leukoderma; Changes in standardized symptom scores; Gastrointestinal symptoms; Sleep disturbance; Behavior changes; Changes in appetite	Good
Manor , 2012 <sup>53</sup>	RCT Middle East 162	Inattentive: 31%, 34% Hyperactive: 3%, 0% Combined: 66%, 65.9%	Arm 1: 9.2 (SD: 2.0) Arm 2: 9.2 (SD: 1.8)	PS-Omega 3 vs. Placebo	Chemical leukoderma; Changes in standardized symptom scores; Elevated blood pressure; Increased heart rate; Weight decrease; Growth suppression; Sleep disturbance; Behavior changes; Changes in appetite; Gastrointestinal symptoms; Tics or other movement disorders; Personality change	Good
Mautone, 2012 <sup>54</sup>	RCT U.S. 53	Inattentive: 10.3%, 15.6% Hyperactive: 27.6%, 28.1% Combined: 62.1%, 56.3%	Unclear NR	Family-School Success—Early, Elementary (school-based intervention) vs. Parent support and education program	Academic performance	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Milte, 2012 <sup>55</sup>	RCT Australia/N.Z. 70	Unclear/NR	Arm 1: 8.77 (SD: 1.76) Arm 2: 8.89 (SD: 1.6) Arm 3: 9.14 (SD: 2.03)	Fish oil rich in the omega-3 fatty acid, eicosapentaenoic acid vs. Fish oil rich in the omega-3 fatty acid, docosahexaenoic acid vs. Safflower oil	Changes in standardized symptom scores	Good
Mohammadi, 2012 <sup>56</sup>	RCT Middle East 50	Combined: 100%	Arm 1 Median: 9.57 (SD: 1.65) Arm 2 Median: 8.83 (SD: 1.82)	MPH + melatonin vs. MPH + placebo	Changes in standardized symptom scores; Sleep disturbance; Changes in appetite; Weight decrease; Gastrointestinal symptoms; Behavior changes; Tics or other movement disorders	Fair
Molina, 2009 <sup>57</sup>	RCT U.S. 346 at 10-year follow-up; 436 at 8-year follow-up	Unclear/NR	Total: 16.8 (SD: 1.0)	Medication Management vs. Behavioral training (parent group, parent individual, classroom (student), and teacher sessions) vs. Combination: Medication management and Behavioral training vs. Usual care	Aggression; Incarceration; Depression or anxiety; Academic performance; Motor vehicle collisions; Elevated blood pressure; Increased heart rate	Fair
Montoya, 2014 <sup>58</sup>	RCT Latin America 208	Inattentive: 32.6%, 16.7% Hyperactive: 5.6%, 1.6% Combined: 61.8%, 81.7%	Arm 1: 9.3 (SD: 1.9) Arm 2: 8.8 (SD: 1.8)	Psychosocial education + medical management. vs. Medical management only	Acceptability of treatment; Changes in standardized symptom scores	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Moreno-García, 2015 <sup>59</sup>	RCT UK/Europe 57	Inattentive: 42.1%, 42.1%, 57.9% Hyperactive: 21.05%, 15.78%, 15.78% Combined: 36.84%, 42.10%, 26.31%	Arm 1: 9.21 (SD: 1.9) Arm 2: 9.21 (SD: 2.2) Arm 3: 8.11 (SD: 1.3)	Neurofeedback vs. Standard Pharmacological Treatment vs. Behavioral Treatment	Changes in standardized symptom scores	Fair
Myers, 2015 <sup>60</sup>	RCT U.S. NR	Inattentive: 82.8%, 82.1% Hyperactive: 66.6%, 58% Combined: 60.3%, 51.8%	Arm 1: 9.2 (SD: 2) Arm 2: 9.3 (SD: 2)	6 telehealth sessions using both synchronous and asynchronous technologies vs. Single consultation with a tele psychiatrist	Behavior changes	Fair
Oberai, 2013 <sup>61</sup>	RCT Asia 54	Unclear/NR	Arm 1: 8.6 (SD: 2.2) Arm 2: 9.9 (SD: 2.8)	Homeopathy vs. Placebo	Behavior changes	Fair
Ostberg, 2012 <sup>62</sup>	RCT UK/Europe 61	Unclear/NR	Arm 1: 11.1 (SD: 2.1) Arm 2: 10.8 (SD: 1.8)	Barkley Parent + Teacher behavioral intervention vs. Waitlist control	Changes in standardized symptom scores	Good
Pane, 2010 <sup>63</sup>	Observational UK/Europe 1424	Inattentive: 11.7% Hyperactive: 5% Combined: 83.3%	Median: 10.8 Min. age: 6 Max. age: 18	Atomoxetine vs. Methylphenidate	Suicide ideation; Conduction abnormalities; Tics or other movement disorders; Changes in appetite; Gastrointestinal symptoms; Elevated blood pressure	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Pelsser, 2011 <sup>64</sup>	RCT UK/Europe 100 analyzed in first phase	Inattentive: 6%, 6% Hyperactive: 12%, 6% Combined: 82%, 88%	Arm 1: 6.8 (SD: 1.3) Arm 2: 7.0 (SD: 1.3)	Restricted elimination diet vs. No elimination diet	Changes in standardized symptom scores  (ADHD Presentation)	Good
Perera, 2012 <sup>65</sup>	RCT Asia 94	Unclear/NR	Arm 1: 9.4 (SD: 1.5) Arm 2: 9.2 (SD: 1.5)	Omega 3/6 fatty acid supplementation vs. Placebo	Changes in standardized symptom scores; Academic performance	Good
Pfiffner, 2014 <sup>66</sup>	RCT U.S. 195	Inattentive: 100%	Arm 1: 8.8 (SD: 1.2) Arm 2: 8.7 (SD: 1.2) Arm 3: 8.4 (SD: 1.1)	Child Life and Attention Skills Treatment for children and parents vs. Child Life and Attention Skills Treatment—parents group component only vs. Usual care	Changes in standardized symptom scores; Functional impairment	Good
Power, 2012 <sup>67</sup>	RCT U.S. 181	Inattentive: 55%, 48.5% Combined: 45%, 51.5%	Unclear NR	Family-School Success—Early, Elementary (school-based intervention) vs. Parent support and education program	Changes in standardized symptom scores; Academic performance	Fair
Raz, 2009 <sup>68</sup>	RCT Middle East 63	Inattentive: 94%, 94% Hyperactive: 44%, 47%	Arm 1: 10.46 (SD: 1.42) Arm 2: 10.51 (SD: 1.47)	Omega-3 fatty acid supplementation vs. Placebo	Changes in standardized symptom scores	Fair
Salehi, 2010 <sup>69</sup>	RCT Middle East 46	Unclear/NR	Arm 1: 9.12 (SD: 1.61) Arm 2: 9.61 (SD: 2.26)	Ginkgo biloba vs. MPH (up to 30 mg/day)	Changes in standardized symptom scores; Changes in appetite; Depression or anxiety; Sleep disturbance; Weight decrease	Good

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Sallee, 2009 <sup>70</sup>	RCT Unclear/NR 60	Inattentive: 23.9% Hyperactive: 3.1% Combined: 73%	Total: 10.7 (SD: 2.6)	Guanfacine XR 1 mg/day with or without amphetamine or MPH vs. Guanfacine XR 2 mg/day with or without amphetamine or MPH vs. Guanfacine XR 3 mg/day with or without amphetamine or MPH vs. Guanfacine XR 4 mg/day with or without amphetamine or MPH	Changes in standardized symptom scores	Poor
Shakibaei, 2015 <sup>71</sup>	RCT Middle East 60	Unclear/NR	Arm 1: 7.83 (SD: 1.12) Arm 2: 8.41 (SD: 1.40)	Methylphenidate and Ginkgo Biloba vs. Methylphenidate and placebo	Behavior changes	Good
Steiner, 2014 <sup>72</sup>	RCT U.S. 98	Unclear/NR	Arm 1: 8.4 (SD: 1.1) Arm 2: 8.9 (SD: 1.0) Arm 3: 8.4 (SD: 1.1)	Neurofeedback vs. Cognitive Training vs. Waitlist control	Changes in standardized symptom scores	Good
Storebo, 2012 <sup>73</sup>	RCT UK/Europe 55	Inattentive: 35.7%, 22.2% Hyperactive: 0%, 7.4% Combined: 31.4%, 59.2%	Arm 1: 10.6 (SD: 1.29) Arm 2: 10.2 (SD: 1.34)	Social Skills Group vs. Usual care	Academic performance	Good
Tamm, 2013 <sup>74</sup>	RCT U.S. 94	Inattentive: 38.9%, 39.2% Combined: 59.2%, 58.8%	Arm 1: 9.1 (SD: 1.2) Arm 2: 9.5 (SD: 1.5)	Pay Attention! Program (attention training) vs. Waitlist control	Changes in standardized symptom scores	Fair
Tobaigy, 2011 <sup>75</sup>	Observational UK/Europe 200	Unclear/NR	Max. age: 16	No arms. Questionnaire administered to elicit retrospective data to assess self-reported AEs for many different drugs used for ADHD.	Changes in standardized symptom scores	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Trzepacz, 2011 <sup>76</sup>	RCT UK/Europe, Australia/N.Z. 394	Inattentive: 23.1%, 19.4% Hyperactive: 4.6%, 5.3% Combined: 7.1%, 75.2%	Arm 1 Median: 10.6 (SD: 2.3) Arm 2 Median: 10.2 (SD: 2.2)	12 month follow up on atomoxetine after 3 month initial trial vs. 12 month follow up on placebo after 3 month initial trial	Growth suppression; Changes in appetite; Gastrointestinal symptoms	Fair
van der Donk, 2015 <sup>77</sup>	RCT UK/Europe 100	Inattentive: 30%, 20% Combined: 58%, 70%	Arm 1: 9.8 (SD: 1.3) Arm 2: 10.0 (SD: 1.3)	Cogmed Working Memory Training vs. Paying Attention in Class (experimental, combined working memory and compensatory training)	Changes in standardized symptom scores	Fair
van Dongen-Boomsma, 2014 <sup>78</sup>	RCT UK/Europe 47	Inattentive: 7.7%, 9.5% Hyperactive: 11.5%, 33.3% Combined: 80.8%, 57.1%	Arm 1: 6.5 (SD: 0.6) Arm 2: 6.6 (SD: 0.7)	Cogmed training program vs. Cogmed training program without adjustment of patient skill level (control group)	Changes in standardized symptom scores	Good
Vidal, 2015 <sup>79</sup>	RCT UK/Europe 89	Inattentive: 35.6%, 0% Hyperactive: 1.7%, 41.6% Combined: 62.7%, 58.3%	Arm 1: 17.47 (SD: 1.88) Arm 2: 16.9 (SD: 1.75)	CBT vs. Usual care	Behavior changes	Good
Webster-Stratton, 2011 <sup>80</sup>	RCT U.S. 94	Unclear/NR	Arm 1: 64.1 months (SD: 11.3) Arm 2: 64.4 months (SD: 10.6)	Incredible Years Program (a parent training intervention) vs. Waitlist control	Changes in standardized symptom scores	Fair
Widenhorn-Muller, 2014 <sup>81</sup>	RCT UK/Europe 95	Inattentive: 54.7% Hyperactive: 2.1% Combined: 43.2%	Arm 1: 8.90 (SD: 1.48) Arm 2: 8.92 (SD: 1.24)	Omega-3 fatty acid supplementation (720 mg daily) plus 15 mg vitamin E vs. Placebo	Changes in standardized symptom scores	Fair

Study	Study Design Geographic Location N Completed	Percent ADHD Subtype*	Mean Age (Years unless specified)	Interventions	Outcomes (Subgroups analyzed)	Quality
Winterstein, 2009 <sup>82</sup>	Observational U.S. Unclear/NR	Unclear/NR	Arm 1: 8.3 for current users; 9.1 for former users (SD: 3.2 for current users; 3.3 for former users)  Arm 2: 8.5 for current users; 9.2 for former users (SD: 2.9 for current users; 3.0 for former users)	Receipt of amphetamine as identified by Medicaid claims vs. Receipt of methylphenidate as identified by Medicaid claims	Cardiac arrhythmias	Fair
Zhang, 2010 <sup>83</sup>	Observational Asia 175	Inattentive: 16.4%, 24.1% Hyperactive: 8.9%, 27.6% Combined: 74.7%, 48.3%	Arm 1: 7.42 Min. age: 6.0 Max. age: 9.8 Arm 2: 8.35 Min. age: 6.0 Max. age: 12.5	Methylphenidate, 10-20 mg/d, 0.27-0.64 mg/kg for about 40 wks/yr (they also took a drug holiday). vs. Control	Growth suppression	Poor

\* = Multiple values are listed for percent female and age in instances where baseline data is reported by study arm rather than for the total population.

Abbreviations: ART=assisted reproductive technology; BID=two times per day; BMI=body mass index; CARE Consortium=Centres for Assisted Reproduction; CC=clomiphene citrate; COH=controlled ovarian hyperstimulation; COS=controlled ovarian stimulation; DHEA=dehydroepiandrosterone; FASTT=Fast Track and Standard Treatment Trial; FISH=fluorescence in situ hybridization

## References to Appendix F:

1. Berger I, Goldzweig G. Objective measures of attention-deficit/hyperactivity disorder: a pilot study. *Isr Med Assoc J*. 2010 Sep;12(9):531-5. PMID: 21287795.
2. Bloch Y, Fixman M, Maoz H, et al. Can computerized cognitive tests assist in the clinical diagnosis of attention-deficit hyperactivity disorder? *J Neuropsychiatry Clin Neurosci*. 2012 Winter;24(1):111-4. doi: 10.1176/appi.neuropsych.11010014. PMID: 22450621.
3. Bunte TL, Schoemaker K, Hessen DJ, et al. Clinical usefulness of the Kiddie-Disruptive Behavior Disorder Schedule in the diagnosis of DBD and ADHD in preschool children. *J Abnorm Child Psychol*. 2013 Jul;41(5):681-90. doi: 10.1007/s10802-013-9732-1. PMID: 23474833.
4. Carballo JJ, Rodriguez-Blanco L, Garcia-Nieto R, et al. Screening for the ADHD Phenotype Using the Strengths and Difficulties Questionnaire in a Clinical Sample of Newly Referred Children and Adolescents. *J Atten Disord*. 2014 Dec 16;doi: 10.1177/1087054714561858. PMID: 25515677.
5. Castro-Cabrera P, Gomez-Garcia J, Restrepo F, et al. Evaluation of feature extraction techniques on event-related potentials for detection of attention-deficit/hyperactivity disorder. *Conf Proc IEEE Eng Med Biol Soc*. 2010;2010:851-4. doi: 10.1109/iembs.2010.5626862. PMID: 21096317.
6. Caudal F. New marker using bioimpedance technology in screening for attention deficit/hyperactivity disorder (ADHD) in children as an adjunct to conventional diagnostic methods. *Psychol Res Behav Manag*. 2011;4:113-7. doi: 10.2147/prbm.s22924. PMID: 22114541.
7. dosReis S, Barksdale CL, Sherman A, et al. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. *Psychiatric Services*. 2010;61(8):811-6. doi: 10.1176/appi.ps.61.8.811. PMID: 2010-16657-009.
8. Ferrin M, Vance A. Examination of neurological subtle signs in ADHD as a clinical tool for the diagnosis and their relationship to spatial working memory. *J Child Psychol Psychiatry*. 2012 Apr;53(4):390-400. doi: 10.1111/j.1469-7610.2011.02496.x. PMID: 22141455.
9. Gonzalez JJ, Mendez LD, Manas S, et al. Performance analysis of univariate and multivariate EEG measurements in the diagnosis of ADHD. *Clin Neurophysiol*. 2013 Jun;124(6):1139-50. doi: 10.1016/j.clinph.2012.12.006. PMID: 23332776.
10. Kim JW, Lee J, Kim BN, et al. Theta-phase gamma-amplitude coupling as a neurophysiological marker of attention deficit/hyperactivity disorder in children. *Neurosci Lett*. 2015 Aug 31;603:25-30. doi: 10.1016/j.neulet.2015.07.006. PMID: 26170246.
11. Kim J, Lee Y, Han D, et al. The utility of quantitative electroencephalography and Integrated Visual and Auditory Continuous Performance Test as auxiliary tools for the Attention Deficit Hyperactivity Disorder diagnosis. *Clin Neurophysiol*. 2015 Mar;126(3):532-40. doi: 10.1016/j.clinph.2014.06.034. PMID: 25088931.
12. Klenberg L, Jamsa S, Hayrinen T, et al. The Attention and Executive Function Rating Inventory (ATTEX): Psychometric properties and clinical utility in diagnosing ADHD subtypes. *Scand J Psychol*. 2010 Mar 19;51(5):439-48. doi: 10.1111/j.1467-9450.2010.00812.x. PMID: 20338019.
13. Liechti MD, Valko L, Muller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. *Brain Topogr*. 2013 Jan;26(1):135-51. doi: 10.1007/s10548-012-0258-6. PMID: 23053601.

14. Martin-Martinez D, Casaseca-de-la-Higuera P, Alberola-Lopez S, et al. Nonlinear analysis of actigraphic signals for the assessment of the attention-deficit/hyperactivity disorder (ADHD). *Med Eng Phys.* 2012 Nov;34(9):1317-29. doi: 10.1016/j.medengphy.2011.12.023. PMID: 22297088.
15. Ogrim G, Kropotov J, Hestad K. The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: sensitivity, specificity, and behavioral correlates. *Psychiatry Res.* 2012 Aug 15;198(3):482-8. doi: 10.1016/j.psychres.2011.12.041. PMID: 22425468.
16. Ohan JL, Visser TAW, Strain MC, et al. Teachers' and education students' perceptions of and reactions to children with and without the diagnostic label 'ADHD'. *Journal of School Psychology.* 2011;49(1):81-105. doi: 10.1016/j.jsp.2010.10.001. PMID: 2011-00464-004.
17. Soliva JC, Fauquet J, Bielsa A, et al. Quantitative MR analysis of caudate abnormalities in pediatric ADHD: proposal for a diagnostic test. *Psychiatry Res.* 2010 Jun 30;182(3):238-43. doi: 10.1016/j.psychres.2010.01.013. PMID: 20488672.
18. Thorell LB, Eninger L, Brocki KC, et al. Childhood executive function inventory (CHEXI): a promising measure for identifying young children with ADHD? *J Clin Exp Neuropsychol.* 2010 Jan;32(1):38-43. doi: 10.1080/13803390902806527. PMID: 19381995.
19. Zelnik N, Bennett-Back O, Miari W, et al. Is the test of variables of attention reliable for the diagnosis of attention-deficit hyperactivity disorder (ADHD)? *J Child Neurol.* 2012 Jun;27(6):703-7. doi: 10.1177/0883073811423821. PMID: 22378668.
20. Abikoff H, Gallagher R, Wells KC, et al. Remediating organizational functioning in children with ADHD: immediate and long-term effects from a randomized controlled trial. *J Consult Clin Psychol.* 2013 Feb;81(1):113-28. doi: 10.1037/a0029648. PMID: 22889336.
21. Abikoff HB, Thompson M, Laver-Bradbury C, et al. Parent training for preschool ADHD: a randomized controlled trial of specialized and generic programs. *J Child Psychol Psychiatry.* 2015 Jun;56(6):618-31. doi: 10.1111/jcpp.12346. PMID: 25318650.
22. Arcieri R, Germinario EA, Bonati M, et al. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. *J Child Adolesc Psychopharmacol.* 2012 Dec;22(6):423-31. PMID: 23362511.
23. Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. *J Child Adolesc Psychopharmacol.* 2011 Feb;21(1):1-19. doi: 10.1089/cap.2010.0073. PMID: 21309695.
24. Bai GN, Wang YF, Yang L, et al. Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: Improvement of medication adherence and symptoms. *Neuropsychiatric Disease and Treatment.* 2015;11:2721-35.
25. Banaschewski T, Johnson M, Lecendreux M, et al. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. *CNS Drugs.* 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z. PMID: 25139785.
26. Barragan E, Breuer D, Dopfner M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. *J Atten Disord.* 2014 Jan 24;doi: 10.1177/1087054713518239. PMID: 24464327.

27. Beck SJ, Hanson CA, Puffenberger SS, et al. A controlled trial of working memory training for children and adolescents with ADHD. *J Clin Child Adolesc Psychol*. 2010;39(6):825-36. doi: 10.1080/15374416.2010.517162. PMID: 21058129.
28. Bink M, van Nieuwenhuizen C, Popma A, et al. Behavioral effects of neurofeedback in adolescents with ADHD: a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2015 Sep;24(9):1035-48. doi: 10.1007/s00787-014-0655-3. PMID: 25477074.
29. Boyer BE, Geurts HM, Prins PJ, et al. Two novel CBTs for adolescents with ADHD: the value of planning skills. *Eur Child Adolesc Psychiatry*. 2015 Sep;24(9):1075-90. doi: 10.1007/s00787-014-0661-5. PMID: 25549767.
30. Çetin FH, Taş Torun Y, Işık Taner Y. Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: A six-month follow up study for efficacy and adverse effects. *Turkiye Klinikleri Journal of Medical Sciences*. 2015;35(2):88-96.
31. Chacko A, Bedard AC, Marks DJ, et al. A randomized clinical trial of Cogmed Working Memory Training in school-age children with ADHD: a replication in a diverse sample using a control condition. *J Child Psychol Psychiatry*. 2014 Mar;55(3):247-55. doi: 10.1111/jcpp.12146. PMID: 24117656.
32. Chacko A, Wymbs BT, Wymbs FA, et al. Enhancing traditional behavioral parent training for single mothers of children with ADHD. *J Clin Child Adolesc Psychol*. 2009 Mar;38(2):206-18. doi: 10.1080/15374410802698388. PMID: 19283599.
33. Clemow DB, Mason OW, Sarkis EH, et al. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. *Expert Rev Neurother*. 2015 Oct 21:1-14. doi: 10.1586/14737175.2015.1102060. PMID: 26488905.
34. Cortese S, Panei P, Arcieri R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. *CNS Drugs*. 2015 Oct;29(10):865-77. doi: 10.1007/s40263-015-0266-7. PMID: 26293742.
35. Didoni A, Sequi M, Panei P, et al. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. *Eur J Clin Pharmacol*. 2011 Oct;67(10):1061-7. doi: 10.1007/s00228-011-1050-3. PMID: 21538145.
36. Dosis S, Van der Oord S, Wiers RW, et al. Improving executive functioning in children with ADHD: training multiple executive functions within the context of a computer game. a randomized double-blind placebo controlled trial. *PLoS One*. 2015;10(4):e0121651. doi: 10.1371/journal.pone.0121651. PMID: 25844638.
37. Duric NS, Assmus J, Gundersen D, et al. Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports. *BMC Psychiatry*. 2012;12:107. doi: 10.1186/1471-244x-12-107. PMID: 22877086.
38. Dutta B, Barua TK, Ray J, et al. A study of evaluation of safety and efficacy of memomet, a multi herbal formulation (memomet) in the treatment of behavioural disorder in children. *International Journal of Research in Pharmaceutical Sciences*. 2012;3(2):282-6.
39. Egeland J, Aarlien AK, Saunes BK. Few effects of far transfer of working memory training in ADHD: a randomized controlled trial. *PLoS One*. 2013;8(10):e75660. doi: 10.1371/journal.pone.0075660. PMID: 24124503.

40. Ercan ES, Ardic UA, Kutlu A, et al. No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. *J Atten Disord*. 2014 Feb;18(2):145-57. doi: 10.1177/1087054711432884. PMID: 22522574.
41. Evans SW, Langberg JM, Schultz BK, et al. Evaluation of a School-Based Treatment Program for Young Adolescents With ADHD. *Journal of Consulting and Clinical Psychology*. 2015.
42. Ferrin M, Moreno-Granados JM, Salcedo-Marin MD, et al. Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: immediate and long-term effects using a blind randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2014 Aug;23(8):637-47. doi: 10.1007/s00787-013-0494-7. PMID: 24292412.
43. Findling RL, Adeyi B, Chen G, et al. Clinical response and symptomatic remission in children treated with lisdexamfetamine dimesylate for attention-deficit/hyperactivity disorder. *CNS Spectrums*. 2010;15(9):559-68.
44. Gevensleben H, Holl B, Albrecht B, et al. Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. *J Child Psychol Psychiatry*. 2009 Jul;50(7):780-9. doi: 10.1111/j.1469-7610.2008.02033.x. PMID: 19207632.
45. Gustafsson PA, Birberg-Thornberg U, Duchon K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr*. 2010 Oct;99(10):1540-9. doi: 10.1111/j.1651-2227.2010.01871.x. PMID: 20491709.
46. Hammerness P, Petty C, Faraone SV, et al. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. *J Atten Disord*. 2012 Dec 20doi: 10.1177/1087054712468051. PMID: 23264367.
47. Hariri M, Djazayeri A, Djalali M, et al. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. *Malays J Nutr*. 2012 Dec;18(3):329-35. PMID: 24568073.
48. Hiscock H, Sciberras E, Mensah F, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. *Bmj*. 2015;350:h68. doi: 10.1136/bmj.h68. PMID: 25646809.
49. Huang YH, Chung CY, Ou HY, et al. Treatment effects of combining social skill training and parent training in Taiwanese children with attention deficit hyperactivity disorder. *Journal of the Formosan Medical Association*. 2015;114(3):260-7.
50. Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. *J Atten Disord*. 2009 Mar;12(5):394-401. doi: 10.1177/1087054708316261. PMID: 18448859.
51. Katz M, Levine AA, Kol-Degani H, et al. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. *J Atten Disord*. 2010 Nov;14(3):281-91. doi: 10.1177/1087054709356388. PMID: 20228219.
52. Li JJ, Li ZW, Wang SZ, et al. Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder. *Psychopharmacology (Berl)*. 2011 Aug;216(4):501-9. doi: 10.1007/s00213-011-2238-z. PMID: 21416235.
53. Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit

- hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. *Eur Psychiatry*. 2012 Jul;27(5):335-42. doi: 10.1016/j.eurpsy.2011.05.004. PMID: 21807480.
54. Mautone JA, Marshall SA, Sharman J, et al. Development of a Family-School Intervention for Young Children With Attention Deficit Hyperactivity Disorder. *School Psych Rev*. 2012;41(4):447-66. PMID: 24353368.
55. Milte CM, Parletta N, Buckley JD, et al. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. *Nutrition*. 2012 Jun;28(6):670-7. doi: 10.1016/j.nut.2011.12.009. PMID: 22541055.
56. Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. *Iran J Psychiatry*. 2012 Spring;7(2):87-92. PMID: 22952551.
57. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. *J Am Acad Child Adolesc Psychiatry*. 2009 May;48(5):484-500. doi: 10.1097/CHI.0b013e31819c23d0. PMID: 19318991.
58. Montoya A, Hervas A, Fuentes J, et al. Cluster-randomized, controlled 12-month trial to evaluate the effect of a parental psychoeducation program on medication persistence in children with attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat*. 2014;10:1081-92. doi: 10.2147/ndt.s62487. PMID: 24966679.
59. Moreno-García I, Delgado-Pardo G, de Reya CC-V, et al. Neurofeedback, pharmacological treatment and behavioral therapy in hyperactivity: Multilevel analysis of treatment effects on electroencephalography. *International Journal of Clinical and Health Psychology*. 2015;15(3):217-25. doi: 10.1016/j.ijchp.2015.04.003. PMID: 2015-48012-005.
60. Myers K, Vander Stoep A, Zhou C, et al. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2015 Apr;54(4):263-74. doi: 10.1016/j.jaac.2015.01.009. PMID: 25791143.
61. Oberai P, Gopinadhan S, Varanasi R, et al. Homoeopathic management of attention deficit hyperactivity disorder: A randomised placebo-controlled pilot trial. *Indian Journal of Research in Homeopathy*. 2013;7(4):158-67.
62. Ostberg M, Rydell AM. An efficacy study of a combined parent and teacher management training programme for children with ADHD. *Nord J Psychiatry*. 2012 Apr;66(2):123-30. doi: 10.3109/08039488.2011.641587. PMID: 22150634.
63. Pane P, Arcieri R, Bonati M, et al. Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy. *Adverse Drug Reaction Bulletin*. 2010(260):999-1002.
64. Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. *Lancet*. 2011 Feb 5;377(9764):494-503. doi: 10.1016/s0140-6736(10)62227-1. PMID: 21296237.
65. Perera H, Jeewandara KC, Seneviratne S, et al. Combined omega3 and omega6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. *J Child Neurol*. 2012 Jun;27(6):747-53. doi: 10.1177/0883073811435243. PMID: 22596014.

66. Pfiffner LJ, Hinshaw SP, Owens E, et al. A two-site randomized clinical trial of integrated psychosocial treatment for ADHD-inattentive type. *J Consult Clin Psychol.* 2014 Dec;82(6):1115-27. doi: 10.1037/a0036887. PMID: 24865871.
67. Power TJ, Mautone JA, Soffer SL, et al. A family-school intervention for children with ADHD: results of a randomized clinical trial. *J Consult Clin Psychol.* 2012 Aug;80(4):611-23. doi: 10.1037/a0028188. PMID: 22506793.
68. Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. *J Child Adolesc Psychopharmacol.* 2009 Apr;19(2):167-77. doi: 10.1089/cap.2008.070. PMID: 19364294.
69. Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry.* 2010 Feb 1;34(1):76-80. doi: 10.1016/j.pnpbp.2009.09.026. PMID: 19815048.
70. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol.* 2009 Jun;19(3):215-26. doi: 10.1089/cap.2008.0080. PMID: 19519256.
71. Shakibaei F, Radmanesh M, Salari E, et al. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. *Complement Ther Clin Pract.* 2015 May;21(2):61-7. doi: 10.1016/j.ctcp.2015.04.001. PMID: 25925875.
72. Steiner NJ, Frenette EC, Rene KM, et al. Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. *J Dev Behav Pediatr.* 2014 Jan;35(1):18-27. doi: 10.1097/dbp.000000000000009. PMID: 24399101.
73. Storebo OJ, Gluud C, Winkel P, et al. Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial. *PLoS One.* 2012;7(6):e37280. doi: 10.1371/journal.pone.0037280. PMID: 22745657.
74. Tamm L, Epstein JN, Peugh JL, et al. Preliminary data suggesting the efficacy of attention training for school-aged children with ADHD. *Dev Cogn Neurosci.* 2013 Apr;4:16-28. doi: 10.1016/j.dcn.2012.11.004. PMID: 23219490.
75. Tobaiqy M, Stewart D, Helms PJ, et al. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK. *Drug Saf.* 2011 Mar 1;34(3):211-9. doi: 10.2165/11586050-000000000-00000. PMID: 21332245.
76. Trzepacz PT, Spencer TJ, Zhang S, et al. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. *Curr Med Res Opin.* 2011;27 Suppl 2:45-52. doi: 10.1185/03007995.2011.599372. PMID: 21973230.
77. van der Donk M, Hiemstra-Beernink AC, Tjeenk-Kalff A, et al. Cognitive training for children with ADHD: a randomized controlled trial of cogmed working memory training and 'paying attention in class'. *Front Psychol.* 2015;6:1081. doi: 10.3389/fpsyg.2015.01081. PMID: 26284005.
78. van Dongen-Boomsma M, Vollebregt MA, Buitelaar JK, et al. Working memory training in young children with ADHD: a randomized placebo-controlled trial. *J Child*

- Psychol Psychiatry. 2014 Aug;55(8):886-96. doi: 10.1111/jcpp.12218. PMID: 24628438.
79. Vidal R, Castells J, Richarte V, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2015 Apr;54(4):275-82. doi: 10.1016/j.jaac.2014.12.016. PMID: 25791144.
80. Webster-Stratton CH, Reid MJ, Beauchaine T. Combining parent and child training for young children with ADHD. *J Clin Child Adolesc Psychol*. 2011;40(2):191-203. doi: 10.1080/15374416.2011.546044. PMID: 21391017.
81. Widenhorn-Muller K, Schwanda S, Scholz E, et al. Effect of supplementation with long-chain omega-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial. *Prostaglandins Leukot Essent Fatty Acids*. 2014 Jul-Aug;91(1-2):49-60. doi: 10.1016/j.plefa.2014.04.004. PMID: 24958525.
82. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. *Pediatrics*. 2009 Jul;124(1):e75-80. doi: 10.1542/peds.2008-3138. PMID: 19564272.
83. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. *Neuropediatrics*. 2010 Aug;41(2):55-9. doi: 10.1055/s-0030-1261893. PMID: 20799150.